reference_id,authors,title,journal,year,volume,citation_footer,citation_type,citation,urls,pubmed_id,doi,header,reference_type,study_id,exclusion_reason
CD012930-bib-0001,"Asai K, Hirata K, Hashimoto S, Fukuchi Y, Kitawaki T, Ikeda K, et al. ",Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: pooled analysis of SHINE and ARISE, Respiratory Investigation ,2016,54,    ,['citation-journal']," Asai K, Hirata K, Hashimoto S, Fukuchi Y, Kitawaki T, Ikeda K, et al. Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: pooled analysis of SHINE and ARISE.  Respiratory Investigation 2016;54(6):428‐35. [2212‐5353]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.resinv.2016.06.006', 'https://www.ncbi.nlm.nih.gov/pubmed/27886854', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+indacaterol/glycopyrronium+in+Japanese+patients+with+COPD:+pooled+analysis+of+SHINE+and+ARISE+&author=K+Asai&author=K+Hirata&author=S+Hashimoto&author=Y+Fukuchi&author=T+Kitawaki&author=K+Ikeda&publication_year=2016&hl=en']",27886854,https://doi.org/10.1016/j.resinv.2016.06.006, Bateman 2013 {published data only}  ,included,CD012930-bbs2-0001,
CD012930-bib-0002,"Barnes N, Bateman E, Gallagher N, Green Y, Horton R, Henley M, et al. ","QVA149 once daily provides superior bronchodilation versus indacaterol, glycopyrronium, tiotropium and placebo: the SHINE study",,2012,,    ,['citation-other']," Barnes N, Bateman E, Gallagher N, Green Y, Horton R, Henley M, et al. QVA149 once daily provides superior bronchodilation versus indacaterol, glycopyrronium, tiotropium and placebo: the SHINE study. Thorax2012; Vol. 67:A147 [P192]. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=QVA149+once+daily+provides+superior+bronchodilation+versus+indacaterol,+glycopyrronium,+tiotropium+and+placebo:+the+SHINE+study+&author=N+Barnes&author=E+Bateman&author=N+Gallagher&author=Y+Green&author=R+Horton&author=M+Henley&publication_year=2012&hl=en']",,, Bateman 2013 {published data only}  ,included,CD012930-bbs2-0001,
CD012930-bib-0003,"Bateman E, Ferguson GT, Barnes N, Gallagher N, Green Y, Horton R, et al. ","Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the SHINE study",,2012,,    ,['citation-other']," Bateman E, Ferguson GT, Barnes N, Gallagher N, Green Y, Horton R, et al. Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the SHINE study. European Respiratory Journal. 2012; Vol. 40:509s [2810]. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Benefits+of+dual+bronchodilation+with+QVA149+once+daily+versus+placebo,+indacaterol,+NVA237+and+tiotropium+in+patients+with+COPD:+the+SHINE+study+&author=E+Bateman&author=GT+Ferguson&author=N+Barnes&author=N+Gallagher&author=Y+Green&author=R+Horton&publication_year=2012&hl=en']",,, Bateman 2013 {published data only}  ,included,CD012930-bbs2-0001,
CD012930-bib-0004,"Bateman ED, Ferguson GT, Barnes N, Gallagher N, Green Y, Henley M, et al. ",Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study, European Respiratory Journal ,2013,42,    ,['citation-journal']," Bateman ED, Ferguson GT, Barnes N, Gallagher N, Green Y, Henley M, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study.  European Respiratory Journal 2013;42(6):1484‐94. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1183/09031936.00200212', 'https://www.ncbi.nlm.nih.gov/pubmed/23722616', 'https://scholar.google.com/scholar_lookup?title=Dual+bronchodilation+with+QVA149+versus+single+bronchodilator+therapy:+the+SHINE+study&author=ED+Bateman&author=GT+Ferguson&author=N+Barnes&author=N+Gallagher&author=Y+Green&author=M+Henley&publication_year=2013&hl=en']",23722616,https://doi.org/10.1183/09031936.00200212, Bateman 2013 {published data only}  ,included,CD012930-bbs2-0001,
CD012930-bib-0005,"Bateman ED, Welte T, Hashimoto S, Gallagher N, Green Y, Horton R, et al. ",Dual bronchodilation with once‐daily QVA149 provides superior bronchodilation compared to its mono‐components and tiotropium in all subgroups of patients with COPD: the shine study, American Journal of Respiratory and Critical Care Medicine ,2013,187,    ,['citation-journal']," Bateman ED, Welte T, Hashimoto S, Gallagher N, Green Y, Horton R, et al. Dual bronchodilation with once‐daily QVA149 provides superior bronchodilation compared to its mono‐components and tiotropium in all subgroups of patients with COPD: the shine study.  American Journal of Respiratory and Critical Care Medicine 2013;187:A4263. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Dual+bronchodilation+with+once‐daily+QVA149+provides+superior+bronchodilation+compared+to+its+mono‐components+and+tiotropium+in+all+subgroups+of+patients+with+COPD:+the+shine+study+&author=ED+Bateman&author=T+Welte&author=S+Hashimoto&author=N+Gallagher&author=Y+Green&author=R+Horton&publication_year=2013&hl=en']",,, Bateman 2013 {published data only}  ,included,CD012930-bbs2-0001,
CD012930-bib-0006,CQVA149A2303. ,"A 26‐week treatment, multi‐center, randomized, double‐blind, parallel‐group, placebo and active controlled (open label) study to assess the efficacy, safety and tolerability of QVA149 (110/50 μg q.d.) in patients with moderate to severe chronic obstructive pulmonary disease (COPD)",,,,   ,['citation-other']," CQVA149A2303. A 26‐week treatment, multi‐center, randomized, double‐blind, parallel‐group, placebo and active controlled (open label) study to assess the efficacy, safety and tolerability of QVA149 (110/50 μg q.d.) in patients with moderate to severe chronic obstructive pulmonary disease (COPD). www.novctrd.com/ctrdWebApp/clinicaltrialrepository/ (first received 21 September 2010). CENTRAL    ",[''],,, Bateman 2013 {published data only}  ,included,CD012930-bbs2-0001,
CD012930-bib-0007,"Chapman K, Bateman E, Gallagher N, Hu H, Banerji D. ","Once‐daily QVA149 improves lung function, dyspnea, and health status independent of disease severity and prior medications: the shine study", Chest ,2014,145,    ,['citation-journal']," Chapman K, Bateman E, Gallagher N, Hu H, Banerji D. Once‐daily QVA149 improves lung function, dyspnea, and health status independent of disease severity and prior medications: the shine study.  Chest 2014;145:3. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1378/chest.1813585', 'https://scholar.google.com/scholar_lookup?title=Once‐daily+QVA149+improves+lung+function,+dyspnea,+and+health+status+independent+of+disease+severity+and+prior+medications:+the+shine+study+&author=K+Chapman&author=E+Bateman&author=N+Gallagher&author=H+Hu&author=D+Banerji&publication_year=2014&hl=en']",,https://doi.org/10.1378/chest.1813585, Bateman 2013 {published data only}  ,included,CD012930-bbs2-0001,
CD012930-bib-0008,"Chapman KR, Bateman ED, Gallagher N, Hu H, Banerji D. ","QVA149 once daily improves lung function, dyspnoea and health status independent of prior medications and disease severity: the SHINE study", Thorax ,2013,68,    ,['citation-journal']," Chapman KR, Bateman ED, Gallagher N, Hu H, Banerji D. QVA149 once daily improves lung function, dyspnoea and health status independent of prior medications and disease severity: the SHINE study.  Thorax 2013;68:A182 [P234]. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1136/thoraxjnl-2013-204457.386', 'https://scholar.google.com/scholar_lookup?title=QVA149+once+daily+improves+lung+function,+dyspnoea+and+health+status+independent+of+prior+medications+and+disease+severity:+the+SHINE+study+&author=KR+Chapman&author=ED+Bateman&author=N+Gallagher&author=H+Hu&author=D+Banerji&publication_year=2013&hl=en']",,https://doi.org/10.1136/thoraxjnl-2013-204457.386, Bateman 2013 {published data only}  ,included,CD012930-bbs2-0001,
CD012930-bib-0009,"Chapman KR, Bateman ED, Gallagher N, Hu H, Kim HJ, Banerji D. ","Once‐daily QVA149 improves lung function, dyspnea and health status regardless of disease severity and prior medications: the SHINE study", Respirology ,2013,18,    ,['citation-journal']," Chapman KR, Bateman ED, Gallagher N, Hu H, Kim HJ, Banerji D. Once‐daily QVA149 improves lung function, dyspnea and health status regardless of disease severity and prior medications: the SHINE study.  Respirology 2013;18:31 [OS100]. [1323‐7799]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Once‐daily+QVA149+improves+lung+function,+dyspnea+and+health+status+regardless+of+disease+severity+and+prior+medications:+the+SHINE+study+&author=KR+Chapman&author=ED+Bateman&author=N+Gallagher&author=H+Hu&author=HJ+Kim&author=D+Banerji&publication_year=2013&hl=en']",,, Bateman 2013 {published data only}  ,included,CD012930-bbs2-0001,
CD012930-bib-0010,"Frith P, Thompson P, Wark P, Lindstrom S, Bateman E. ","Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the Shine study", Respirology ,2013,18,    ,['citation-journal']," Frith P, Thompson P, Wark P, Lindstrom S, Bateman E. Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the Shine study.  Respirology 2013;18:20 [O041]. [1323‐7799]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Benefits+of+dual+bronchodilation+with+QVA149+once+daily+versus+placebo,+indacaterol,+NVA237+and+tiotropium+in+patients+with+COPD:+the+Shine+study+&author=P+Frith&author=P+Thompson&author=P+Wark&author=S+Lindstrom&author=E+Bateman&publication_year=2013&hl=en']",,, Bateman 2013 {published data only}  ,included,CD012930-bbs2-0001,
CD012930-bib-0011,"Hashimoto S, Ikeuchi H, Murata S, Kitawaki T, Ikeda K, Banerji D. ",Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: a subgroup analysis from the SHINE study, International Journal of Chronic Obstructive Pulmonary Disease ,2016,11,    ,['citation-journal']," Hashimoto S, Ikeuchi H, Murata S, Kitawaki T, Ikeda K, Banerji D. Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: a subgroup analysis from the SHINE study.  International Journal of Chronic Obstructive Pulmonary Disease 2016;11:2543‐51. [1178‐2005]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.2147/COPD.S111408', 'https://www.ncbi.nlm.nih.gov/pubmed/27785010', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+indacaterol/glycopyrronium+in+Japanese+patients+with+COPD:+a+subgroup+analysis+from+the+SHINE+study+&author=S+Hashimoto&author=H+Ikeuchi&author=S+Murata&author=T+Kitawaki&author=K+Ikeda&author=D+Banerji&publication_year=2016&hl=en']",27785010,https://doi.org/10.2147/COPD.S111408, Bateman 2013 {published data only}  ,included,CD012930-bbs2-0001,
CD012930-bib-0012,NCT01202188. ,"A study to assess the efficacy, safety and tolerability of once‐daily (q.d.) QVA149 in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (SHINE)",,,,   ,['citation-other']," NCT01202188. A study to assess the efficacy, safety and tolerability of once‐daily (q.d.) QVA149 in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (SHINE). clinicaltrials.gov/ct2/show/NCT01202188 (first received 15 September 2010). CENTRAL    ",[''],,, Bateman 2013 {published data only}  ,included,CD012930-bbs2-0001,
CD012930-bib-0013,"Wark P, Chapman K, Bateman E, Olsson P, Chen H, Banerji D, et al. ",Effect of QVA149 on lung function in the subgroup of patients with a history of exacerbations in the previous year and baseline ICS use from the shine study, Respirology ,2015,20,    ,['citation-journal']," Wark P, Chapman K, Bateman E, Olsson P, Chen H, Banerji D, et al. Effect of QVA149 on lung function in the subgroup of patients with a history of exacerbations in the previous year and baseline ICS use from the shine study.  Respirology 2015;20:81. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Effect+of+QVA149+on+lung+function+in+the+subgroup+of+patients+with+a+history+of+exacerbations+in+the+previous+year+and+baseline+ICS+use+from+the+shine+study+&author=P+Wark&author=K+Chapman&author=E+Bateman&author=P+Olsson&author=H+Chen&author=D+Banerji&publication_year=2015&hl=en']",,, Bateman 2013 {published data only}  ,included,CD012930-bbs2-0001,
CD012930-bib-0014,"Wark P, Tillmann H, Jones I, Fogel R, Banerji D. ",Qva149 provides significant symptomatic benefit to COPD patients as measured by a new symptom e‐diary: the SHINE study, Respirology ,2016,21,    ,['citation-journal']," Wark P, Tillmann H, Jones I, Fogel R, Banerji D. Qva149 provides significant symptomatic benefit to COPD patients as measured by a new symptom e‐diary: the SHINE study.  Respirology 2016;21:128 [TP 065]. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Qva149+provides+significant+symptomatic+benefit+to+COPD+patients+as+measured+by+a+new+symptom+e‐diary:+the+SHINE+study+&author=P+Wark&author=H+Tillmann&author=I+Jones&author=R+Fogel&author=D+Banerji&publication_year=2016&hl=en']",,, Bateman 2013 {published data only}  ,included,CD012930-bbs2-0001,
CD012930-bib-0015,"Welte T, Barnes N, Nagase T, Gallagher N, Green Y, Horton R, et al. ",QVA149 once daily is safe and well tolerated in patients with COPD: the SHINE Study, American Journal of Respiratory and Critical Care Medicine ,2013,187,    ,['citation-journal']," Welte T, Barnes N, Nagase T, Gallagher N, Green Y, Horton R, et al. QVA149 once daily is safe and well tolerated in patients with COPD: the SHINE Study.  American Journal of Respiratory and Critical Care Medicine 2013;187:A1478. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=QVA149+once+daily+is+safe+and+well+tolerated+in+patients+with+COPD:+the+SHINE+Study&author=T+Welte&author=N+Barnes&author=T+Nagase&author=N+Gallagher&author=Y+Green&author=R+Horton&publication_year=2013&hl=en']",,, Bateman 2013 {published data only}  ,included,CD012930-bbs2-0001,
CD012930-bib-0016,"Welte T, Gallagher N, Green Y, Henley M, Banerji D. ",Dual bronchodilation with once‐daily QVA149 provides significantly improved clinical outcomes versus mono‐bronchodilator therapy: the SHINE study, American Journal of Respiratory and Critical Care Medicine ,2013,187,    ,['citation-journal']," Welte T, Gallagher N, Green Y, Henley M, Banerji D. Dual bronchodilation with once‐daily QVA149 provides significantly improved clinical outcomes versus mono‐bronchodilator therapy: the SHINE study.  American Journal of Respiratory and Critical Care Medicine 2013;187:A4272. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Dual+bronchodilation+with+once‐daily+QVA149+provides+significantly+improved+clinical+outcomes+versus+mono‐bronchodilator+therapy:+the+SHINE+study+&author=T+Welte&author=N+Gallagher&author=Y+Green&author=M+Henley&author=D+Banerji&publication_year=2013&hl=en']",,, Bateman 2013 {published data only}  ,included,CD012930-bbs2-0001,
CD012930-bib-0017,"Beeh KM, Korn S, Beier J, Jadayel D, Henley M, D'Andrea P, et al. ",Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study, Respiratory Medicine ,2014,108,    ,['citation-journal']," Beeh KM, Korn S, Beier J, Jadayel D, Henley M, D'Andrea P, et al. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study.  Respiratory Medicine 2014;108(4):584‐92. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.rmed.2014.01.006', 'https://www.ncbi.nlm.nih.gov/pubmed/24534204', ""https://scholar.google.com/scholar_lookup?title=Effect+of+QVA149+on+lung+volumes+and+exercise+tolerance+in+COPD+patients:+the+BRIGHT+study+&author=KM+Beeh&author=S+Korn&author=J+Beier&author=D+Jadayel&author=M+Henley&author=P+D'Andrea&publication_year=2014&hl=en""]",24534204,https://doi.org/10.1016/j.rmed.2014.01.006, Beeh 2014 {published data only}  ,included,CD012930-bbs2-0002,
CD012930-bib-0018,"Beeh KM, Korn S, Beier J, Jadayel D, Henley M, Tylek J, et al. ",QVA149 once daily improves exercise tolerance and lung function in patients with moderate to severe COPD: the BRIGHT study, Thorax ,2012,67,    ,['citation-journal']," Beeh KM, Korn S, Beier J, Jadayel D, Henley M, Tylek J, et al. QVA149 once daily improves exercise tolerance and lung function in patients with moderate to severe COPD: the BRIGHT study.  Thorax 2012;67:A147 [P191]. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1136/thoraxjnl-2012-202678.252', 'https://scholar.google.com/scholar_lookup?title=QVA149+once+daily+improves+exercise+tolerance+and+lung+function+in+patients+with+moderate+to+severe+COPD:+the+BRIGHT+study+&author=KM+Beeh&author=S+Korn&author=J+Beier&author=D+Jadayel&author=M+Henley&author=J+Tylek&publication_year=2012&hl=en']",,https://doi.org/10.1136/thoraxjnl-2012-202678.252, Beeh 2014 {published data only}  ,included,CD012930-bbs2-0002,
CD012930-bib-0019,"Beeh KM, Korn S, Beier J, Jadayel D, Henley M, Tylek J, et al. ","QVA149 once daily reduces lung hyperinflation, improves lung function and volumes as measured by body plethysomography: the BRIGHT study", American Journal of Respiratory and Critical Care Medicine ,2013,187,    ,['citation-journal']," Beeh KM, Korn S, Beier J, Jadayel D, Henley M, Tylek J, et al. QVA149 once daily reduces lung hyperinflation, improves lung function and volumes as measured by body plethysomography: the BRIGHT study.  American Journal of Respiratory and Critical Care Medicine 2013;187:A4259. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=QVA149+once+daily+reduces+lung+hyperinflation,+improves+lung+function+and+volumes+as+measured+by+body+plethysomography:+the+BRIGHT+study+&author=KM+Beeh&author=S+Korn&author=J+Beier&author=D+Jadayel&author=M+Henley&author=J+Tylek&publication_year=2013&hl=en']",,, Beeh 2014 {published data only}  ,included,CD012930-bbs2-0002,
CD012930-bib-0020,"Beeh K, Westerman J, Kirsten A, Hebert J, Gronke L, Hamilton A, et al. ",The 24‐h lung‐function profile of once‐daily tiotropium and olodaterol fixed‐dose combination in chronic obstructive pulmonary disease, Pulmonary Pharmacology and Therapeutics ,2015,32,    ,['citation-journal']," Beeh K, Westerman J, Kirsten A, Hebert J, Gronke L, Hamilton A, et al. The 24‐h lung‐function profile of once‐daily tiotropium and olodaterol fixed‐dose combination in chronic obstructive pulmonary disease.  Pulmonary Pharmacology and Therapeutics 2015;32:53‐9. [1094‐5539]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.pupt.2015.04.002', 'https://www.ncbi.nlm.nih.gov/pubmed/25956072', 'https://scholar.google.com/scholar_lookup?title=The+24‐h+lung‐function+profile+of+once‐daily+tiotropium+and+olodaterol+fixed‐dose+combination+in+chronic+obstructive+pulmonary+disease+&author=K+Beeh&author=J+Westerman&author=A+Kirsten&author=J+Hebert&author=L+Gronke&author=A+Hamilton&publication_year=2015&hl=en']",25956072,https://doi.org/10.1016/j.pupt.2015.04.002, Beeh 2015 {published data only}  ,included,CD012930-bbs2-0003,
CD012930-bib-0021,"Derom E, Westerman J, Groenke L, Hamilton A, Li C, Beeh K. ",The 24‐hour lung function profile of once‐daily tiotropium and olodaterol fixed‐dose combination compared with placebo and monotherapies in chronic obstructive pulmonary disease, American Journal of Respiratory and Critical Care Medicine ,2014,69,    ,['citation-journal']," Derom E, Westerman J, Groenke L, Hamilton A, Li C, Beeh K. The 24‐hour lung function profile of once‐daily tiotropium and olodaterol fixed‐dose combination compared with placebo and monotherapies in chronic obstructive pulmonary disease.  American Journal of Respiratory and Critical Care Medicine 2014;69:A190‐1. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=The+24‐hour+lung+function+profile+of+once‐daily+tiotropium+and+olodaterol+fixed‐dose+combination+compared+with+placebo+and+monotherapies+in+chronic+obstructive+pulmonary+disease+&author=E+Derom&author=J+Westerman&author=L+Groenke&author=A+Hamilton&author=C+Li&author=K+Beeh&publication_year=2014&hl=en']",,, Beeh 2015 {published data only}  ,included,CD012930-bbs2-0003,
CD012930-bib-0022,NCT01559116. ,Characterization of 24‐hour lung function profiles of inhaled tiotropium + olodaterol fixed dose combination in patients suffering from chronic obstructive pulmonary disease,,,,   ,['citation-other'], NCT01559116. Characterization of 24‐hour lung function profiles of inhaled tiotropium + olodaterol fixed dose combination in patients suffering from chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT01559116 (first received 21 March 2012). CENTRAL    ,[''],,, Beeh 2015 {published data only}  ,included,CD012930-bbs2-0003,
CD012930-bib-0023,"Celli B, Crater G, Kilbride S, Mehta R, Tabberer M, Kalberg C, et al. ","Once‐daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study", Chest ,2014,145,    ,['citation-journal']," Celli B, Crater G, Kilbride S, Mehta R, Tabberer M, Kalberg C, et al. Once‐daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study.  Chest 2014;145(5):981‐91. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1378/chest.13-1579', 'https://www.ncbi.nlm.nih.gov/pubmed/24385182', 'https://scholar.google.com/scholar_lookup?title=Once‐daily+umeclidinium/vilanterol+125/25+mcg+in+COPD:+a+randomized,+controlled+study&author=B+Celli&author=G+Crater&author=S+Kilbride&author=R+Mehta&author=M+Tabberer&author=C+Kalberg&publication_year=2014&hl=en']",24385182,https://doi.org/10.1378/chest.13-1579, Celli 2014 {published data only}  ,included,CD012930-bbs2-0004,
CD012930-bib-0024,"Celli BR, Crater G, Kilbride S, Mehta R, Tabberer M, Kalberg CJ, et al. ","A 24‐week randomized, double‐blind, placebo‐controlled study of the efficacy and safety of once‐daily umeclidinium/vilanterol 125/25 mcg in COPD", American Journal of Respiratory and Critical Care Medicine ,2013,187,    ,['citation-journal']," Celli BR, Crater G, Kilbride S, Mehta R, Tabberer M, Kalberg CJ, et al. A 24‐week randomized, double‐blind, placebo‐controlled study of the efficacy and safety of once‐daily umeclidinium/vilanterol 125/25 mcg in COPD.  American Journal of Respiratory and Critical Care Medicine 2013;187:A2435. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=A+24‐week+randomized,+double‐blind,+placebo‐controlled+study+of+the+efficacy+and+safety+of+once‐daily+umeclidinium/vilanterol+125/25+mcg+in+COPD+&author=BR+Celli&author=G+Crater&author=S+Kilbride&author=R+Mehta&author=M+Tabberer&author=CJ+Kalberg&publication_year=2013&hl=en']",,, Celli 2014 {published data only}  ,included,CD012930-bbs2-0004,
CD012930-bib-0025,"Donohue JF, Niewoehner D, Brooks J, O'Dell D, Church A. ","Safety and tolerability of once‐daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52‐week, randomized, double‐blind, placebo‐controlled study", Respiratory Research ,2014,15,    ,['citation-journal']," Donohue JF, Niewoehner D, Brooks J, O'Dell D, Church A. Safety and tolerability of once‐daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52‐week, randomized, double‐blind, placebo‐controlled study.  Respiratory Research 2014;15:78. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1186/1465-9921-15-78', 'https://www.ncbi.nlm.nih.gov/pubmed/25015176', ""https://scholar.google.com/scholar_lookup?title=Safety+and+tolerability+of+once‐daily+umeclidinium/vilanterol+125/25+mcg+and+umeclidinium+125+mcg+in+patients+with+chronic+obstructive+pulmonary+disease:+results+from+a+52‐week,+randomized,+double‐blind,+placebo‐controlled+study+&author=JF+Donohue&author=D+Niewoehner&author=J+Brooks&author=D+O'Dell&author=A+Church&publication_year=2014&hl=en""]",25015176,https://doi.org/10.1186/1465-9921-15-78, Celli 2014 {published data only}  ,included,CD012930-bbs2-0004,
CD012930-bib-0026,NCT01313637. ,A 24‐week evaluation of GSK573719/Vilanterol (125/25mcg) and components in COPD,,,,   ,['citation-other'], NCT01313637. A 24‐week evaluation of GSK573719/Vilanterol (125/25mcg) and components in COPD. clinicaltrials.gov/ct2/show/NCT01313637 (first received 14 March 2011). CENTRAL    ,[''],,, Celli 2014 {published data only}  ,included,CD012930-bbs2-0004,
CD012930-bib-0027,"Dahl R, Chapman K, Rudolf M, Mehta R, Kho P, Alagappan V, et al. ",QVA149 administered once daily provides significant improvements in lung function over 1 year in patients with COPD: the ENLIGHTEN study, European Respiratory Journal ,2012,40,    ,['citation-journal']," Dahl R, Chapman K, Rudolf M, Mehta R, Kho P, Alagappan V, et al. QVA149 administered once daily provides significant improvements in lung function over 1 year in patients with COPD: the ENLIGHTEN study.  European Respiratory Journal 2012;40:529s [P2896]. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=QVA149+administered+once+daily+provides+significant+improvements+in+lung+function+over+1+year+in+patients+with+COPD:+the+ENLIGHTEN+study+&author=R+Dahl&author=K+Chapman&author=M+Rudolf&author=R+Mehta&author=P+Kho&author=V+Alagappan&publication_year=2012&hl=en']",,, Dahl 2013 {published data only}  ,included,CD012930-bbs2-0005,
CD012930-bib-0028,"Dahl R, Chapman K, Rudolf M, Mehta R, Kho P, Alagappan V, et al. ",QVA149 once daily provides significant improvements in lung function over 1 year in patients with COPD: the Enlighten study, Thorax ,2012,67,    ,['citation-journal']," Dahl R, Chapman K, Rudolf M, Mehta R, Kho P, Alagappan V, et al. QVA149 once daily provides significant improvements in lung function over 1 year in patients with COPD: the Enlighten study.  Thorax 2012;67:A146 [P190]. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1136/thoraxjnl-2012-202678.251', 'https://scholar.google.com/scholar_lookup?title=QVA149+once+daily+provides+significant+improvements+in+lung+function+over+1+year+in+patients+with+COPD:+the+Enlighten+study+&author=R+Dahl&author=K+Chapman&author=M+Rudolf&author=R+Mehta&author=P+Kho&author=V+Alagappan&publication_year=2012&hl=en']",,https://doi.org/10.1136/thoraxjnl-2012-202678.251, Dahl 2013 {published data only}  ,included,CD012930-bbs2-0005,
CD012930-bib-0029,"Dahl R, Chapman KR, Rudolf M, Mehta R, Kho P, Alagappan VK, et al. ",Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study, Respiratory Medicine ,2013,107,    ,['citation-journal']," Dahl R, Chapman KR, Rudolf M, Mehta R, Kho P, Alagappan VK, et al. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study.  Respiratory Medicine 2013;107(10):1558‐67. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.rmed.2013.05.016', 'https://www.ncbi.nlm.nih.gov/pubmed/23867808', 'https://scholar.google.com/scholar_lookup?title=Safety+and+efficacy+of+dual+bronchodilation+with+QVA149+in+COPD+patients:+the+ENLIGHTEN+study+&author=R+Dahl&author=KR+Chapman&author=M+Rudolf&author=R+Mehta&author=P+Kho&author=VK+Alagappan&publication_year=2013&hl=en']",23867808,https://doi.org/10.1016/j.rmed.2013.05.016, Dahl 2013 {published data only}  ,included,CD012930-bbs2-0005,
CD012930-bib-0030,"Dahl R, Jadayel D, Alagappan V, Chen H, Banerji D. ",Once‐daily QVA149 provides the same efficacy as the free combination of its monocomponents indacaterol and glycopyrronium: the BEACON study,,2013,,    ,['citation-other']," Dahl R, Jadayel D, Alagappan V, Chen H, Banerji D. Once‐daily QVA149 provides the same efficacy as the free combination of its monocomponents indacaterol and glycopyrronium: the BEACON study. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42:694s [P3390]. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Once‐daily+QVA149+provides+the+same+efficacy+as+the+free+combination+of+its+monocomponents+indacaterol+and+glycopyrronium:+the+BEACON+study+&author=R+Dahl&author=D+Jadayel&author=V+Alagappan&author=H+Chen&author=D+Banerji&publication_year=2013&hl=en']",,, Dahl 2013 {published data only}  ,included,CD012930-bbs2-0005,
CD012930-bib-0031,NCT01120717. ,A study to assess the long‐term safety of QVA149 (ENLIGHTEN),,,,   ,['citation-other'], NCT01120717. A study to assess the long‐term safety of QVA149 (ENLIGHTEN). clinicaltrials.gov/ct2/show/NCT01120717 (first received 11 May 2010). CENTRAL    ,[''],,, Dahl 2013 {published data only}  ,included,CD012930-bbs2-0005,
CD012930-bib-0032,"Donohue JF, Maleki‐Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A. ",Efficacy and safety of once‐daily umeclidinium/vilanterol 62.5/25 mcg in COPD, Respiratory Medicine ,2013,107,    ,['citation-journal']," Donohue JF, Maleki‐Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A. Efficacy and safety of once‐daily umeclidinium/vilanterol 62.5/25 mcg in COPD.  Respiratory Medicine 2013;107(10):1538‐46. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.rmed.2013.06.001', 'https://www.ncbi.nlm.nih.gov/pubmed/23830094', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+once‐daily+umeclidinium/vilanterol+62.5/25+mcg+in+COPD&author=JF+Donohue&author=MR+Maleki‐Yazdi&author=S+Kilbride&author=R+Mehta&author=C+Kalberg&author=A+Church&publication_year=2013&hl=en']",23830094,https://doi.org/10.1016/j.rmed.2013.06.001, Donohue 2013 {published data only}  ,included,CD012930-bbs2-0006,
CD012930-bib-0033,NCT01313650. ,A 24‐week evaluation of GSK573719/Vilanterol (62.5/25mcg) and components in COPD (DB2113373),,,,   ,['citation-other'], NCT01313650. A 24‐week evaluation of GSK573719/Vilanterol (62.5/25mcg) and components in COPD (DB2113373). clinicaltrials.gov/ct2/show/NCT01313650 (first received 14 March 2011). CENTRAL    ,[''],,, Donohue 2013 {published data only}  ,included,CD012930-bbs2-0006,
CD012930-bib-0034,"Feldman G, Walker RR, Brooks J, Mehta R, Crater G. ",28‐day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo‐controlled trial, Pulmonary Pharmacology and Therapeutics ,2012,25,    ,['citation-journal']," Feldman G, Walker RR, Brooks J, Mehta R, Crater G. 28‐day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo‐controlled trial.  Pulmonary Pharmacology and Therapeutics 2012;25(6):465‐71. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.pupt.2012.08.007', 'https://www.ncbi.nlm.nih.gov/pubmed/22955035', 'https://scholar.google.com/scholar_lookup?title=28‐day+safety+and+tolerability+of+umeclidinium+in+combination+with+vilanterol+in+COPD:+a+randomized+placebo‐controlled+trial+&author=G+Feldman&author=RR+Walker&author=J+Brooks&author=R+Mehta&author=G+Crater&publication_year=2012&hl=en']",22955035,https://doi.org/10.1016/j.pupt.2012.08.007, Feldman 2012 {published data only}  ,included,CD012930-bbs2-0007,
CD012930-bib-0035,"Larbig M, Fowler‐taylor A, Maitra S, Schubert‐Tennigkeit A, Banerji D. ",Efficacy and safety of IND/GLY versus placebo and tiotropium in symptomatic patients with moderate‐to‐severe COPD: the 52‐week radiate study, Respirology ,2015,20,    ,['citation-journal']," Larbig M, Fowler‐taylor A, Maitra S, Schubert‐Tennigkeit A, Banerji D. Efficacy and safety of IND/GLY versus placebo and tiotropium in symptomatic patients with moderate‐to‐severe COPD: the 52‐week radiate study.  Respirology 2015;20:44. [1323‐7799]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+IND/GLY+versus+placebo+and+tiotropium+in+symptomatic+patients+with+moderate‐to‐severe+COPD:+the+52‐week+radiate+study+&author=M+Larbig&author=A+Fowler‐taylor&author=S+Maitra&author=A+Schubert‐Tennigkeit&author=D+Banerji&publication_year=2015&hl=en']",,, Larbig 2015 {published data only}  ,included,CD012930-bbs2-0008,
CD012930-bib-0036,NCT01610037. ,Comparison of long‐term safety of the combination product QVA149A against placebo and standard of care treatment in chronic obstructive pulmonary disease patients with moderate to severe airflow limitation,,,,   ,['citation-other'], NCT01610037. Comparison of long‐term safety of the combination product QVA149A against placebo and standard of care treatment in chronic obstructive pulmonary disease patients with moderate to severe airflow limitation. clinicaltrials.gov/ct2/show/NCT01610037 (first received 1 June 2012). CENTRAL    ,[''],,, Larbig 2015 {published data only}  ,included,CD012930-bbs2-0008,
CD012930-bib-0037,"D'Urzo A, Mahler D, Worth H, White T, Alagappan V, Chen H, et al. ",Patients with severe COPD show significant improvements in dyspnea and lung function with once‐daily QVA149: the blaze study,,2014,,    ,['citation-other']," D'Urzo A, Mahler D, Worth H, White T, Alagappan V, Chen H, et al. Patients with severe COPD show significant improvements in dyspnea and lung function with once‐daily QVA149: the blaze study. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2014; Vol. 145. CENTRAL    Google Scholar     ","['', ""https://scholar.google.com/scholar_lookup?title=Patients+with+severe+COPD+show+significant+improvements+in+dyspnea+and+lung+function+with+once‐daily+QVA149:+the+blaze+study+&author=A+D'Urzo&author=D+Mahler&author=H+Worth&author=T+White&author=V+Alagappan&author=H+Chen&publication_year=2014&hl=en""]",,, Mahler 2014 {published data only}  ,included,CD012930-bbs2-0009,
CD012930-bib-0038,"D'Urzo A, Mahler DA, Decramer M, Worth H, White T, Alagappan VKT, et al. ",Superior lung function with once‐daily QVA149 translates into improvements in patient‐reported breathlessness compared with placebo and tiotropium in COPD patients: the BLAZE study,,2013,,    ,['citation-other']," D'Urzo A, Mahler DA, Decramer M, Worth H, White T, Alagappan VKT, et al. Superior lung function with once‐daily QVA149 translates into improvements in patient‐reported breathlessness compared with placebo and tiotropium in COPD patients: the BLAZE study. Thorax. 2013:A184 [P236]. CENTRAL    Google Scholar     ","['', ""https://scholar.google.com/scholar_lookup?title=Superior+lung+function+with+once‐daily+QVA149+translates+into+improvements+in+patient‐reported+breathlessness+compared+with+placebo+and+tiotropium+in+COPD+patients:+the+BLAZE+study+&author=A+D'Urzo&author=DA+Mahler&author=M+Decramer&author=H+Worth&author=T+White&author=VKT+Alagappan&publication_year=2013&hl=en""]",,, Mahler 2014 {published data only}  ,included,CD012930-bbs2-0009,
CD012930-bib-0039,"Mahler DA, Decramer M, D'Urzo A, Worth H, White T, Alagappan VKT, et al. ",Dual bronchodilation with QVA149 reduces patient‐reported dyspnoea in COPD: the BLAZE study, European Respiratory Journal ,2014,43,    ,['citation-journal']," Mahler DA, Decramer M, D'Urzo A, Worth H, White T, Alagappan VKT, et al. Dual bronchodilation with QVA149 reduces patient‐reported dyspnoea in COPD: the BLAZE study.  European Respiratory Journal 2014;43(6):1599‐609. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1183/09031936.00124013', 'https://www.ncbi.nlm.nih.gov/pubmed/24176997', ""https://scholar.google.com/scholar_lookup?title=Dual+bronchodilation+with+QVA149+reduces+patient‐reported+dyspnoea+in+COPD:+the+BLAZE+study+&author=DA+Mahler&author=M+Decramer&author=A+D'Urzo&author=H+Worth&author=T+White&author=VKT+Alagappan&publication_year=2014&hl=en""]",24176997,https://doi.org/10.1183/09031936.00124013, Mahler 2014 {published data only}  ,included,CD012930-bbs2-0009,
CD012930-bib-0040,"Mahler DA, Decramer M, D'Urzo AD, Worth H, White T, Alagappan V, et al. ",Superior lung function with once‐daily QVA149 translates into improvements in patient‐reported breathlessness compared with placebo and tiotropium in COPD patients: the BLAZE study, American Journal of Respiratory and Critical Care Medicine ,2013,187,    ,['citation-journal']," Mahler DA, Decramer M, D'Urzo AD, Worth H, White T, Alagappan V, et al. Superior lung function with once‐daily QVA149 translates into improvements in patient‐reported breathlessness compared with placebo and tiotropium in COPD patients: the BLAZE study.  American Journal of Respiratory and Critical Care Medicine 2013;187:A6070. CENTRAL    Google Scholar     ","['', ""https://scholar.google.com/scholar_lookup?title=Superior+lung+function+with+once‐daily+QVA149+translates+into+improvements+in+patient‐reported+breathlessness+compared+with+placebo+and+tiotropium+in+COPD+patients:+the+BLAZE+study+&author=DA+Mahler&author=M+Decramer&author=AD+D'Urzo&author=H+Worth&author=T+White&author=V+Alagappan&publication_year=2013&hl=en""]",,, Mahler 2014 {published data only}  ,included,CD012930-bbs2-0009,
CD012930-bib-0041,"Maltais F, Galdiz Iturri JB, Kirsten A, Singh D, Hamilton A, Tetzlaff K, et al. ",Effects of 12 weeks of once‐daily tiotropium and olodaterol fixed‐dose combination on exercise endurance in patients with COPD, European Respiratory Journal ,2014,44,    ,['citation-journal']," Maltais F, Galdiz Iturri JB, Kirsten A, Singh D, Hamilton A, Tetzlaff K, et al. Effects of 12 weeks of once‐daily tiotropium and olodaterol fixed‐dose combination on exercise endurance in patients with COPD.  European Respiratory Journal 2014;44:P283. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Effects+of+12+weeks+of+once‐daily+tiotropium+and+olodaterol+fixed‐dose+combination+on+exercise+endurance+in+patients+with+COPD+&author=F+Maltais&author=JB+GaldizIturri&author=A+Kirsten&author=D+Singh&author=A+Hamilton&author=K+Tetzlaff&publication_year=2014&hl=en']",,, Maltais 2014 {published data only}  ,included,CD012930-bbs2-0010,
CD012930-bib-0042,"Maltais F, Galdiz Iturri JB, Kirsten A, Singh D, Hamilton A, Tetzlaff K, et al. ",Effects of 12 weeks of once‐daily tiotropium and olodaterol fixed‐dose combination on exercise endurance in patients with COPD, Thorax ,2014,69,    ,['citation-journal']," Maltais F, Galdiz Iturri JB, Kirsten A, Singh D, Hamilton A, Tetzlaff K, et al. Effects of 12 weeks of once‐daily tiotropium and olodaterol fixed‐dose combination on exercise endurance in patients with COPD.  Thorax 2014;69:A186‐7. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1136/thoraxjnl-2014-206260.378', 'https://scholar.google.com/scholar_lookup?title=Effects+of+12+weeks+of+once‐daily+tiotropium+and+olodaterol+fixed‐dose+combination+on+exercise+endurance+in+patients+with+COPD+&author=F+Maltais&author=JB+GaldizIturri&author=A+Kirsten&author=D+Singh&author=A+Hamilton&author=K+Tetzlaff&publication_year=2014&hl=en']",,https://doi.org/10.1136/thoraxjnl-2014-206260.378, Maltais 2014 {published data only}  ,included,CD012930-bbs2-0010,
CD012930-bib-0043,"Maltais F, O'Donnell D, Gáldiz Iturri JB, Kirsten AM, Singh D, Hamilton A, et al. ",Effect of 12 weeks of once‐daily tiotropium/olodaterol on exercise endurance during constant work‐rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease, Therapeutic Advances in Respiratory Disease ,2018,12,    ,['citation-journal']," Maltais F, O'Donnell D, Gáldiz Iturri JB, Kirsten AM, Singh D, Hamilton A, et al. Effect of 12 weeks of once‐daily tiotropium/olodaterol on exercise endurance during constant work‐rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease.  Therapeutic Advances in Respiratory Disease 2018;12:1753465818755091. [DOI: 10.1177/1753465818755091]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1177/1753465818755091', 'https://www.ncbi.nlm.nih.gov/pubmed/29439648', ""https://scholar.google.com/scholar_lookup?title=Effect+of+12+weeks+of+once‐daily+tiotropium/olodaterol+on+exercise+endurance+during+constant+work‐rate+cycling+and+endurance+shuttle+walking+in+chronic+obstructive+pulmonary+disease+&author=F+Maltais&author=D+O'Donnell&author=JB+GáldizIturri&author=AM+Kirsten&author=D+Singh&author=A+Hamilton&publication_year=2018&hl=en""]",29439648,https://doi.org/10.1177/1753465818755091, Maltais 2014 {published data only}  ,included,CD012930-bbs2-0010,
CD012930-bib-0044,NCT01525615. ,A study to determine the effect of tiotropium + olodaterol fixed dose combination on exercise endurance time during constant work rate cycle ergometry test in COPD,,,,   ,['citation-other'], NCT01525615. A study to determine the effect of tiotropium + olodaterol fixed dose combination on exercise endurance time during constant work rate cycle ergometry test in COPD. clinicaltrials.gov/ct2/show/NCT01525615 (first received 3 February 2012). CENTRAL    ,[''],,, Maltais 2014 {published data only}  ,included,CD012930-bbs2-0010,
CD012930-bib-0045,"Maltais F, Singh S, Donald A, Church A, Crater G, Goh A, et al. ",Effects of a combination of vilanterol and umeclidinium on exercise endurance in subjects with COPD: two randomised clinical trials,,,,   ,['citation-other']," Maltais F, Singh S, Donald A, Church A, Crater G, Goh A, et al. Effects of a combination of vilanterol and umeclidinium on exercise endurance in subjects with COPD: two randomised clinical trials. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. Vol. 42:145s [P761]. CENTRAL    ",[''],,, Maltais 2014b {published data only}  ,included,CD012930-bbs2-0011,
CD012930-bib-0046,"Maltais F, Singh S, Donald A, Crater G, Church A, Goh A. ","Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: Two randomized, double‐blind clinical trials", Therapeutic Advances in Respiratory Disease ,2016,10,    ,['citation-journal']," Maltais F, Singh S, Donald A, Crater G, Church A, Goh A. Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: Two randomized, double‐blind clinical trials.  Therapeutic Advances in Respiratory Disease 2016;10(3):Erratum in: Therapeutic Advances in Respiratory Disease 2014; 8: 169‐181; 289. [1753‐4666]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Effects+of+a+combination+of+umeclidinium/vilanterol+on+exercise+endurance+in+patients+with+chronic+obstructive+pulmonary+disease:+Two+randomized,+double‐blind+clinical+trials+&author=F+Maltais&author=S+Singh&author=A+Donald&author=G+Crater&author=A+Church&author=A+Goh&publication_year=2016&hl=en']",,, Maltais 2014b {published data only}  ,included,CD012930-bbs2-0011,
CD012930-bib-0047,"Maltais F, Singh S, Donald AC, Crater G, Church A, Goh AH, et al. ","Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double‐blind clinical trials", Therapeutic Advances in Respiratory Disease ,2014,8,    ,['citation-journal']," Maltais F, Singh S, Donald AC, Crater G, Church A, Goh AH, et al. Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double‐blind clinical trials.  Therapeutic Advances in Respiratory Disease 2014;8(6):169‐81. [1753‐4666]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1177/1753465814559209', 'https://www.ncbi.nlm.nih.gov/pubmed/25452426', 'https://scholar.google.com/scholar_lookup?title=Effects+of+a+combination+of+umeclidinium/vilanterol+on+exercise+endurance+in+patients+with+chronic+obstructive+pulmonary+disease:+two+randomized,+double‐blind+clinical+trials+&author=F+Maltais&author=S+Singh&author=AC+Donald&author=G+Crater&author=A+Church&author=AH+Goh&publication_year=2014&hl=en']",25452426,https://doi.org/10.1177/1753465814559209, Maltais 2014b {published data only}  ,included,CD012930-bbs2-0011,
CD012930-bib-0048,"Singh S, Maltais F, Tombs L, Fahy WA, Vahdati‐Bolouri M, Locantore N, et al. ",Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD, International Journal of Chronic Obstructive Pulmonary Disease ,2018,13,    ,['citation-journal']," Singh S, Maltais F, Tombs L, Fahy WA, Vahdati‐Bolouri M, Locantore N, et al. Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD.  International Journal of Chronic Obstructive Pulmonary Disease 2018;13:203‐15. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.2147/COPD.S145285', 'https://www.ncbi.nlm.nih.gov/pubmed/29386889', 'https://scholar.google.com/scholar_lookup?title=Relationship+between+exercise+endurance+and+static+hyperinflation+in+a+post+hoc+analysis+of+two+clinical+trials+in+patients+with+COPD+&author=S+Singh&author=F+Maltais&author=L+Tombs&author=WA+Fahy&author=M+Vahdati‐Bolouri&author=N+Locantore&publication_year=2018&hl=en']",29386889,https://doi.org/10.2147/COPD.S145285, Maltais 2014b {published data only}  ,included,CD012930-bbs2-0011,
CD012930-bib-0049,"Maltais F, Singh S, Donald A, Church A, Crater G, Goh A, et al. ",Effects of a combination of vilanterol and umeclidinium on exercise endurance in subjects with COPD: two randomised clinical trials,,2013,,    ,['citation-other']," Maltais F, Singh S, Donald A, Church A, Crater G, Goh A, et al. Effects of a combination of vilanterol and umeclidinium on exercise endurance in subjects with COPD: two randomised clinical trials. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42:145s [P761]. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Effects+of+a+combination+of+vilanterol+and+umeclidinium+on+exercise+endurance+in+subjects+with+COPD:+two+randomised+clinical+trials+&author=F+Maltais&author=S+Singh&author=A+Donald&author=A+Church&author=G+Crater&author=A+Goh&publication_year=2013&hl=en']",,, Maltais 2014c {published data only}  ,included,CD012930-bbs2-0012,
CD012930-bib-0050,"Maltais F, Singh S, Donald A, Crater G, Church A, Goh A. ","Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double‐blind clinical trials", Therapeutic Advances in Respiratory Disease ,2016,10,    ,['citation-journal']," Maltais F, Singh S, Donald A, Crater G, Church A, Goh A. Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double‐blind clinical trials.  Therapeutic Advances in Respiratory Disease 2016;10(3):Erratum in: Therapeutic Advances in Respiratory Disease 2014; 8: 169‐181; 289. [1753‐4666]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Effects+of+a+combination+of+umeclidinium/vilanterol+on+exercise+endurance+in+patients+with+chronic+obstructive+pulmonary+disease:+two+randomized,+double‐blind+clinical+trials+&author=F+Maltais&author=S+Singh&author=A+Donald&author=G+Crater&author=A+Church&author=A+Goh&publication_year=2016&hl=en']",,, Maltais 2014c {published data only}  ,included,CD012930-bbs2-0012,
CD012930-bib-0051,"Maltais F, Singh S, Donald AC, Crater G, Church A, Goh AH, et al. ","Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double‐blind clinical trials", Therapeutic Advances in Respiratory Disease ,2014,8,    ,['citation-journal']," Maltais F, Singh S, Donald AC, Crater G, Church A, Goh AH, et al. Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double‐blind clinical trials.  Therapeutic Advances in Respiratory Disease 2014;8(6):169‐81. [1753‐4666]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1177/1753465814559209', 'https://www.ncbi.nlm.nih.gov/pubmed/25452426', 'https://scholar.google.com/scholar_lookup?title=Effects+of+a+combination+of+umeclidinium/vilanterol+on+exercise+endurance+in+patients+with+chronic+obstructive+pulmonary+disease:+two+randomized,+double‐blind+clinical+trials+&author=F+Maltais&author=S+Singh&author=AC+Donald&author=G+Crater&author=A+Church&author=AH+Goh&publication_year=2014&hl=en']",25452426,https://doi.org/10.1177/1753465814559209, Maltais 2014c {published data only}  ,included,CD012930-bbs2-0012,
CD012930-bib-0052,"Singh S, Maltais F, Tombs L, Fahy WA, Vahdati‐Bolouri M, Locantore N, et al. ",Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD, International Journal of Chronic Obstructive Pulmonary Disease ,2018,13,    ,['citation-journal']," Singh S, Maltais F, Tombs L, Fahy WA, Vahdati‐Bolouri M, Locantore N, et al. Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD.  International Journal of Chronic Obstructive Pulmonary Disease 2018;13:203‐15. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.2147/COPD.S145285', 'https://www.ncbi.nlm.nih.gov/pubmed/29386889', 'https://scholar.google.com/scholar_lookup?title=Relationship+between+exercise+endurance+and+static+hyperinflation+in+a+post+hoc+analysis+of+two+clinical+trials+in+patients+with+COPD+&author=S+Singh&author=F+Maltais&author=L+Tombs&author=WA+Fahy&author=M+Vahdati‐Bolouri&author=N+Locantore&publication_year=2018&hl=en']",29386889,https://doi.org/10.2147/COPD.S145285, Maltais 2014c {published data only}  ,included,CD012930-bbs2-0012,
CD012930-bib-0053,NCT00626522. ,Aclidinium/formoterol fixed combination dose finding study,,,,   ,['citation-other'], NCT00626522. Aclidinium/formoterol fixed combination dose finding study. clinicaltrials.gov/ct2/show/NCT00626522 (first received 29 February 2008). CENTRAL    ,[''],,, NCT00626522 {published data only}  ,included,CD012930-bbs2-0013,
CD012930-bib-0054,NCT02275052. ,"A randomized, double‐blind, placebo‐controlled evaluation of the effect of the combination of umeclidinium and vilanterol on exercise endurance time in subjects with COPD",,,,   ,['citation-other']," NCT02275052. A randomized, double‐blind, placebo‐controlled evaluation of the effect of the combination of umeclidinium and vilanterol on exercise endurance time in subjects with COPD. clinicaltrials.gov/ct2/show/NCT02275052 (first received 27 October 2014). CENTRAL    ",[''],,, NCT02275052 {published data only}  ,included,CD012930-bbs2-0014,
CD012930-bib-0055,NCT01533922. ,Effect on exercise endurance and lung hyperinflation of tiotropium + olodaterol in COPD patients,,,,   ,['citation-other'], NCT01533922. Effect on exercise endurance and lung hyperinflation of tiotropium + olodaterol in COPD patients. clinicaltrials.gov/ct2/show/NCT01533922 (first received 16 February 2012). CENTRAL    ,[''],,, O'Donnell 2015a {published data only}  ,included,CD012930-bbs2-0015,
CD012930-bib-0056,NCT01533935. ,Effect on exercise endurance and lung hyperinflation of tiotropium + olodaterol in COPD patients,,,,   ,['citation-other'], NCT01533935. Effect on exercise endurance and lung hyperinflation of tiotropium + olodaterol in COPD patients. clinicaltrials.gov/ct2/show/NCT01533935 (first received 16 February 2012). CENTRAL    ,[''],,, O'Donnell 2015a {published data only}  ,included,CD012930-bbs2-0015,
CD012930-bib-0057,"O'Donnell D, Casaburi R, De Sousa D, Xue W, Frith P, Hamilton A, et al. ",Effects of 6 weeks' treatment with once‐daily tiotropium and olodaterol fixed‐dose combination on inspiratory capacity and exercise endurance in patients with COPD: the MORACTOTM studies, American Journal of Respiratory and Critical Care Medicine ,2015,191,    ,['citation-journal']," O'Donnell D, Casaburi R, De Sousa D, Xue W, Frith P, Hamilton A, et al. Effects of 6 weeks' treatment with once‐daily tiotropium and olodaterol fixed‐dose combination on inspiratory capacity and exercise endurance in patients with COPD: the MORACTOTM studies.  American Journal of Respiratory and Critical Care Medicine 2015;191:A3972. CENTRAL    Google Scholar     ","['', ""https://scholar.google.com/scholar_lookup?title=Effects+of+6+weeks'+treatment+with+once‐daily+tiotropium+and+olodaterol+fixed‐dose+combination+on+inspiratory+capacity+and+exercise+endurance+in+patients+with+COPD:+the+MORACTOTM+studies+&author=D+O'Donnell&author=R+Casaburi&author=D+Sousa&author=W+Xue&author=P+Frith&author=A+Hamilton&publication_year=2015&hl=en""]",,, O'Donnell 2015a {published data only}  ,included,CD012930-bbs2-0015,
CD012930-bib-0058,"O'Donnell DE, Casaburi R, Frith P, Kirsten A, De Sousa D, Hamilton A, et al. ",Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD, European Respiratory Journal ,2017,49,    ,['citation-journal']," O'Donnell DE, Casaburi R, Frith P, Kirsten A, De Sousa D, Hamilton A, et al. Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD.  European Respiratory Journal 2017;49(4):1601348. [DOI: 10.1183/13993003.01348‐2016]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1183/13993003.01348-2016', 'https://www.ncbi.nlm.nih.gov/pubmed/28424359', ""https://scholar.google.com/scholar_lookup?title=Effects+of+combined+tiotropium/olodaterol+on+inspiratory+capacity+and+exercise+endurance+in+COPD+&author=DE+O'Donnell&author=R+Casaburi&author=P+Frith&author=A+Kirsten&author=D+Sousa&author=A+Hamilton&publication_year=2017&hl=en""]",28424359,https://doi.org/10.1183/13993003.01348-2016, O'Donnell 2015a {published data only}  ,included,CD012930-bbs2-0015,
CD012930-bib-0059,NCT01533922. ,Effect on exercise endurance and lung hyperinflation of tiotropium + olodaterol in COPD patients,,,,   ,['citation-other'], NCT01533922. Effect on exercise endurance and lung hyperinflation of tiotropium + olodaterol in COPD patients. clinicaltrials.gov/ct2/show/NCT01533922 (first received 16 February 2012). CENTRAL    ,[''],,, O'Donnell 2015b {published data only}  ,included,CD012930-bbs2-0016,
CD012930-bib-0060,NCT01533935. ,Effect on exercise endurance and lung hyperinflation of tiotropium + olodaterol in COPD patients,,,,   ,['citation-other'], NCT01533935. Effect on exercise endurance and lung hyperinflation of tiotropium + olodaterol in COPD patients. clinicaltrials.gov/ct2/show/NCT01533935 (first received 16 February 2012). CENTRAL    ,[''],,, O'Donnell 2015b {published data only}  ,included,CD012930-bbs2-0016,
CD012930-bib-0061,"O'Donnell D, Casaburi R, De Sousa D, Xue W, Frith P, Hamilton A, et al. ",Effects of 6 weeks' treatment with once‐daily tiotropium and olodaterol fixed‐dose combination on inspiratory capacity and exercise endurance in patients with COPD: the MORACTOTM studies, American Journal of Respiratory and Critical Care Medicine ,2015,191,    ,['citation-journal']," O'Donnell D, Casaburi R, De Sousa D, Xue W, Frith P, Hamilton A, et al. Effects of 6 weeks' treatment with once‐daily tiotropium and olodaterol fixed‐dose combination on inspiratory capacity and exercise endurance in patients with COPD: the MORACTOTM studies.  American Journal of Respiratory and Critical Care Medicine 2015;191:A3972. CENTRAL    Google Scholar     ","['', ""https://scholar.google.com/scholar_lookup?title=Effects+of+6+weeks'+treatment+with+once‐daily+tiotropium+and+olodaterol+fixed‐dose+combination+on+inspiratory+capacity+and+exercise+endurance+in+patients+with+COPD:+the+MORACTOTM+studies+&author=D+O'Donnell&author=R+Casaburi&author=D+Sousa&author=W+Xue&author=P+Frith&author=A+Hamilton&publication_year=2015&hl=en""]",,, O'Donnell 2015b {published data only}  ,included,CD012930-bbs2-0016,
CD012930-bib-0062,"O'Donnell DE, Casaburi R, Frith P, Kirsten A, De Sousa D, Hamilton A, et al. ",Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD, European Respiratory Journal ,2017,49,    ,['citation-journal']," O'Donnell DE, Casaburi R, Frith P, Kirsten A, De Sousa D, Hamilton A, et al. Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD.  European Respiratory Journal 2017;49(4):pii 1601348. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1183/13993003.01348-2016', ""https://scholar.google.com/scholar_lookup?title=Effects+of+combined+tiotropium/olodaterol+on+inspiratory+capacity+and+exercise+endurance+in+COPD+&author=DE+O'Donnell&author=R+Casaburi&author=P+Frith&author=A+Kirsten&author=D+Sousa&author=A+Hamilton&publication_year=2017&hl=en""]",,https://doi.org/10.1183/13993003.01348-2016, O'Donnell 2015b {published data only}  ,included,CD012930-bbs2-0016,
CD012930-bib-0063,NCT02152605. ,A phase IIIb study to evaluate the efficacy of umeclidinium/vilanterol (UMEC/VI) in subjects with chronic obstructive pulmonary disease (COPD),,,,   ,['citation-other'], NCT02152605. A phase IIIb study to evaluate the efficacy of umeclidinium/vilanterol (UMEC/VI) in subjects with chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT02152605 (first received 2 June 2014). CENTRAL    ,[''],,, Siler 2016 {published data only}  ,included,CD012930-bbs2-0017,
CD012930-bib-0064,"Siler TM, Donald AC, O'Dell D, Church A, Fahy WA. ","A randomized, parallel‐group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 mug on health‐related quality of life in patients with COPD", International Journal of Chronic Obstructive Pulmonary Disease ,2016,11,    ,['citation-journal']," Siler TM, Donald AC, O'Dell D, Church A, Fahy WA. A randomized, parallel‐group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 mug on health‐related quality of life in patients with COPD.  International Journal of Chronic Obstructive Pulmonary Disease 2016;11(1):971‐9. [1178‐2005]CENTRAL    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/27274218', ""https://scholar.google.com/scholar_lookup?title=A+randomized,+parallel‐group+study+to+evaluate+the+efficacy+of+umeclidinium/vilanterol+62.5/25+mug+on+health‐related+quality+of+life+in+patients+with+COPD+&author=TM+Siler&author=AC+Donald&author=D+O'Dell&author=A+Church&author=WA+Fahy&publication_year=2016&hl=en""]",27274218,, Siler 2016 {published data only}  ,included,CD012930-bbs2-0017,
CD012930-bib-0065,NCT01964352. ,Tiotropium + olodaterol fixed dose combination (FDC) in chronic obstructive pulmonary disease (OTEMTO 1),,,,   ,['citation-other'], NCT01964352. Tiotropium + olodaterol fixed dose combination (FDC) in chronic obstructive pulmonary disease (OTEMTO 1). clinicaltrials.gov/ct2/show/NCT01964352 (first received 17 October 2013). CENTRAL    ,[''],,, Singh 2016a {published data only}  ,included,CD012930-bbs2-0018,
CD012930-bib-0066,NCT02006732. ,Tiotropium + olodaterol fixed dose combination (FDC) in chronic obstructive pulmonary disease (OTEMTO 2),,,,   ,['citation-other'], NCT02006732. Tiotropium + olodaterol fixed dose combination (FDC) in chronic obstructive pulmonary disease (OTEMTO 2). clinicaltrials.gov/ct2/show/NCT02006732 (first received 10 December 2013). CENTRAL    ,[''],,, Singh 2016a {published data only}  ,included,CD012930-bbs2-0018,
CD012930-bib-0068,"Singh D, Ferguson GT, Bolitschek J, Gronke L, Hallmann C, Bennett N, et al. ",Tiotropium + olodaterol fixed‐dose combination shows clinically meaningful improvements in quality of life versus placebo, European Respiratory Journal ,2015,46,    ,['citation-journal']," Singh D, Ferguson GT, Bolitschek J, Gronke L, Hallmann C, Bennett N, et al. Tiotropium + olodaterol fixed‐dose combination shows clinically meaningful improvements in quality of life versus placebo.  European Respiratory Journal 2015;46:PA2958. [DOI: 10.1183/13993003.congress‐2015.PA2958]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Tiotropium+++olodaterol+fixed‐dose+combination+shows+clinically+meaningful+improvements+in+quality+of+life+versus+placebo+&author=D+Singh&author=GT+Ferguson&author=J+Bolitschek&author=L+Gronke&author=C+Hallmann&author=N+Bennett&publication_year=2015&hl=en']",,, Singh 2016a {published data only}  ,included,CD012930-bbs2-0018,
CD012930-bib-0069,"Singh D, Ferguson GT, Bolitschek J, Gronke L, Hallmann C, Bennett N, et al. ",Tiotropium + olodaterol shows clinically meaningful improvements in quality of life, Respiratory Medicine ,2015,109,    ,['citation-journal']," Singh D, Ferguson GT, Bolitschek J, Gronke L, Hallmann C, Bennett N, et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life.  Respiratory Medicine 2015;109(10):1312‐9. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.rmed.2015.08.002', 'https://www.ncbi.nlm.nih.gov/pubmed/26320402', 'https://scholar.google.com/scholar_lookup?title=Tiotropium+++olodaterol+shows+clinically+meaningful+improvements+in+quality+of+life&author=D+Singh&author=GT+Ferguson&author=J+Bolitschek&author=L+Gronke&author=C+Hallmann&author=N+Bennett&publication_year=2015&hl=en']",26320402,https://doi.org/10.1016/j.rmed.2015.08.002, Singh 2016a {published data only}  ,included,CD012930-bbs2-0018,
CD012930-bib-0067,"Singh D, Ferguson GT, Bolitschek J, Grönke L, Hallmann C, Bennett N, et al. ",Tiotropium + olodaterol shows clinically meaningful improvements in quality of life versus placebo, Primary Care Respiratory Medicine ,2016,26,    ,['citation-journal']," Singh D, Ferguson GT, Bolitschek J, Grönke L, Hallmann C, Bennett N, et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life versus placebo.  Primary Care Respiratory Medicine 2016;26:21‐CR050. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Tiotropium+++olodaterol+shows+clinically+meaningful+improvements+in+quality+of+life+versus+placebo+&author=D+Singh&author=GT+Ferguson&author=J+Bolitschek&author=L+Grönke&author=C+Hallmann&author=N+Bennett&publication_year=2016&hl=en']",,, Singh 2016a {published data only}  ,included,CD012930-bbs2-0018,
CD012930-bib-0070,"Singh D, Gaga M, Schmidt O, Bjermer L, Gronke L, Voss F, et al. ",Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO(R) studies, Respiratory Research ,2016,17,    ,['citation-journal']," Singh D, Gaga M, Schmidt O, Bjermer L, Gronke L, Voss F, et al. Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO(R) studies.  Respiratory Research 2016;17(1):73. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1186/s12931-016-0387-7', 'https://www.ncbi.nlm.nih.gov/pubmed/27316465', 'https://scholar.google.com/scholar_lookup?title=Effects+of+tiotropium+++olodaterol+versus+tiotropium+or+placebo+by+COPD+disease+severity+and+previous+treatment+history+in+the+OTEMTO(R)+studies+&author=D+Singh&author=M+Gaga&author=O+Schmidt&author=L+Bjermer&author=L+Gronke&author=F+Voss&publication_year=2016&hl=en']",27316465,https://doi.org/10.1186/s12931-016-0387-7, Singh 2016a {published data only}  ,included,CD012930-bbs2-0018,
CD012930-bib-0071,"Singh D, Maleki‐Yazdi MR, Tombs L, Iqbal A, Fahy WA, Naya I. ",Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol, International Journal of Chronic Obstructive Pulmonary Disease ,2016,11,    ,['citation-journal']," Singh D, Maleki‐Yazdi MR, Tombs L, Iqbal A, Fahy WA, Naya I. Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol.  International Journal of Chronic Obstructive Pulmonary Disease 2016;11(1):1413‐24. [1178‐2005]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.2147/COPD.S101612', 'https://www.ncbi.nlm.nih.gov/pubmed/27445468', 'https://scholar.google.com/scholar_lookup?title=Prevention+of+clinically+important+deteriorations+in+COPD+with+umeclidinium/vilanterol&author=D+Singh&author=MR+Maleki‐Yazdi&author=L+Tombs&author=A+Iqbal&author=WA+Fahy&author=I+Naya&publication_year=2016&hl=en']",27445468,https://doi.org/10.2147/COPD.S101612, Singh 2016a {published data only}  ,included,CD012930-bbs2-0018,
CD012930-bib-0072,NCT01964352. ,Tiotropium + olodaterol fixed dose combination (FDC) in chronic obstructive pulmonary disease (OTEMTO 1),,,,   ,['citation-other'], NCT01964352. Tiotropium + olodaterol fixed dose combination (FDC) in chronic obstructive pulmonary disease (OTEMTO 1). clinicaltrials.gov/ct2/show/NCT01964352 (first received 17 October 2013). CENTRAL    ,[''],,, Singh 2016b {published data only}  ,included,CD012930-bbs2-0019,
CD012930-bib-0073,NCT02006732. ,Tiotropium+olodaterol fixed dose combination (FDC) in chronic obstructive pulmonary disease (OTEMTO 2),,,,   ,['citation-other'], NCT02006732. Tiotropium+olodaterol fixed dose combination (FDC) in chronic obstructive pulmonary disease (OTEMTO 2). clinicaltrials.gov/ct2/show/NCT02006732 (first received 10 December 2013). CENTRAL    ,[''],,, Singh 2016b {published data only}  ,included,CD012930-bbs2-0019,
CD012930-bib-0075,"Singh D, Ferguson GT, Bolitschek J, Gronke L, Hallmann C, Bennett N, et al. ",Tiotropium + olodaterol fixed‐dose combination shows clinically meaningful improvements in quality of life versus placebo, European Respiratory Journal ,2015,46,    ,['citation-journal']," Singh D, Ferguson GT, Bolitschek J, Gronke L, Hallmann C, Bennett N, et al. Tiotropium + olodaterol fixed‐dose combination shows clinically meaningful improvements in quality of life versus placebo.  European Respiratory Journal 2015;46:PA2958. [DOI: 0.1183/13993003.congress‐2015.PA2958]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Tiotropium+++olodaterol+fixed‐dose+combination+shows+clinically+meaningful+improvements+in+quality+of+life+versus+placebo+&author=D+Singh&author=GT+Ferguson&author=J+Bolitschek&author=L+Gronke&author=C+Hallmann&author=N+Bennett&publication_year=2015&hl=en']",,, Singh 2016b {published data only}  ,included,CD012930-bbs2-0019,
CD012930-bib-0076,"Singh D, Ferguson GT, Bolitschek J, Gronke L, Hallmann C, Bennett N, et al. ",Tiotropium + olodaterol shows clinically meaningful improvements in quality of life, Respiratory Medicine ,2015,109,    ,['citation-journal']," Singh D, Ferguson GT, Bolitschek J, Gronke L, Hallmann C, Bennett N, et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life.  Respiratory Medicine 2015;109(10):1312‐9. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.rmed.2015.08.002', 'https://www.ncbi.nlm.nih.gov/pubmed/26320402', 'https://scholar.google.com/scholar_lookup?title=Tiotropium+++olodaterol+shows+clinically+meaningful+improvements+in+quality+of+life&author=D+Singh&author=GT+Ferguson&author=J+Bolitschek&author=L+Gronke&author=C+Hallmann&author=N+Bennett&publication_year=2015&hl=en']",26320402,https://doi.org/10.1016/j.rmed.2015.08.002, Singh 2016b {published data only}  ,included,CD012930-bbs2-0019,
CD012930-bib-0074,"Singh D, Ferguson GT, Bolitschek J, Grönke L, Hallmann C, Bennett N, et al. ",Tiotropium + olodaterol shows clinically meaningful improvements in quality of life versus placebo, Primary Care Respiratory Medicine ,2016,26,    ,['citation-journal']," Singh D, Ferguson GT, Bolitschek J, Grönke L, Hallmann C, Bennett N, et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life versus placebo.  Primary Care Respiratory Medicine 2016;26(16022):21‐CR050. [ES:2055‐1010: IL:2055‐1010]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Tiotropium+++olodaterol+shows+clinically+meaningful+improvements+in+quality+of+life+versus+placebo+&author=D+Singh&author=GT+Ferguson&author=J+Bolitschek&author=L+Grönke&author=C+Hallmann&author=N+Bennett&publication_year=2016&hl=en']",,, Singh 2016b {published data only}  ,included,CD012930-bbs2-0019,
CD012930-bib-0077,"Singh D, Gaga M, Schmidt O, Bjermer L, Gronke L, Voss F, et al. ",Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO(R) studies, Respiratory Research ,2016,17,    ,['citation-journal']," Singh D, Gaga M, Schmidt O, Bjermer L, Gronke L, Voss F, et al. Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO(R) studies.  Respiratory Research 2016;17(1):73. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1186/s12931-016-0387-7', 'https://www.ncbi.nlm.nih.gov/pubmed/27316465', 'https://scholar.google.com/scholar_lookup?title=Effects+of+tiotropium+++olodaterol+versus+tiotropium+or+placebo+by+COPD+disease+severity+and+previous+treatment+history+in+the+OTEMTO(R)+studies+&author=D+Singh&author=M+Gaga&author=O+Schmidt&author=L+Bjermer&author=L+Gronke&author=F+Voss&publication_year=2016&hl=en']",27316465,https://doi.org/10.1186/s12931-016-0387-7, Singh 2016b {published data only}  ,included,CD012930-bbs2-0019,
CD012930-bib-0078,"Singh D, Maleki‐Yazdi MR, Tombs L, Iqbal A, Fahy WA, Naya I. ",Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol, International Journal of Chronic Obstructive Pulmonary Disease ,2016,11,    ,['citation-journal']," Singh D, Maleki‐Yazdi MR, Tombs L, Iqbal A, Fahy WA, Naya I. Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol.  International Journal of Chronic Obstructive Pulmonary Disease 2016;11(1):1413‐24. [1178‐2005]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.2147/COPD.S101612', 'https://www.ncbi.nlm.nih.gov/pubmed/27445468', 'https://scholar.google.com/scholar_lookup?title=Prevention+of+clinically+important+deteriorations+in+COPD+with+umeclidinium/vilanterol&author=D+Singh&author=MR+Maleki‐Yazdi&author=L+Tombs&author=A+Iqbal&author=WA+Fahy&author=I+Naya&publication_year=2016&hl=en']",27445468,https://doi.org/10.2147/COPD.S101612, Singh 2016b {published data only}  ,included,CD012930-bbs2-0019,
CD012930-bib-0079,"Bourbeau J, Lavoie KL, Sedeno M, De Sousa D, Erzen D, Hamilton A, et al. ","Behaviour‐change intervention in a multicentre, randomised, placebo‐controlled COPD study: methodological considerations and implementation", BMJ Open ,2016,6,    ,['citation-journal']," Bourbeau J, Lavoie KL, Sedeno M, De Sousa D, Erzen D, Hamilton A, et al. Behaviour‐change intervention in a multicentre, randomised, placebo‐controlled COPD study: methodological considerations and implementation.  BMJ Open 2016;6(4):e010109. [2044‐6055]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1136/bmjopen-2015-010109', 'https://www.ncbi.nlm.nih.gov/pubmed/27044576', 'https://scholar.google.com/scholar_lookup?title=Behaviour‐change+intervention+in+a+multicentre,+randomised,+placebo‐controlled+COPD+study:+methodological+considerations+and+implementation+&author=J+Bourbeau&author=KL+Lavoie&author=M+Sedeno&author=D+Sousa&author=D+Erzen&author=A+Hamilton&publication_year=2016&hl=en']",27044576,https://doi.org/10.1136/bmjopen-2015-010109, Troosters 2016 {published data only}  ,included,CD012930-bbs2-0020,
CD012930-bib-0080,"Lavoie K, Sedeno M, Li P, Troosters T, Hamilton A, De Sousa D, et al. ",Effects of bronchodilator therapy and exercise with self‐management behaviour‐modification on psychological and cognitive outcomes in COPD, European Respiratory Journal ,2017,50,    ,['citation-journal']," Lavoie K, Sedeno M, Li P, Troosters T, Hamilton A, De Sousa D, et al. Effects of bronchodilator therapy and exercise with self‐management behaviour‐modification on psychological and cognitive outcomes in COPD.  European Respiratory Journal 2017;50:OA4669. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Effects+of+bronchodilator+therapy+and+exercise+with+self‐management+behaviour‐modification+on+psychological+and+cognitive+outcomes+in+COPD+&author=K+Lavoie&author=M+Sedeno&author=P+Li&author=T+Troosters&author=A+Hamilton&author=D+Sousa&publication_year=2017&hl=en']",,, Troosters 2016 {published data only}  ,included,CD012930-bbs2-0020,
CD012930-bib-0081,NCT02085161. ,To evaluate the effect of inhaled medication together with exercise and activity training on exercise capacity and daily activities in patients with chronic lung disease with obstruction of airways,,,,   ,['citation-other'], NCT02085161. To evaluate the effect of inhaled medication together with exercise and activity training on exercise capacity and daily activities in patients with chronic lung disease with obstruction of airways. clinicaltrials.gov/ct2/show/NCT02085161 (first received 12 March 2014). CENTRAL    ,[''],,, Troosters 2016 {published data only}  ,included,CD012930-bbs2-0020,
CD012930-bib-0082,"Troosters T, Bourbeau J, Maltais F, Leidy N, Erzen D, De Sousa D, et al. ","Effect of 8 and 12 weeks' once‐daily tiotropium and olodaterol, alone and combined with exercise training, on exercise endurance during walking in patients with COPD", Pneumologie ,2017,71,    ,['citation-journal']," Troosters T, Bourbeau J, Maltais F, Leidy N, Erzen D, De Sousa D, et al. Effect of 8 and 12 weeks' once‐daily tiotropium and olodaterol, alone and combined with exercise training, on exercise endurance during walking in patients with COPD.  Pneumologie 2017;71(1):159‐60. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1055/s-0037-1598307', ""https://scholar.google.com/scholar_lookup?title=Effect+of+8+and+12+weeks'+once‐daily+tiotropium+and+olodaterol,+alone+and+combined+with+exercise+training,+on+exercise+endurance+during+walking+in+patients+with+COPD+&author=T+Troosters&author=J+Bourbeau&author=F+Maltais&author=N+Leidy&author=D+Erzen&author=D+Sousa&publication_year=2017&hl=en""]",,https://doi.org/10.1055/s-0037-1598307, Troosters 2016 {published data only}  ,included,CD012930-bbs2-0020,
CD012930-bib-0083,"Troosters T, Bourbeau J, Maltais F, Leidy N, Erzen D, De Sousa D, et al. ","Enhancing exercise tolerance and physical activity in COPD with combined pharmacological and non‐pharmacological interventions: PHYSACTO randomised, placebo‐controlled study design", BMJ Open ,2016,6,    ,['citation-journal']," Troosters T, Bourbeau J, Maltais F, Leidy N, Erzen D, De Sousa D, et al. Enhancing exercise tolerance and physical activity in COPD with combined pharmacological and non‐pharmacological interventions: PHYSACTO randomised, placebo‐controlled study design.  BMJ Open 2016;6(4):e010106. [2044‐6055]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1136/bmjopen-2015-010106', 'https://www.ncbi.nlm.nih.gov/pubmed/27075841', 'https://scholar.google.com/scholar_lookup?title=Enhancing+exercise+tolerance+and+physical+activity+in+COPD+with+combined+pharmacological+and+non‐pharmacological+interventions:+PHYSACTO+randomised,+placebo‐controlled+study+design+&author=T+Troosters&author=J+Bourbeau&author=F+Maltais&author=N+Leidy&author=D+Erzen&author=D+Sousa&publication_year=2016&hl=en']",27075841,https://doi.org/10.1136/bmjopen-2015-010106, Troosters 2016 {published data only}  ,included,CD012930-bbs2-0020,
CD012930-bib-0084,"Troosters T, Maltais F, Leidy N, Lavoie KL, Sedeno M, Janssens W, et al. ",Effect of bronchodilation and exercise training with behavior modification on exercise tolerance and downstream effects on symptoms and physical activity in COPD, American Journal of Respiratory and Critical Care Medicine ,2018,198,    ,['citation-journal']," Troosters T, Maltais F, Leidy N, Lavoie KL, Sedeno M, Janssens W, et al. Effect of bronchodilation and exercise training with behavior modification on exercise tolerance and downstream effects on symptoms and physical activity in COPD.  American Journal of Respiratory and Critical Care Medicine 2018;198:1021‐32. [DOI: 10.1164/rccm.201706‐1288OC]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1164/rccm.201706-1288OC', 'https://www.ncbi.nlm.nih.gov/pubmed/29664681', 'https://scholar.google.com/scholar_lookup?title=Effect+of+bronchodilation+and+exercise+training+with+behavior+modification+on+exercise+tolerance+and+downstream+effects+on+symptoms+and+physical+activity+in+COPD+&author=T+Troosters&author=F+Maltais&author=N+Leidy&author=KL+Lavoie&author=M+Sedeno&author=W+Janssens&publication_year=2018&hl=en']",29664681,https://doi.org/10.1164/rccm.201706-1288OC, Troosters 2016 {published data only}  ,included,CD012930-bbs2-0020,
CD012930-bib-0085,"Watz H, Mailaender C, Kirsten AM. ",Effects of indacaterol/glycopyrronium on lung function and physical activity in patients with moderate to severe COPD, Thorax ,2015,70,    ,['citation-journal']," Watz H, Mailaender C, Kirsten AM. Effects of indacaterol/glycopyrronium on lung function and physical activity in patients with moderate to severe COPD.  Thorax 2015;70:A146‐7. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1136/thoraxjnl-2015-207770.277', 'https://scholar.google.com/scholar_lookup?title=Effects+of+indacaterol/glycopyrronium+on+lung+function+and+physical+activity+in+patients+with+moderate+to+severe+COPD+&author=H+Watz&author=C+Mailaender&author=AM+Kirsten&publication_year=2015&hl=en']",,https://doi.org/10.1136/thoraxjnl-2015-207770.277, Watz 2016 {published data only}  ,included,CD012930-bbs2-0021,
CD012930-bib-0086,"Watz H, Mailander C, Baier M, Kirsten A. ","Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo‐controlled, crossover study (the MOVE Study)", BMC Pulmonary Medicine ,2016,16,    ,['citation-journal']," Watz H, Mailander C, Baier M, Kirsten A. Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo‐controlled, crossover study (the MOVE Study).  BMC Pulmonary Medicine 2016;16(1):95. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1186/s12890-016-0256-7', 'https://www.ncbi.nlm.nih.gov/pubmed/27301417', 'https://scholar.google.com/scholar_lookup?title=Effects+of+indacaterol/glycopyrronium+(QVA149)+on+lung+hyperinflation+and+physical+activity+in+patients+with+moderate+to+severe+COPD:+a+randomised,+placebo‐controlled,+crossover+study+(the+MOVE+Study)+&author=H+Watz&author=C+Mailander&author=M+Baier&author=A+Kirsten&publication_year=2016&hl=en']",27301417,https://doi.org/10.1186/s12890-016-0256-7, Watz 2016 {published data only}  ,included,CD012930-bbs2-0021,
CD012930-bib-0087,"Zheng J, Zhong N, Newlands A, Church A, Goh AH. ","Efficacy and safety of once‐daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo‐controlled study", International Journal of Chronic Obstructive Pulmonary Disease ,2015,10,    ,['citation-journal']," Zheng J, Zhong N, Newlands A, Church A, Goh AH. Efficacy and safety of once‐daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo‐controlled study.  International Journal of Chronic Obstructive Pulmonary Disease 2015;10(1):1753‐67. [1178‐2005]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.2147/COPD.S81053', 'https://www.ncbi.nlm.nih.gov/pubmed/26366068', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+once‐daily+inhaled+umeclidinium/vilanterol+in+Asian+patients+with+COPD:+results+from+a+randomized,+placebo‐controlled+study+&author=J+Zheng&author=N+Zhong&author=A+Newlands&author=A+Church&author=AH+Goh&publication_year=2015&hl=en']",26366068,https://doi.org/10.2147/COPD.S81053, Zheng 2014 {published data only}  ,included,CD012930-bbs2-0022,
CD012930-bib-0088,"Zheng JP, Newlands AH, Church A, Goh AH. ",The efficacy and safety of inhaled umeclidinium bromide/vilanterol in Asian patients with chronic obstructive pulmonary disease, Respirology ,2014,19,    ,['citation-journal']," Zheng JP, Newlands AH, Church A, Goh AH. The efficacy and safety of inhaled umeclidinium bromide/vilanterol in Asian patients with chronic obstructive pulmonary disease.  Respirology 2014;19:22. CENTRAL    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/24256183', 'https://scholar.google.com/scholar_lookup?title=The+efficacy+and+safety+of+inhaled+umeclidinium+bromide/vilanterol+in+Asian+patients+with+chronic+obstructive+pulmonary+disease+&author=JP+Zheng&author=AH+Newlands&author=A+Church&author=AH+Goh&publication_year=2014&hl=en']",24256183,, Zheng 2014 {published data only}  ,included,CD012930-bbs2-0022,
CD012930-bib-0089,"Aalbers R, Maleki‐Yazdi M, Hamilton A, Waitere‐Wijker S, Zhao Y, Amatto V, et al. ","Randomized, double‐blind, dose‐finding study for tiotropium when added to olodaterol, administered via the Respimat(R) inhaler in patients with chronic obstructive pulmonary disease", Advances in Therapy ,2015,32,    ,['citation-journal']," Aalbers R, Maleki‐Yazdi M, Hamilton A, Waitere‐Wijker S, Zhao Y, Amatto V, et al. Randomized, double‐blind, dose‐finding study for tiotropium when added to olodaterol, administered via the Respimat(R) inhaler in patients with chronic obstructive pulmonary disease.  Advances in Therapy 2015;32(9):809‐22. [0741‐238X]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1007/s12325-015-0239-8', 'https://www.ncbi.nlm.nih.gov/pubmed/26404912', 'https://scholar.google.com/scholar_lookup?title=Randomized,+double‐blind,+dose‐finding+study+for+tiotropium+when+added+to+olodaterol,+administered+via+the+Respimat(R)+inhaler+in+patients+with+chronic+obstructive+pulmonary+disease+&author=R+Aalbers&author=M+Maleki‐Yazdi&author=A+Hamilton&author=S+Waitere‐Wijker&author=Y+Zhao&author=V+Amatto&publication_year=2015&hl=en']",26404912,https://doi.org/10.1007/s12325-015-0239-8, Aalbers 2015 {published data only}  ,excluded,CD012930-bbs2-0023, Wrong intervention (combination inhaler not used) 
CD012930-bib-0090,"Aalbers R, Reza Maleki‐Yazdi M, Hamilton A, Waitere‐Wijker S, Pivovarova A, Schmidt O, et al. ",Dose‐finding study for tiotropium and olodaterol when administered in combination via the Respimat inhaler in patients with COPD [Abstract], European Respiratory Journal ,2012,40,    ,['citation-journal']," Aalbers R, Reza Maleki‐Yazdi M, Hamilton A, Waitere‐Wijker S, Pivovarova A, Schmidt O, et al. Dose‐finding study for tiotropium and olodaterol when administered in combination via the Respimat inhaler in patients with COPD [Abstract].  European Respiratory Journal 2012;40:525s [P2882]. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Dose‐finding+study+for+tiotropium+and+olodaterol+when+administered+in+combination+via+the+Respimat+inhaler+in+patients+with+COPD+[Abstract]+&author=R+Aalbers&author=M+RezaMaleki‐Yazdi&author=A+Hamilton&author=S+Waitere‐Wijker&author=A+Pivovarova&author=O+Schmidt&publication_year=2012&hl=en']",,, Aalbers 2015 {published data only}  ,excluded,CD012930-bbs2-0023, Wrong intervention (combination inhaler not used) 
CD012930-bib-0091,NCT01040403. ,Determining optimal free dose combination of tiotropium bromide and BI 1744 CL in chronic obstructive pulmonary disease (COPD),,,,   ,['citation-other'], NCT01040403. Determining optimal free dose combination of tiotropium bromide and BI 1744 CL in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01040403 (first received 29 December 2009). CENTRAL    ,[''],,, Aalbers 2015 {published data only}  ,excluded,CD012930-bbs2-0023, Wrong intervention (combination inhaler not used) 
CD012930-bib-0092,"Asai K, Hirata K, Hashimoto S, Fukuchi Y, Kitawaki T, Ikeda K, et al. ",Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: pooled analysis of SHINE and ARISE, Respiratory Investigation ,2016,54,    ,['citation-journal']," Asai K, Hirata K, Hashimoto S, Fukuchi Y, Kitawaki T, Ikeda K, et al. Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: pooled analysis of SHINE and ARISE.  Respiratory Investigation 2016;54(6):428‐35. [2212‐5353]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.resinv.2016.06.006', 'https://www.ncbi.nlm.nih.gov/pubmed/27886854', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+indacaterol/glycopyrronium+in+Japanese+patients+with+COPD:+pooled+analysis+of+SHINE+and+ARISE+&author=K+Asai&author=K+Hirata&author=S+Hashimoto&author=Y+Fukuchi&author=T+Kitawaki&author=K+Ikeda&publication_year=2016&hl=en']",27886854,https://doi.org/10.1016/j.resinv.2016.06.006, Asai 2013 {published data only}  ,excluded,CD012930-bbs2-0024, Wrong comparator (different LABA used in control arm) 
CD012930-bib-0093,"Asai K, Minakata Y, Hirata K, Fukuchi Y, Kitawaki T, Ikeda K, et al. ",QVA149 once‐daily is safe and well tolerated and improves lung function and health status in Japanese patients with COPD: the ARISE study,,2013,,    ,['citation-other']," Asai K, Minakata Y, Hirata K, Fukuchi Y, Kitawaki T, Ikeda K, et al. QVA149 once‐daily is safe and well tolerated and improves lung function and health status in Japanese patients with COPD: the ARISE study. European Respiratory Society 23rdAnnual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42:694s [P3392]. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=QVA149+once‐daily+is+safe+and+well+tolerated+and+improves+lung+function+and+health+status+in+Japanese+patients+with+COPD:+the+ARISE+study+&author=K+Asai&author=Y+Minakata&author=K+Hirata&author=Y+Fukuchi&author=T+Kitawaki&author=K+Ikeda&publication_year=2013&hl=en']",,, Asai 2013 {published data only}  ,excluded,CD012930-bbs2-0024, Wrong comparator (different LABA used in control arm) 
CD012930-bib-0094,"Berton D, Reis M, Siqueira A, Barroco A, Takara L, Bravo D. ",Comparative effects of formoterol monotherapy versus formoterol plus tiotropium on dynamic hyperinflation and exercise tolerance in COPD,,2009,,    ,['citation-other']," Berton D, Reis M, Siqueira A, Barroco A, Takara L, Bravo D. Comparative effects of formoterol monotherapy versus formoterol plus tiotropium on dynamic hyperinflation and exercise tolerance in COPD. European Respiratory Society 19th Annual Congress; 2009 Sep 12‐15; Vienna. 2009:[199]. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Comparative+effects+of+formoterol+monotherapy+versus+formoterol+plus+tiotropium+on+dynamic+hyperinflation+and+exercise+tolerance+in+COPD+&author=D+Berton&author=M+Reis&author=A+Siqueira&author=A+Barroco&author=L+Takara&author=D+Bravo&publication_year=2009&hl=en']",,, Berton 2009 {published data only}  ,excluded,CD012930-bbs2-0025, Wrong intervention (LABA/LAMA not administered in combined inhaler) 
CD012930-bib-0095,"Berton DC, Chiappa GR, Takara LS, Figueiredo P, Reis M, Teixeira PJZ, et al. ",LABA‐LAMA combination is superior to LABA monotherapy in improving the cardiocirculatory responses to treadmill exercise in patients with moderate‐to‐severe COPD,,2010,,    ,['citation-other']," Berton DC, Chiappa GR, Takara LS, Figueiredo P, Reis M, Teixeira PJZ, et al. LABA‐LAMA combination is superior to LABA monotherapy in improving the cardiocirculatory responses to treadmill exercise in patients with moderate‐to‐severe COPD. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010:[E5411]. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=LABA‐LAMA+combination+is+superior+to+LABA+monotherapy+in+improving+the+cardiocirculatory+responses+to+treadmill+exercise+in+patients+with+moderate‐to‐severe+COPD+&author=DC+Berton&author=GR+Chiappa&author=LS+Takara&author=P+Figueiredo&author=M+Reis&author=PJZ+Teixeira&publication_year=2010&hl=en']",,, Berton 2009 {published data only}  ,excluded,CD012930-bbs2-0025, Wrong intervention (LABA/LAMA not administered in combined inhaler) 
CD012930-bib-0096,"Berton DC, Reis M, Siqueira AC, Barroco AC, Takara LS, Bravo DM, et al. ",Effects of tiotropium and formoterol on dynamic hyperinflation and exercise endurance in COPD, Respiratory Medicine ,2010,104,    ,['citation-journal']," Berton DC, Reis M, Siqueira AC, Barroco AC, Takara LS, Bravo DM, et al. Effects of tiotropium and formoterol on dynamic hyperinflation and exercise endurance in COPD.  Respiratory Medicine 2010;104(9):1288‐96. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.rmed.2010.05.017', 'https://www.ncbi.nlm.nih.gov/pubmed/20580216', 'https://scholar.google.com/scholar_lookup?title=Effects+of+tiotropium+and+formoterol+on+dynamic+hyperinflation+and+exercise+endurance+in+COPD+&author=DC+Berton&author=M+Reis&author=AC+Siqueira&author=AC+Barroco&author=LS+Takara&author=DM+Bravo&publication_year=2010&hl=en']",20580216,https://doi.org/10.1016/j.rmed.2010.05.017, Berton 2009 {published data only}  ,excluded,CD012930-bbs2-0025, Wrong intervention (LABA/LAMA not administered in combined inhaler) 
CD012930-bib-0097,"Buhl R, Dunn LJ, Disdier C, Lassen C, Amos C, Henley M, et al. ",Blinded 12‐week comparison of once‐daily indacaterol and tiotropium in COPD, European Respiratory Journal ,2011,38,    ,['citation-journal']," Buhl R, Dunn LJ, Disdier C, Lassen C, Amos C, Henley M, et al. Blinded 12‐week comparison of once‐daily indacaterol and tiotropium in COPD.  European Respiratory Journal 2011;38(4):797‐803. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1183/09031936.00191810', 'https://www.ncbi.nlm.nih.gov/pubmed/21622587', 'https://scholar.google.com/scholar_lookup?title=Blinded+12‐week+comparison+of+once‐daily+indacaterol+and+tiotropium+in+COPD&author=R+Buhl&author=LJ+Dunn&author=C+Disdier&author=C+Lassen&author=C+Amos&author=M+Henley&publication_year=2011&hl=en']",21622587,https://doi.org/10.1183/09031936.00191810, Buhl 2011 INTENSITY {published data only}  ,excluded,CD012930-bbs2-0026, Wrong intervention (LABA/LAMA combination not evaluated) 
CD012930-bib-0098,"Dunn L, Buhl R, Lassen C, Henley M, Kramer B. ",Blinded 12‐week comparison of once‐daily indacaterol and tiotropium in COPD, Chest ,2010,138,    ,['citation-journal']," Dunn L, Buhl R, Lassen C, Henley M, Kramer B. Blinded 12‐week comparison of once‐daily indacaterol and tiotropium in COPD.  Chest 2010;138(4):719A. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1378/chest.90001', 'https://scholar.google.com/scholar_lookup?title=Blinded+12‐week+comparison+of+once‐daily+indacaterol+and+tiotropium+in+COPD&author=L+Dunn&author=R+Buhl&author=C+Lassen&author=M+Henley&author=B+Kramer&publication_year=2010&hl=en']",,https://doi.org/10.1378/chest.90001, Buhl 2011 INTENSITY {published data only}  ,excluded,CD012930-bbs2-0026, Wrong intervention (LABA/LAMA combination not evaluated) 
CD012930-bib-0099,NCT00900731. ,A study to compare the lung effect of indacaterol and tiotropium in chronic obstructive pulmonary disease (COPD),,,,   ,['citation-other'], NCT00900731. A study to compare the lung effect of indacaterol and tiotropium in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT00900731 (first received 13 May 2009). CENTRAL    ,[''],,, Buhl 2011 INTENSITY {published data only}  ,excluded,CD012930-bbs2-0026, Wrong intervention (LABA/LAMA combination not evaluated) 
CD012930-bib-0100,"Abrahams R, Ferguson G, Clerisme‐Beaty E, Groenke L, Voss F, Korducki L, et al. ","Effect of tiotropium + olodaterol on the use of nighttime rescue medication in patients with COPD: results from four randomized, double‐blind studies", Chest ,2015,148,    ,['citation-journal']," Abrahams R, Ferguson G, Clerisme‐Beaty E, Groenke L, Voss F, Korducki L, et al. Effect of tiotropium + olodaterol on the use of nighttime rescue medication in patients with COPD: results from four randomized, double‐blind studies.  Chest 2015;148(4):731A. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1378/chest.2275112', 'https://scholar.google.com/scholar_lookup?title=Effect+of+tiotropium+++olodaterol+on+the+use+of+nighttime+rescue+medication+in+patients+with+COPD:+results+from+four+randomized,+double‐blind+studies+&author=R+Abrahams&author=G+Ferguson&author=E+Clerisme‐Beaty&author=L+Groenke&author=F+Voss&author=L+Korducki&publication_year=2015&hl=en']",,https://doi.org/10.1378/chest.2275112, Buhl 2015 TONADO {published data only}  ,excluded,CD012930-bbs2-0027, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0101,"Bai C, Buhl R, Lee SH, Lee KH, Jons O, Bothner U, et al. ",Safety of once‐daily tiotropium plus olodaterol via the respimat in East Asian patients with chronic obstructive pulmonary disease (COPD), Respirology ,2015,20,    ,['citation-journal']," Bai C, Buhl R, Lee SH, Lee KH, Jons O, Bothner U, et al. Safety of once‐daily tiotropium plus olodaterol via the respimat in East Asian patients with chronic obstructive pulmonary disease (COPD).  Respirology 2015;20:55. [1323‐7799]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Safety+of+once‐daily+tiotropium+plus+olodaterol+via+the+respimat+in+East+Asian+patients+with+chronic+obstructive+pulmonary+disease+(COPD)+&author=C+Bai&author=R+Buhl&author=SH+Lee&author=KH+Lee&author=O+Jons&author=U+Bothner&publication_year=2015&hl=en']",,, Buhl 2015 TONADO {published data only}  ,excluded,CD012930-bbs2-0027, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0102,"Bai C, Buhl R, Lee SH, Lee KH, Jons O, Zhao Y, et al. ",Lung function with tiotropium plus olodaterol in East Asian patients with chronic obstructive pulmonary disease (COPD), Respirology ,2015,20,    ,['citation-journal']," Bai C, Buhl R, Lee SH, Lee KH, Jons O, Zhao Y, et al. Lung function with tiotropium plus olodaterol in East Asian patients with chronic obstructive pulmonary disease (COPD).  Respirology 2015;20:53. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Lung+function+with+tiotropium+plus+olodaterol+in+East+Asian+patients+with+chronic+obstructive+pulmonary+disease+(COPD)+&author=C+Bai&author=R+Buhl&author=SH+Lee&author=KH+Lee&author=O+Jons&author=Y+Zhao&publication_year=2015&hl=en']",,, Buhl 2015 TONADO {published data only}  ,excluded,CD012930-bbs2-0027, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0103,"Buhl R, Abrahams R, Bjermer L, Derom E, Flezar M, Hebert J, et al. ",Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies, Chest ,2014,146,    ,['citation-journal']," Buhl R, Abrahams R, Bjermer L, Derom E, Flezar M, Hebert J, et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies.  Chest 2014;146(4):48A. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1378/chest.1994476', 'https://scholar.google.com/scholar_lookup?title=Pooled+safety+analysis+of+once‐daily+tiotropium+and+olodaterol+fixed‐dose+combination+via+the+respimat+in+patients+with+chronic+obstructive+pulmonary+disease:+two+1‐year+studies+&author=R+Buhl&author=R+Abrahams&author=L+Bjermer&author=E+Derom&author=M+Flezar&author=J+Hebert&publication_year=2014&hl=en']",,https://doi.org/10.1378/chest.1994476, Buhl 2015 TONADO {published data only}  ,excluded,CD012930-bbs2-0027, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0104,"Buhl R, Abrahams R, Bjermer L, Derom E, Flezar M, Hebert J, et al. ",Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the respimat in chronic obstructive pulmonary disease in two 1‐year studies, Thorax ,2014,69,    ,['citation-journal']," Buhl R, Abrahams R, Bjermer L, Derom E, Flezar M, Hebert J, et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the respimat in chronic obstructive pulmonary disease in two 1‐year studies.  Thorax 2014;69:A189‐90. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1136/thoraxjnl-2014-206260.384', 'https://scholar.google.com/scholar_lookup?title=Safety+of+once‐daily+tiotropium+and+olodaterol+fixed‐dose+combination+via+the+respimat+in+chronic+obstructive+pulmonary+disease+in+two+1‐year+studies+&author=R+Buhl&author=R+Abrahams&author=L+Bjermer&author=E+Derom&author=M+Flezar&author=J+Hebert&publication_year=2014&hl=en']",,https://doi.org/10.1136/thoraxjnl-2014-206260.384, Buhl 2015 TONADO {published data only}  ,excluded,CD012930-bbs2-0027, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0105,"Buhl R, Derom E, Ferguson G, Pizzichini E, Reid J, Watz H, et al. ",Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies, Thorax ,2014,69,    ,['citation-journal']," Buhl R, Derom E, Ferguson G, Pizzichini E, Reid J, Watz H, et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies.  Thorax 2014;69:A188‐9. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1136/thoraxjnl-2014-206260.382', 'https://scholar.google.com/scholar_lookup?title=Once‐daily+tiotropium+and+olodaterol+fixed‐dose+combination+via+the+Respimat+improves+outcomes+versus+mono‐components+in+COPD+in+two+1‐year+studies+&author=R+Buhl&author=E+Derom&author=G+Ferguson&author=E+Pizzichini&author=J+Reid&author=H+Watz&publication_year=2014&hl=en']",,https://doi.org/10.1136/thoraxjnl-2014-206260.382, Buhl 2015 TONADO {published data only}  ,excluded,CD012930-bbs2-0027, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0106,"Buhl R, Jons O, Bothner U, Tetzlaff K, Zhao Y, Ichinose M. ",Safety of once‐daily tiotropium plus olodaterol via the respimat in East Asian patients with chronic obstructive pulmonary disease (COPD), Respirology ,2015,20,    ,['citation-journal']," Buhl R, Jons O, Bothner U, Tetzlaff K, Zhao Y, Ichinose M. Safety of once‐daily tiotropium plus olodaterol via the respimat in East Asian patients with chronic obstructive pulmonary disease (COPD).  Respirology 2015;20:47. [1323‐7799]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Safety+of+once‐daily+tiotropium+plus+olodaterol+via+the+respimat+in+East+Asian+patients+with+chronic+obstructive+pulmonary+disease+(COPD)+&author=R+Buhl&author=O+Jons&author=U+Bothner&author=K+Tetzlaff&author=Y+Zhao&author=M+Ichinose&publication_year=2015&hl=en']",,, Buhl 2015 TONADO {published data only}  ,excluded,CD012930-bbs2-0027, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0107,"Buhl R, Jons O, Zhao Y, Ichinose M. ",Lung function with tiotropium plus olodaterol in East Asian patients with chronic obstructive pulmonary disease (COPD), Respirology ,2015,20,    ,['citation-journal']," Buhl R, Jons O, Zhao Y, Ichinose M. Lung function with tiotropium plus olodaterol in East Asian patients with chronic obstructive pulmonary disease (COPD).  Respirology 2015;20:51. [1323‐7799]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Lung+function+with+tiotropium+plus+olodaterol+in+East+Asian+patients+with+chronic+obstructive+pulmonary+disease+(COPD)+&author=R+Buhl&author=O+Jons&author=Y+Zhao&author=M+Ichinose&publication_year=2015&hl=en']",,, Buhl 2015 TONADO {published data only}  ,excluded,CD012930-bbs2-0027, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0108,"Buhl R, Magder S, Bothner U, Tetzlaff K, Voss F, Loaiza L, et al. ",Long‐term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease, Respiratory Medicine ,2017,122,    ,['citation-journal']," Buhl R, Magder S, Bothner U, Tetzlaff K, Voss F, Loaiza L, et al. Long‐term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease.  Respiratory Medicine 2017;122:58‐66. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.rmed.2016.11.011', 'https://www.ncbi.nlm.nih.gov/pubmed/27993292', 'https://scholar.google.com/scholar_lookup?title=Long‐term+general+and+cardiovascular+safety+of+tiotropium/olodaterol+in+patients+with+moderate+to+very+severe+chronic+obstructive+pulmonary+disease+&author=R+Buhl&author=S+Magder&author=U+Bothner&author=K+Tetzlaff&author=F+Voss&author=L+Loaiza&publication_year=2017&hl=en']",27993292,https://doi.org/10.1016/j.rmed.2016.11.011, Buhl 2015 TONADO {published data only}  ,excluded,CD012930-bbs2-0027, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0109,"Buhl R, Maltais F, Abrahams R, Bjermer L, Derom E, Ferguson G, et al. ",Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4), European Respiratory Journal ,2015,45,    ,['citation-journal']," Buhl R, Maltais F, Abrahams R, Bjermer L, Derom E, Ferguson G, et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4).  European Respiratory Journal 2015;45(4):969‐79. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1183/09031936.00136014', 'https://www.ncbi.nlm.nih.gov/pubmed/25573406', 'https://scholar.google.com/scholar_lookup?title=Tiotropium+and+olodaterol+fixed‐dose+combination+versus+mono‐components+in+COPD+(GOLD+2‐4)+&author=R+Buhl&author=F+Maltais&author=R+Abrahams&author=L+Bjermer&author=E+Derom&author=G+Ferguson&publication_year=2015&hl=en']",25573406,https://doi.org/10.1183/09031936.00136014, Buhl 2015 TONADO {published data only}  ,excluded,CD012930-bbs2-0027, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0110,"Chia M, Reid J, Buhl R, Abrahams R, Bjermer L, Derom E, et al. ",Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the respimat in chronic obstructive pulmonary disease in two 1‐year studies, Respirology ,2015,20,    ,['citation-journal']," Chia M, Reid J, Buhl R, Abrahams R, Bjermer L, Derom E, et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the respimat in chronic obstructive pulmonary disease in two 1‐year studies.  Respirology 2015;20:77. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Safety+of+once‐daily+tiotropium+and+olodaterol+fixed‐dose+combination+via+the+respimat+in+chronic+obstructive+pulmonary+disease+in+two+1‐year+studies+&author=M+Chia&author=J+Reid&author=R+Buhl&author=R+Abrahams&author=L+Bjermer&author=E+Derom&publication_year=2015&hl=en']",,, Buhl 2015 TONADO {published data only}  ,excluded,CD012930-bbs2-0027, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0111,"Chia M, Reid J, Buhl R, Derom E, Ferguson G, Maltais F, et al. ",Once‐daily tiotropium and olodaterol fixed‐dose combination via the respimat improves outcomes vs mono‐components in COPD in two 1‐year studies, Respirology ,2015,20,    ,['citation-journal']," Chia M, Reid J, Buhl R, Derom E, Ferguson G, Maltais F, et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the respimat improves outcomes vs mono‐components in COPD in two 1‐year studies.  Respirology 2015;20:77. [1323‐7799]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Once‐daily+tiotropium+and+olodaterol+fixed‐dose+combination+via+the+respimat+improves+outcomes+vs+mono‐components+in+COPD+in+two+1‐year+studies+&author=M+Chia&author=J+Reid&author=R+Buhl&author=E+Derom&author=G+Ferguson&author=F+Maltais&publication_year=2015&hl=en']",,, Buhl 2015 TONADO {published data only}  ,excluded,CD012930-bbs2-0027, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0112,"Derom E, Flezar M, Gronke L, Vob F, Buhl R. ",Effect of tiotropium + olodaterol therapy on COPD exacerbations in the TONADO studies, American Journal of Respiratory and Critical Care Medicine ,2016,193,    ,['citation-journal']," Derom E, Flezar M, Gronke L, Vob F, Buhl R. Effect of tiotropium + olodaterol therapy on COPD exacerbations in the TONADO studies.  American Journal of Respiratory and Critical Care Medicine 2016;193:A6805. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Effect+of+tiotropium+++olodaterol+therapy+on+COPD+exacerbations+in+the+TONADO+studies&author=E+Derom&author=M+Flezar&author=L+Gronke&author=F+Vob&author=R+Buhl&publication_year=2016&hl=en']",,, Buhl 2015 TONADO {published data only}  ,excluded,CD012930-bbs2-0027, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0113,"Ferguson G, Clerisme‐Beaty E, Groenke L, Voss F, Karpel J. ",Lung function response with tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO and OTEMTO studies: a subgroup analysis by age, Chest ,2015,148,    ,['citation-journal']," Ferguson G, Clerisme‐Beaty E, Groenke L, Voss F, Karpel J. Lung function response with tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO and OTEMTO studies: a subgroup analysis by age.  Chest 2015;148:4. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1378/chest.2277971', 'https://www.ncbi.nlm.nih.gov/pubmed/26149547', 'https://scholar.google.com/scholar_lookup?title=Lung+function+response+with+tiotropium+++olodaterol+maintenance+treatment+in+patients+with+COPD+in+the+TONADO+and+OTEMTO+studies:+a+subgroup+analysis+by+age+&author=G+Ferguson&author=E+Clerisme‐Beaty&author=L+Groenke&author=F+Voss&author=J+Karpel&publication_year=2015&hl=en']",26149547,https://doi.org/10.1378/chest.2277971, Buhl 2015 TONADO {published data only}  ,excluded,CD012930-bbs2-0027, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0114,"Ferguson G, Clerisme‐Beaty E, Groenke L, Voss F, Korducki L, Bennett N, et al. ","Tiotropium + olodaterol provides improvements in SGRQ and dyspnea compared with monotherapy components in patients with COPD: results from four randomized, double‐blind studies", Chest ,2015,148,    ,['citation-journal']," Ferguson G, Clerisme‐Beaty E, Groenke L, Voss F, Korducki L, Bennett N, et al. Tiotropium + olodaterol provides improvements in SGRQ and dyspnea compared with monotherapy components in patients with COPD: results from four randomized, double‐blind studies.  Chest 2015;148(4):726A. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1378/chest.2277942', 'https://scholar.google.com/scholar_lookup?title=Tiotropium+++olodaterol+provides+improvements+in+SGRQ+and+dyspnea+compared+with+monotherapy+components+in+patients+with+COPD:+results+from+four+randomized,+double‐blind+studies+&author=G+Ferguson&author=E+Clerisme‐Beaty&author=L+Groenke&author=F+Voss&author=L+Korducki&author=N+Bennett&publication_year=2015&hl=en']",,https://doi.org/10.1378/chest.2277942, Buhl 2015 TONADO {published data only}  ,excluded,CD012930-bbs2-0027, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0115,"Ferguson GT, Flezar M, Korn S, Korducki L, Gronke L, Abrahams R, et al. ",Efficacy of tiotropium + olodaterol in patients with chronic obstructive pulmonary disease by initial disease severity and treatment intensity: a post hoc analysis, Advances in Therapy ,2015,32,    ,['citation-journal']," Ferguson GT, Flezar M, Korn S, Korducki L, Gronke L, Abrahams R, et al. Efficacy of tiotropium + olodaterol in patients with chronic obstructive pulmonary disease by initial disease severity and treatment intensity: a post hoc analysis.  Advances in Therapy 2015;32(6):523‐36. [0741‐238X]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1007/s12325-015-0218-0', 'https://www.ncbi.nlm.nih.gov/pubmed/26112656', 'https://scholar.google.com/scholar_lookup?title=Efficacy+of+tiotropium+++olodaterol+in+patients+with+chronic+obstructive+pulmonary+disease+by+initial+disease+severity+and+treatment+intensity:+a+post+hoc+analysis+&author=GT+Ferguson&author=M+Flezar&author=S+Korn&author=L+Korducki&author=L+Gronke&author=R+Abrahams&publication_year=2015&hl=en']",26112656,https://doi.org/10.1007/s12325-015-0218-0, Buhl 2015 TONADO {published data only}  ,excluded,CD012930-bbs2-0027, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0116,"Ferguson GT, Karpel JP, Clerisme‐Beaty E, Gronke L, Voss F, Buhl R. ",Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO(R) and OTEMTO(R) studies: a subgroup analysis by age, International Journal of Chronic Obstructive Pulmonary Disease ,2016,11,    ,['citation-journal']," Ferguson GT, Karpel JP, Clerisme‐Beaty E, Gronke L, Voss F, Buhl R. Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO(R) and OTEMTO(R) studies: a subgroup analysis by age.  International Journal of Chronic Obstructive Pulmonary Disease 2016;11(1):2701‐10. [1178‐2005]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.2147/COPD.S108758', 'https://www.ncbi.nlm.nih.gov/pubmed/27843306', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+tiotropium+++olodaterol+maintenance+treatment+in+patients+with+COPD+in+the+TONADO(R)+and+OTEMTO(R)+studies:+a+subgroup+analysis+by+age+&author=GT+Ferguson&author=JP+Karpel&author=E+Clerisme‐Beaty&author=L+Gronke&author=F+Voss&author=R+Buhl&publication_year=2016&hl=en']",27843306,https://doi.org/10.2147/COPD.S108758, Buhl 2015 TONADO {published data only}  ,excluded,CD012930-bbs2-0027, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0117,"Ferguson GT, Pizzichini E, Flezar M, Gronke L, Korducki L. ",The fixed‐dose combination of tiotropium + olodaterol has a rapid onset of action in patients with COPD, European Respiratory Journal ,2015,46,    ,['citation-journal']," Ferguson GT, Pizzichini E, Flezar M, Gronke L, Korducki L. The fixed‐dose combination of tiotropium + olodaterol has a rapid onset of action in patients with COPD.  European Respiratory Journal 2015;46:PA2957. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=The+fixed‐dose+combination+of+tiotropium+++olodaterol+has+a+rapid+onset+of+action+in+patients+with+COPD+&author=GT+Ferguson&author=E+Pizzichini&author=M+Flezar&author=L+Gronke&author=L+Korducki&publication_year=2015&hl=en']",,, Buhl 2015 TONADO {published data only}  ,excluded,CD012930-bbs2-0027, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0118,"Ichinose M, Takizawa A, Gronke L, Vos F, Fukuchi Y. ",Analysis of the efficacy and safety of tiotropium and olodaterol fixed‐dose combination via the respimat in patients with COPD by disease severity: Tonado trials, Respirology ,2015,20,    ,['citation-journal']," Ichinose M, Takizawa A, Gronke L, Vos F, Fukuchi Y. Analysis of the efficacy and safety of tiotropium and olodaterol fixed‐dose combination via the respimat in patients with COPD by disease severity: Tonado trials.  Respirology 2015;20:66. CENTRAL    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/25257809', 'https://scholar.google.com/scholar_lookup?title=Analysis+of+the+efficacy+and+safety+of+tiotropium+and+olodaterol+fixed‐dose+combination+via+the+respimat+in+patients+with+COPD+by+disease+severity:+Tonado+trials+&author=M+Ichinose&author=A+Takizawa&author=L+Gronke&author=F+Vos&author=Y+Fukuchi&publication_year=2015&hl=en']",25257809,, Buhl 2015 TONADO {published data only}  ,excluded,CD012930-bbs2-0027, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0119,"Ichinose M, Takizawa A, Hamilton A, Zhao Y, Fukuchi Y. ",Efficacy and safety of tiotropium and olodaterol fixed‐dose combination via the respimat in COPD patients: Japanese subgroup analysis of tonado 1 and 2, Respirology ,2015,20,    ,['citation-journal']," Ichinose M, Takizawa A, Hamilton A, Zhao Y, Fukuchi Y. Efficacy and safety of tiotropium and olodaterol fixed‐dose combination via the respimat in COPD patients: Japanese subgroup analysis of tonado 1 and 2.  Respirology 2015;20:64. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+tiotropium+and+olodaterol+fixed‐dose+combination+via+the+respimat+in+COPD+patients:+Japanese+subgroup+analysis+of+tonado+1+and+2+&author=M+Ichinose&author=A+Takizawa&author=A+Hamilton&author=Y+Zhao&author=Y+Fukuchi&publication_year=2015&hl=en']",,, Buhl 2015 TONADO {published data only}  ,excluded,CD012930-bbs2-0027, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0120,"Ichinose M, Taniguchi H, Takizawa A, Gronke L, Loaiza L, Voss F, et al. ",The efficacy and safety of combined tiotropium and olodaterol via the Respimat((R)) inhaler in patients with COPD: results from the Japanese sub‐population of the Tonado((R)) studies, International Journal of Chronic Obstructive Pulmonary Disease ,2016,11,    ,['citation-journal']," Ichinose M, Taniguchi H, Takizawa A, Gronke L, Loaiza L, Voss F, et al. The efficacy and safety of combined tiotropium and olodaterol via the Respimat((R)) inhaler in patients with COPD: results from the Japanese sub‐population of the Tonado((R)) studies.  International Journal of Chronic Obstructive Pulmonary Disease 2016;11(1):2017‐27. [1178‐2005]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.2147/COPD.S110389', 'https://www.ncbi.nlm.nih.gov/pubmed/27621608', 'https://scholar.google.com/scholar_lookup?title=The+efficacy+and+safety+of+combined+tiotropium+and+olodaterol+via+the+Respimat((R))+inhaler+in+patients+with+COPD:+results+from+the+Japanese+sub‐population+of+the+Tonado((R))+studies+&author=M+Ichinose&author=H+Taniguchi&author=A+Takizawa&author=L+Gronke&author=L+Loaiza&author=F+Voss&publication_year=2016&hl=en']",27621608,https://doi.org/10.2147/COPD.S110389, Buhl 2015 TONADO {published data only}  ,excluded,CD012930-bbs2-0027, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0121,"Korn S, Buhl R, Gronke L, Korducki L, Amato V, Ferguson G, et al. ",Analysis of the efficacy and safety of the combination of tiotropium + olodaterol in patients with COPD by previous usage of inhaled corticosteroids, Thorax ,2015,70,    ,['citation-journal']," Korn S, Buhl R, Gronke L, Korducki L, Amato V, Ferguson G, et al. Analysis of the efficacy and safety of the combination of tiotropium + olodaterol in patients with COPD by previous usage of inhaled corticosteroids.  Thorax 2015;70:A37. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1136/thoraxjnl-2015-207770.67', 'https://scholar.google.com/scholar_lookup?title=Analysis+of+the+efficacy+and+safety+of+the+combination+of+tiotropium+++olodaterol+in+patients+with+COPD+by+previous+usage+of+inhaled+corticosteroids+&author=S+Korn&author=R+Buhl&author=L+Gronke&author=L+Korducki&author=V+Amato&author=G+Ferguson&publication_year=2015&hl=en']",,https://doi.org/10.1136/thoraxjnl-2015-207770.67, Buhl 2015 TONADO {published data only}  ,excluded,CD012930-bbs2-0027, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0122,"Maltais F, Groenke L, Korducki L, Buhl R. ",Efficacy of once‐daily tiotropium and olodaterol maintenance treatment for COPD: patient‐reported outcomes, Chest ,2015,148,    ,['citation-journal']," Maltais F, Groenke L, Korducki L, Buhl R. Efficacy of once‐daily tiotropium and olodaterol maintenance treatment for COPD: patient‐reported outcomes.  Chest 2015;148(4):638A. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1378/chest.2347832', 'https://scholar.google.com/scholar_lookup?title=Efficacy+of+once‐daily+tiotropium+and+olodaterol+maintenance+treatment+for+COPD:+patient‐reported+outcomes+&author=F+Maltais&author=L+Groenke&author=L+Korducki&author=R+Buhl&publication_year=2015&hl=en']",,https://doi.org/10.1378/chest.2347832, Buhl 2015 TONADO {published data only}  ,excluded,CD012930-bbs2-0027, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0123,NCT01431274. ,Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD),,,,   ,['citation-other'], NCT01431274. Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01431274 (first received 9 September 2011). CENTRAL    ,[''],,, Buhl 2015 TONADO {published data only}  ,excluded,CD012930-bbs2-0027, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0124,NCT01431287. ,Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD),,,,   ,['citation-other'], NCT01431287. Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01431287 (first received 9 September 2011). CENTRAL    ,[''],,, Buhl 2015 TONADO {published data only}  ,excluded,CD012930-bbs2-0027, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0125,"Tashkin D, Ferguson G, Clerisme‐Beaty E, Vob F, Buhl R. ",Lung‐function response to tiotropium + olodaterol in patients with COPD with beta2‐agonist reversibility, American Journal of Respiratory and Critical Care Medicine ,2016,193,    ,['citation-journal']," Tashkin D, Ferguson G, Clerisme‐Beaty E, Vob F, Buhl R. Lung‐function response to tiotropium + olodaterol in patients with COPD with beta2‐agonist reversibility.  American Journal of Respiratory and Critical Care Medicine 2016;193:A6808. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Lung‐function+response+to+tiotropium+++olodaterol+in+patients+with+COPD+with+beta2‐agonist+reversibility+&author=D+Tashkin&author=G+Ferguson&author=E+Clerisme‐Beaty&author=F+Vob&author=R+Buhl&publication_year=2016&hl=en']",,, Buhl 2015 TONADO {published data only}  ,excluded,CD012930-bbs2-0027, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0126,"D'Urzo A, Mergel V, Leselbaum A, Caracta C. ",Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial, Chest ,2013,144,    ,['citation-journal']," D'Urzo A, Mergel V, Leselbaum A, Caracta C. Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial.  Chest 2013;144(4):1025A. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1378/chest.1780390', ""https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+fixed‐dose+combination+aclidinium+bromide/formoterol+fumarate+in+patients+with+COPD:+results+from+the+AUGMENT+COPD+trial+&author=A+D'Urzo&author=V+Mergel&author=A+Leselbaum&author=C+Caracta&publication_year=2013&hl=en""]",,https://doi.org/10.1378/chest.1780390, D'Urzo 2014 AUGMENT {published data only}  ,excluded,CD012930-bbs2-0028, 2nd ROUND: Wrong intervention ‐ LAMA/LABA administered twice daily 
CD012930-bib-0127,"D'Urzo A, Rennard S, Kerwin E, Mergel V, He T, Leselbaum A, et al. ",One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study, European Respiratory Journal ,2014,44,    ,['citation-journal']," D'Urzo A, Rennard S, Kerwin E, Mergel V, He T, Leselbaum A, et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study.  European Respiratory Journal 2014;44:P286. CENTRAL    Google Scholar     ","['', ""https://scholar.google.com/scholar_lookup?title=One‐year+efficacy+of+aclidinium/formoterol+fixed‐dose+combination+in+COPD+patients:+the+AUGMENT+COPD+study+&author=A+D'Urzo&author=S+Rennard&author=E+Kerwin&author=V+Mergel&author=T+He&author=A+Leselbaum&publication_year=2014&hl=en""]",,, D'Urzo 2014 AUGMENT {published data only}  ,excluded,CD012930-bbs2-0028, 2nd ROUND: Wrong intervention ‐ LAMA/LABA administered twice daily 
CD012930-bib-0128,"D'Urzo A, Rennard S, Mergel V, Garcia Gil E, Leselbaum A, Caracta C. ",The augment COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients, Chest ,2014,145,    ,['citation-journal']," D'Urzo A, Rennard S, Mergel V, Garcia Gil E, Leselbaum A, Caracta C. The augment COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients.  Chest 2014;145(3):426A. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1378/chest.1821799', ""https://scholar.google.com/scholar_lookup?title=The+augment+COPD+trial:+efficacy+and+safety+of+a+fixed‐dose+combination+of+aclidinium+bromide+and+formoterol+fumarate+in+COPD+patients+&author=A+D'Urzo&author=S+Rennard&author=V+Mergel&author=E+GarciaGil&author=A+Leselbaum&author=C+Caracta&publication_year=2014&hl=en""]",,https://doi.org/10.1378/chest.1821799, D'Urzo 2014 AUGMENT {published data only}  ,excluded,CD012930-bbs2-0028, 2nd ROUND: Wrong intervention ‐ LAMA/LABA administered twice daily 
CD012930-bib-0129,"D'Urzo AD, Rennard SI, Kerwin EM, He T, Leselbaum A, Caracta C. ",Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD, American Journal of Respiratory and Critical Care Medicine ,2014,189,    ,['citation-journal']," D'Urzo AD, Rennard SI, Kerwin EM, He T, Leselbaum A, Caracta C. Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD.  American Journal of Respiratory and Critical Care Medicine 2014;189:A6006. CENTRAL    Google Scholar     ","['', ""https://scholar.google.com/scholar_lookup?title=Efficacy+of+fixed‐dose+combination+aclidinium+bromide/formoterol+fumarate+on+bronchodilation+over+1+year:+AUGMENT+COPD+extension+trial+in+patients+with+moderate+to+severe+COPD+&author=AD+D'Urzo&author=SI+Rennard&author=EM+Kerwin&author=T+He&author=A+Leselbaum&author=C+Caracta&publication_year=2014&hl=en""]",,, D'Urzo 2014 AUGMENT {published data only}  ,excluded,CD012930-bbs2-0028, 2nd ROUND: Wrong intervention ‐ LAMA/LABA administered twice daily 
CD012930-bib-0130,"D'Urzo AD, Rennard SI, Kerwin EM, Mergel V, Leselbaum A, Caracta C. ",Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD, American Journal of Respiratory and Critical Care Medicine ,2014,189,    ,['citation-journal']," D'Urzo AD, Rennard SI, Kerwin EM, Mergel V, Leselbaum A, Caracta C. Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD.  American Journal of Respiratory and Critical Care Medicine 2014;189:A3776. CENTRAL    Google Scholar     ","['', ""https://scholar.google.com/scholar_lookup?title=Twice‐daily+aclidinium+bromide/formoterol+fumarate+fixed‐dose+combination:+lung+function+improvements+in+the+AUGMENT+COPD+trial+in+patients+with+moderate+to+severe+COPD+&author=AD+D'Urzo&author=SI+Rennard&author=EM+Kerwin&author=V+Mergel&author=A+Leselbaum&author=C+Caracta&publication_year=2014&hl=en""]",,, D'Urzo 2014 AUGMENT {published data only}  ,excluded,CD012930-bbs2-0028, 2nd ROUND: Wrong intervention ‐ LAMA/LABA administered twice daily 
CD012930-bib-0131,"D'Urzo AD, Rennard SI, Kerwin EM, Mergel V, Leselbaum AR, Caracta CF. ","Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomized, placebo‐controlled AUGMENT COPD study", Respiratory Research ,2014,15,    ,['citation-journal']," D'Urzo AD, Rennard SI, Kerwin EM, Mergel V, Leselbaum AR, Caracta CF. Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomized, placebo‐controlled AUGMENT COPD study.  Respiratory Research 2014;15(1):123‐41. [1465‐993X]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1186/s12931-014-0123-0', 'https://www.ncbi.nlm.nih.gov/pubmed/25756831', ""https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+fixed‐dose+combinations+of+aclidinium+bromide/formoterol+fumarate:+the+24‐week,+randomized,+placebo‐controlled+AUGMENT+COPD+study+&author=AD+D'Urzo&author=SI+Rennard&author=EM+Kerwin&author=V+Mergel&author=AR+Leselbaum&author=CF+Caracta&publication_year=2014&hl=en""]",25756831,https://doi.org/10.1186/s12931-014-0123-0, D'Urzo 2014 AUGMENT {published data only}  ,excluded,CD012930-bbs2-0028, 2nd ROUND: Wrong intervention ‐ LAMA/LABA administered twice daily 
CD012930-bib-0132,"D'Urzo AD, Singh D, Kerwin E, Lakkis H, Chuecos F, De Miquel G. ","Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity", European Respiratory Journal ,2015,46,    ,['citation-journal']," D'Urzo AD, Singh D, Kerwin E, Lakkis H, Chuecos F, De Miquel G. Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity.  European Respiratory Journal 2015;46:PA1499. CENTRAL    Google Scholar     ","['', ""https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+aclidinium/formoterol+fixed‐dose+combination+in+patients+with+moderate+to+severe+airflow+obstruction,+stratified+by+severity+&author=AD+D'Urzo&author=D+Singh&author=E+Kerwin&author=H+Lakkis&author=F+Chuecos&author=G+Miquel&publication_year=2015&hl=en""]",,, D'Urzo 2014 AUGMENT {published data only}  ,excluded,CD012930-bbs2-0028, 2nd ROUND: Wrong intervention ‐ LAMA/LABA administered twice daily 
CD012930-bib-0133,NCT01437397. ,"Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC)",,,,   ,['citation-other']," NCT01437397. Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 (first received 20 September 2011). CENTRAL    ",[''],,, D'Urzo 2014 AUGMENT {published data only}  ,excluded,CD012930-bbs2-0028, 2nd ROUND: Wrong intervention ‐ LAMA/LABA administered twice daily 
CD012930-bib-0134,NCT01572792. ,"Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe, stable chronic obstructive pulmonary disease (COPD)",,,,   ,['citation-other']," NCT01572792. Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe, stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 (first received 6 April 2012). CENTRAL    ",[''],,, D'Urzo 2014 AUGMENT {published data only}  ,excluded,CD012930-bbs2-0028, 2nd ROUND: Wrong intervention ‐ LAMA/LABA administered twice daily 
CD012930-bib-0135,"Rennard SI, D'Urzo AD, Donohue JF, He T, Shrestha P, Leselbaum A, et al. ",Long‐term safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with moderate to severe COPD: the AUGMENT COPD extension trial, American Journal of Respiratory and Critical Care Medicine ,2014,189,    ,['citation-journal']," Rennard SI, D'Urzo AD, Donohue JF, He T, Shrestha P, Leselbaum A, et al. Long‐term safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with moderate to severe COPD: the AUGMENT COPD extension trial.  American Journal of Respiratory and Critical Care Medicine 2014;189:A6008. CENTRAL    Google Scholar     ","['', ""https://scholar.google.com/scholar_lookup?title=Long‐term+safety+of+fixed‐dose+combination+aclidinium+bromide/formoterol+fumarate+in+patients+with+moderate+to+severe+COPD:+the+AUGMENT+COPD+extension+trial+&author=SI+Rennard&author=AD+D'Urzo&author=JF+Donohue&author=T+He&author=P+Shrestha&author=A+Leselbaum&publication_year=2014&hl=en""]",,, D'Urzo 2014 AUGMENT {published data only}  ,excluded,CD012930-bbs2-0028, 2nd ROUND: Wrong intervention ‐ LAMA/LABA administered twice daily 
CD012930-bib-0136,"Rennard SI, D'Urzo AD, Jones PW, Mergel V, Leselbaum A, Caracta C. ",Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial, American Journal of Respiratory and Critical Care Medicine ,2014,189,    ,['citation-journal']," Rennard SI, D'Urzo AD, Jones PW, Mergel V, Leselbaum A, Caracta C. Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial.  American Journal of Respiratory and Critical Care Medicine 2014;189:A6007. CENTRAL    Google Scholar     ","['', ""https://scholar.google.com/scholar_lookup?title=Fixed‐dose+combination+of+aclidinium+bromide/formoterol+fumarate+improve+breathlessness+and+health+status+in+COPD+patients:+AUGMENT+COPD+trial+&author=SI+Rennard&author=AD+D'Urzo&author=PW+Jones&author=V+Mergel&author=A+Leselbaum&author=C+Caracta&publication_year=2014&hl=en""]",,, D'Urzo 2014 AUGMENT {published data only}  ,excluded,CD012930-bbs2-0028, 2nd ROUND: Wrong intervention ‐ LAMA/LABA administered twice daily 
CD012930-bib-0137,"Anzueto A, Decramer M, Kaelin T, Richard N, Tabberer M, Harris S, et al. ",The efficacy and safety of umeclidinium/vilanterol compared with tiotropium or vilanterol over 24 weeks in subjects with COPD, American Journal of Respiratory and Critical Care Medicine ,2013,187,    ,['citation-journal']," Anzueto A, Decramer M, Kaelin T, Richard N, Tabberer M, Harris S, et al. The efficacy and safety of umeclidinium/vilanterol compared with tiotropium or vilanterol over 24 weeks in subjects with COPD.  American Journal of Respiratory and Critical Care Medicine 2013;187:A4268. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=The+efficacy+and+safety+of+umeclidinium/vilanterol+compared+with+tiotropium+or+vilanterol+over+24+weeks+in+subjects+with+COPD+&author=A+Anzueto&author=M+Decramer&author=T+Kaelin&author=N+Richard&author=M+Tabberer&author=S+Harris&publication_year=2013&hl=en']",,, Decramer 2014 {published data only}  ,excluded,CD012930-bbs2-0029, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0138,"Decramer M, Anzueto A, Kerwin E, Kaelin T, Richard N, Crater G, et al. ","Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials", Lancet Respiratory Medicine ,2014,2,    ,['citation-journal']," Decramer M, Anzueto A, Kerwin E, Kaelin T, Richard N, Crater G, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials.  Lancet Respiratory Medicine 2014;2(6):472‐86. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/S2213-2600(14)70065-7', 'https://www.ncbi.nlm.nih.gov/pubmed/24835833', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+umeclidinium+plus+vilanterol+versus+tiotropium,+vilanterol,+or+umeclidinium+monotherapies+over+24+weeks+in+patients+with+chronic+obstructive+pulmonary+disease:+results+from+two+multicentre,+blinded,+randomised+controlled+trials+&author=M+Decramer&author=A+Anzueto&author=E+Kerwin&author=T+Kaelin&author=N+Richard&author=G+Crater&publication_year=2014&hl=en']",24835833,https://doi.org/10.1016/S2213-2600(14)70065-7, Decramer 2014 {published data only}  ,excluded,CD012930-bbs2-0029, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0139,"Decramer M, Anzueto A, Kerwin E, Richard N, Crater G, Tabberer M, et al. ",Efficacy and safety of umeclidinium/vilanterol compared with umeclidinium or tiotropium in COPD,,2013,,    ,['citation-other']," Decramer M, Anzueto A, Kerwin E, Richard N, Crater G, Tabberer M, et al. Efficacy and safety of umeclidinium/vilanterol compared with umeclidinium or tiotropium in COPD. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42:751s [P3640]. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+umeclidinium/vilanterol+compared+with+umeclidinium+or+tiotropium+in+COPD+&author=M+Decramer&author=A+Anzueto&author=E+Kerwin&author=N+Richard&author=G+Crater&author=M+Tabberer&publication_year=2013&hl=en']",,, Decramer 2014 {published data only}  ,excluded,CD012930-bbs2-0029, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0140,NCT01316900. ,24‐week trial comparing GSK573719/GW642444 with GW642444 and with tiotropium in chronic obstructive pulmonary disease,,,,   ,['citation-other'], NCT01316900. 24‐week trial comparing GSK573719/GW642444 with GW642444 and with tiotropium in chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT01316900 (first received 16 March 2011). CENTRAL    ,[''],,, Decramer 2014 {published data only}  ,excluded,CD012930-bbs2-0029, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0141,NCT01316913. ,24‐week trial comparing GSK573719/GW642444 with GSK573719 and with tiotropium in chronic obstructive pulmonary disease,,,,   ,['citation-other'], NCT01316913. 24‐week trial comparing GSK573719/GW642444 with GSK573719 and with tiotropium in chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT01316913 (first received 16 March 2011). CENTRAL    ,[''],,, Decramer 2014 {published data only}  ,excluded,CD012930-bbs2-0029, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0142,"Di Marco F, Verga M, Santus P, Cazzola M, Mondoni M, Belloi E, et al. ","Formoterol (Modulite®), tiotropium and their combination in patients with acute exacerbations of chronic bronchitis: preliminary data", European Respiratory Journal ,2005,26,    ,['citation-journal']," Di Marco F, Verga M, Santus P, Cazzola M, Mondoni M, Belloi E, et al. Formoterol (Modulite®), tiotropium and their combination in patients with acute exacerbations of chronic bronchitis: preliminary data.  European Respiratory Journal 2005;26:1905. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Formoterol+(Modulite®),+tiotropium+and+their+combination+in+patients+with+acute+exacerbations+of+chronic+bronchitis:+preliminary+data+&author=F+Marco&author=M+Verga&author=P+Santus&author=M+Cazzola&author=M+Mondoni&author=E+Belloi&publication_year=2005&hl=en']",,, Di Marco 2005 {published data only}  ,excluded,CD012930-bbs2-0030, Duration of treatment < 3 weeks 
CD012930-bib-0143,"Di Marcoa F, Verga M, Santus P, Morelli N, Cazzola M, Centanni S. ","Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot study", Respiratory Medicine ,2006,11,    ,['citation-journal']," Di Marcoa F, Verga M, Santus P, Morelli N, Cazzola M, Centanni S. Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot study.  Respiratory Medicine 2006;11:1925‐32. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Effect+of+formoterol,+tiotropium,+and+their+combination+in+patients+with+acute+exacerbation+of+chronic+obstructive+pulmonary+disease:+a+pilot+study+&author=F+Marcoa&author=M+Verga&author=P+Santus&author=N+Morelli&author=M+Cazzola&author=S+Centanni&publication_year=2006&hl=en']",,, Di Marco 2005 {published data only}  ,excluded,CD012930-bbs2-0030, Duration of treatment < 3 weeks 
CD012930-bib-0144,"Donohue J, Niewoehner D, Brooks J, O'Dell D, Church A. ",Long‐term safety and tolerability of umeclidinium/vilanterol and umeclidinium in COPD,,2013,,    ,['citation-other']," Donohue J, Niewoehner D, Brooks J, O'Dell D, Church A. Long‐term safety and tolerability of umeclidinium/vilanterol and umeclidinium in COPD. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42:144s [P760]. CENTRAL    Google Scholar     ","['', ""https://scholar.google.com/scholar_lookup?title=Long‐term+safety+and+tolerability+of+umeclidinium/vilanterol+and+umeclidinium+in+COPD&author=J+Donohue&author=D+Niewoehner&author=J+Brooks&author=D+O'Dell&author=A+Church&publication_year=2013&hl=en""]",,, Donohue 2013b {published data only}  ,excluded,CD012930-bbs2-0031, 2nd ROUND: Wrong intervention ‐ LAMA/LABA administered twice daily 
CD012930-bib-0145,"Donohue J, Singh D, Munzu C, Kilbride S, Church A. ",Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: results from two randomised controlled trials, Respiratory Medicine ,2016,112,    ,['citation-journal']," Donohue J, Singh D, Munzu C, Kilbride S, Church A. Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: results from two randomised controlled trials.  Respiratory Medicine 2016;112:65‐74. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.rmed.2016.01.001', 'https://www.ncbi.nlm.nih.gov/pubmed/26797016', 'https://scholar.google.com/scholar_lookup?title=Magnitude+of+umeclidinium/vilanterol+lung+function+effect+depends+on+monotherapy+responses:+results+from+two+randomised+controlled+trials+&author=J+Donohue&author=D+Singh&author=C+Munzu&author=S+Kilbride&author=A+Church&publication_year=2016&hl=en']",26797016,https://doi.org/10.1016/j.rmed.2016.01.001, Donohue 2016 {published data only}  ,excluded,CD012930-bbs2-0032, Duration of treatment < 3 weeks 
CD012930-bib-0146,"Donohue JF, Soong W, Wu X, Shrestha P, Lei A. ",Long‐term safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a randomized 1‐year trial in patients with COPD, Respiratory Medicine ,2016,116,    ,['citation-journal']," Donohue JF, Soong W, Wu X, Shrestha P, Lei A. Long‐term safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a randomized 1‐year trial in patients with COPD.  Respiratory Medicine 2016;116:41‐8. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.rmed.2016.05.007', 'https://www.ncbi.nlm.nih.gov/pubmed/27296819', 'https://scholar.google.com/scholar_lookup?title=Long‐term+safety+of+aclidinium+bromide/formoterol+fumarate+fixed‐dose+combination:+results+of+a+randomized+1‐year+trial+in+patients+with+COPD+&author=JF+Donohue&author=W+Soong&author=X+Wu&author=P+Shrestha&author=A+Lei&publication_year=2016&hl=en']",27296819,https://doi.org/10.1016/j.rmed.2016.05.007, Donohue 2016b {published data only}  ,excluded,CD012930-bbs2-0033, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0147,"Make B, Donohue J, Zhong X, Leselbaum A, Caracta C. ",Long‐term safety of a fixed‐dose combination of aclidinium bromide/formoterol fumarate in patients with stable moderate to severe COPD, Chest ,2014,145,    ,['citation-journal']," Make B, Donohue J, Zhong X, Leselbaum A, Caracta C. Long‐term safety of a fixed‐dose combination of aclidinium bromide/formoterol fumarate in patients with stable moderate to severe COPD.  Chest 2014;145(3):386A. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1378/chest.1825327', 'https://scholar.google.com/scholar_lookup?title=Long‐term+safety+of+a+fixed‐dose+combination+of+aclidinium+bromide/formoterol+fumarate+in+patients+with+stable+moderate+to+severe+COPD+&author=B+Make&author=J+Donohue&author=X+Zhong&author=A+Leselbaum&author=C+Caracta&publication_year=2014&hl=en']",,https://doi.org/10.1378/chest.1825327, Donohue 2016b {published data only}  ,excluded,CD012930-bbs2-0033, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0148,"Make B, Donohue JF, Soong W, Zhong X, Leselbaum A, Caracta C. ",Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed‐dose combination in patients with COPD: a 1‐year study, European Respiratory Journal ,2014,44,    ,['citation-journal']," Make B, Donohue JF, Soong W, Zhong X, Leselbaum A, Caracta C. Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed‐dose combination in patients with COPD: a 1‐year study.  European Respiratory Journal 2014;44:P2413. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+tolerability+of+aclidinium+bromide/formoterol+fumarate+fixed‐dose+combination+in+patients+with+COPD:+a+1‐year+study+&author=B+Make&author=JF+Donohue&author=W+Soong&author=X+Zhong&author=A+Leselbaum&author=C+Caracta&publication_year=2014&hl=en']",,, Donohue 2016b {published data only}  ,excluded,CD012930-bbs2-0033, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0149,"Make BJ, Donohue JF, Soong W, Zhong X, Leselbaum A, Caracta C. ",Lung function and safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a 1‐year trial in patients with COPD, American Journal of Respiratory and Critical Care Medicine ,2014,189,    ,['citation-journal']," Make BJ, Donohue JF, Soong W, Zhong X, Leselbaum A, Caracta C. Lung function and safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a 1‐year trial in patients with COPD.  American Journal of Respiratory and Critical Care Medicine 2014;189:A6010. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Lung+function+and+safety+of+aclidinium+bromide/formoterol+fumarate+fixed‐dose+combination:+results+of+a+1‐year+trial+in+patients+with+COPD+&author=BJ+Make&author=JF+Donohue&author=W+Soong&author=X+Zhong&author=A+Leselbaum&author=C+Caracta&publication_year=2014&hl=en']",,, Donohue 2016b {published data only}  ,excluded,CD012930-bbs2-0033, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0150,EUCTR2007‐003648‐31. ,"A phase IIa, randomised, multicentre, evaluator‐blinded, 4‐way crossover clinical trial to study the pharmacokinetics, safety, tolerability and effects on lung function of one day treatment of formoterol 12 Âµg qd delivered by 2 different dry powder inhalers (AerolizerÂ® and Almirall Inhaler), of the fixed dose combination formoterol 12 Âµg + aclidinium bromide 200 Âµg qd delivered by Almirall Inhaler, and of formoterol 12 Âµg bid delivered by AerolizerÂ®, in moderate to severe chronic obstructive pulmonary disease patients",,,,   ,['citation-other']," EUCTR2007‐003648‐31. A phase IIa, randomised, multicentre, evaluator‐blinded, 4‐way crossover clinical trial to study the pharmacokinetics, safety, tolerability and effects on lung function of one day treatment of formoterol 12 Âµg qd delivered by 2 different dry powder inhalers (AerolizerÂ® and Almirall Inhaler), of the fixed dose combination formoterol 12 Âµg + aclidinium bromide 200 Âµg qd delivered by Almirall Inhaler, and of formoterol 12 Âµg bid delivered by AerolizerÂ®, in moderate to severe chronic obstructive pulmonary disease patients. www.clinicaltrialsregister.eu/ctr‐search/trial/2007‐003648‐31/DE (first received 21 February 2008). CENTRAL    ",[''],,, EUCTR2007‐003648‐31 {published data only}  ,excluded,CD012930-bbs2-0034, Duration of treatment < 3 weeks 
CD012930-bib-0151,EUCTR2007‐004435‐30. ,"A randomised, 4‐week, placebo‐controlled, double‐blind, 6 arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 & 18 µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe Chronic Obstructive Pulmonary Disease",,,,   ,['citation-other']," EUCTR2007‐004435‐30. A randomised, 4‐week, placebo‐controlled, double‐blind, 6 arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 & 18 µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe Chronic Obstructive Pulmonary Disease. www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2007‐004435‐30 (first received 14 April 2008). CENTRAL    ",[''],,, EUCTR2007‐004435‐30 {published data only}  ,excluded,CD012930-bbs2-0035, Wrong intervention (combination inhaler not used) 
CD012930-bib-0152,EUCTR2009‐015901‐38. ,"Efficacy, safety and tolerability of two fixed‐dose combinations of aclidinium bromide with two doses of formoterol fumarate compared with aclidinium bromide, formoterol fumarate and placebo all administered twice daily in stable, moderate to severe chronic obstructive pulmonary disease patients",,,,   ,['citation-other']," EUCTR2009‐015901‐38. Efficacy, safety and tolerability of two fixed‐dose combinations of aclidinium bromide with two doses of formoterol fumarate compared with aclidinium bromide, formoterol fumarate and placebo all administered twice daily in stable, moderate to severe chronic obstructive pulmonary disease patients. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2009‐015901‐38‐DE (first received 11 November 2009). CENTRAL    ",[''],,, EUCTR2009‐015901‐38 {published data only}  ,excluded,CD012930-bbs2-0036, Duration of treatment < 3 weeks 
CD012930-bib-0153,"Evdokimov V, Evdokimova A, Sheyanov M, Kozhina N. ",Clinical efficacy and safety of formoterol and tiotropium administration in patient with chronic heart failure due to coronary artery disease combined with chronic obstructive pulmonary disease, European Journal of Heart Failure ,2015,17,    ,['citation-journal']," Evdokimov V, Evdokimova A, Sheyanov M, Kozhina N. Clinical efficacy and safety of formoterol and tiotropium administration in patient with chronic heart failure due to coronary artery disease combined with chronic obstructive pulmonary disease.  European Journal of Heart Failure 2015;17:68. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Clinical+efficacy+and+safety+of+formoterol+and+tiotropium+administration+in+patient+with+chronic+heart+failure+due+to+coronary+artery+disease+combined+with+chronic+obstructive+pulmonary+disease+&author=V+Evdokimov&author=A+Evdokimova&author=M+Sheyanov&author=N+Kozhina&publication_year=2015&hl=en']",,, Evdokimov 2015 {published data only}  ,excluded,CD012930-bbs2-0037, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0155,"Evdokimov V, Evdokimova A, Kovalenko E, Tebloev K. ",Prolonged use (18 months) of tiotropium and indacaterol in patient with chronic heart failure due to coronary artery disease combined with chronic obstructive pulmonary disease, European Journal of Heart Failure ,2016,18,    ,['citation-journal']," Evdokimov V, Evdokimova A, Kovalenko E, Tebloev K. Prolonged use (18 months) of tiotropium and indacaterol in patient with chronic heart failure due to coronary artery disease combined with chronic obstructive pulmonary disease.  European Journal of Heart Failure 2016;18:369. [1879‐0844]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Prolonged+use+(18+months)+of+tiotropium+and+indacaterol+in+patient+with+chronic+heart+failure+due+to+coronary+artery+disease+combined+with+chronic+obstructive+pulmonary+disease+&author=V+Evdokimov&author=A+Evdokimova&author=E+Kovalenko&author=K+Tebloev&publication_year=2016&hl=en']",,, Evdokimov 2015b {published data only}  ,excluded,CD012930-bbs2-0038, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0154,"Evdokimov V, Evdokimova A, Kovalenko E, Tebloev K, Zolotova O. ",Clinical efficacy and safety of tiotropium and indacaterol administration in patient with chronic heart failure due to coronary artery disease combined with chronic obstructive pulmonary disease, European Heart Journal ,2015,36,    ,['citation-journal']," Evdokimov V, Evdokimova A, Kovalenko E, Tebloev K, Zolotova O. Clinical efficacy and safety of tiotropium and indacaterol administration in patient with chronic heart failure due to coronary artery disease combined with chronic obstructive pulmonary disease.  European Heart Journal 2015;36:664. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Clinical+efficacy+and+safety+of+tiotropium+and+indacaterol+administration+in+patient+with+chronic+heart+failure+due+to+coronary+artery+disease+combined+with+chronic+obstructive+pulmonary+disease+&author=V+Evdokimov&author=A+Evdokimova&author=E+Kovalenko&author=K+Tebloev&author=O+Zolotova&publication_year=2015&hl=en']",,, Evdokimov 2015b {published data only}  ,excluded,CD012930-bbs2-0038, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0156,"Evdokimov V, Evdokimova A, Tebloev K, Kovalenko E, Kozhina N, Zolotova O. ",Efficacy and safety of different types of bronchodilator therapy in patients with chronic heart failure due to coronary artery disease combined with chronic obstructive pulmonary disease, European Heart Journal ,2014,35,    ,['citation-journal']," Evdokimov V, Evdokimova A, Tebloev K, Kovalenko E, Kozhina N, Zolotova O. Efficacy and safety of different types of bronchodilator therapy in patients with chronic heart failure due to coronary artery disease combined with chronic obstructive pulmonary disease.  European Heart Journal 2014;35:385‐6. CENTRAL    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/24227808', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+different+types+of+bronchodilator+therapy+in+patients+with+chronic+heart+failure+due+to+coronary+artery+disease+combined+with+chronic+obstructive+pulmonary+disease+&author=V+Evdokimov&author=A+Evdokimova&author=K+Tebloev&author=E+Kovalenko&author=N+Kozhina&author=O+Zolotova&publication_year=2014&hl=en']",24227808,, Evdokimov 2015b {published data only}  ,excluded,CD012930-bbs2-0038, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0157,"Evdokimov V, Evdokimova A, Tebloev K, Zolotova O. ",Clinical efficacy and safety of tiotropium and indacaterol administration in patient with chronic heart failure due to coronary artery disease combined with chronic obstructive pulmonary disease, European Journal of Heart Failure ,2014,16,    ,['citation-journal']," Evdokimov V, Evdokimova A, Tebloev K, Zolotova O. Clinical efficacy and safety of tiotropium and indacaterol administration in patient with chronic heart failure due to coronary artery disease combined with chronic obstructive pulmonary disease.  European Journal of Heart Failure 2014;16:251. [1879‐0844]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Clinical+efficacy+and+safety+of+tiotropium+and+indacaterol+administration+in+patient+with+chronic+heart+failure+due+to+coronary+artery+disease+combined+with+chronic+obstructive+pulmonary+disease+&author=V+Evdokimov&author=A+Evdokimova&author=K+Tebloev&author=O+Zolotova&publication_year=2014&hl=en']",,, Evdokimov 2015b {published data only}  ,excluded,CD012930-bbs2-0038, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0158,"Ferguson GT, Fowler‐Taylor A, Thach C, Wang Q, Schubert‐Tennigkeit AA, Banerji D. ","QVA149 is safe and well tolerated in patients with moderate‐to‐severe COPD: FLIGHT3, a 52 week safety study", American Journal of Respiratory and Critical Care Medicine ,2015,191,    ,['citation-journal']," Ferguson GT, Fowler‐Taylor A, Thach C, Wang Q, Schubert‐Tennigkeit AA, Banerji D. QVA149 is safe and well tolerated in patients with moderate‐to‐severe COPD: FLIGHT3, a 52 week safety study.  American Journal of Respiratory and Critical Care Medicine 2015;191:A5762. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=QVA149+is+safe+and+well+tolerated+in+patients+with+moderate‐to‐severe+COPD:+FLIGHT3,+a+52+week+safety+study+&author=GT+Ferguson&author=A+Fowler‐Taylor&author=C+Thach&author=Q+Wang&author=AA+Schubert‐Tennigkeit&author=D+Banerji&publication_year=2015&hl=en']",,, Ferguson 2015 {published data only}  ,excluded,CD012930-bbs2-0039, Wrong comparator (dose of indacaterol in the control group was greater than that in combination arm)  
CD012930-bib-0159,"Fogarty C, Ortiz S. ","Pharmacokinetics, safety, and tolerability of aclidinium/formoterol fixed dose combination via pressair/genuair vs formoterol via foradil aerolizer in patients with moderate to severe COPD", Chest ,2014,146,    ,['citation-journal']," Fogarty C, Ortiz S. Pharmacokinetics, safety, and tolerability of aclidinium/formoterol fixed dose combination via pressair/genuair vs formoterol via foradil aerolizer in patients with moderate to severe COPD.  Chest 2014;146(4 (2)):45A. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1378/chest.1991652', 'https://scholar.google.com/scholar_lookup?title=Pharmacokinetics,+safety,+and+tolerability+of+aclidinium/formoterol+fixed+dose+combination+via+pressair/genuair+vs+formoterol+via+foradil+aerolizer+in+patients+with+moderate+to+severe+COPD+&author=C+Fogarty&author=S+Ortiz&publication_year=2014&hl=en']",,https://doi.org/10.1378/chest.1991652, Fogarty 2014 {published data only}  ,excluded,CD012930-bbs2-0040, Duration of treatment < 3 weeks 
CD012930-bib-0160,"Hanania NA, Tashkin DP, Kerwin E, Donohue J, Denenberg M, O'Donnell D, et al. ",Safety and efficacy of a novel LAMA/LABA co‐suspension technology glycopyrrolate/formoterol fixed‐dose combination delivered by MDI: results of a one‐year extension study in patients with COPD (PINNACLE‐3), American Journal of Respiratory and Critical Care Medicine ,2016,193,    ,['citation-journal']," Hanania NA, Tashkin DP, Kerwin E, Donohue J, Denenberg M, O'Donnell D, et al. Safety and efficacy of a novel LAMA/LABA co‐suspension technology glycopyrrolate/formoterol fixed‐dose combination delivered by MDI: results of a one‐year extension study in patients with COPD (PINNACLE‐3).  American Journal of Respiratory and Critical Care Medicine 2016;193:A6791. CENTRAL    Google Scholar     ","['', ""https://scholar.google.com/scholar_lookup?title=Safety+and+efficacy+of+a+novel+LAMA/LABA+co‐suspension+technology+glycopyrrolate/formoterol+fixed‐dose+combination+delivered+by+MDI:+results+of+a+one‐year+extension+study+in+patients+with+COPD+(PINNACLE‐3)+&author=NA+Hanania&author=DP+Tashkin&author=E+Kerwin&author=J+Donohue&author=M+Denenberg&author=D+O'Donnell&publication_year=2016&hl=en""]",,, Hanania 2016 {published data only}  ,excluded,CD012930-bbs2-0041, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0161,"Hanania NA, Tashkin DP, Kerwin EM, Donohue JF, Denenberg M, O'Donnell DE, et al. ",Long‐term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co‐Suspension Delivery Technology in patients with chronic obstructive pulmonary disease, Respiratory Medicine ,2017,126,    ,['citation-journal']," Hanania NA, Tashkin DP, Kerwin EM, Donohue JF, Denenberg M, O'Donnell DE, et al. Long‐term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co‐Suspension Delivery Technology in patients with chronic obstructive pulmonary disease.  Respiratory Medicine 2017;126:105‐15. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.rmed.2017.03.015', 'https://www.ncbi.nlm.nih.gov/pubmed/28427541', ""https://scholar.google.com/scholar_lookup?title=Long‐term+safety+and+efficacy+of+glycopyrrolate/formoterol+metered+dose+inhaler+using+novel+Co‐Suspension+Delivery+Technology+in+patients+with+chronic+obstructive+pulmonary+disease+&author=NA+Hanania&author=DP+Tashkin&author=EM+Kerwin&author=JF+Donohue&author=M+Denenberg&author=DE+O'Donnell&publication_year=2017&hl=en""]",28427541,https://doi.org/10.1016/j.rmed.2017.03.015, Hanania 2016 {published data only}  ,excluded,CD012930-bbs2-0041, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0163,Hoshino M. ,Quantitative computed tomography assessment of airway dimensions by combining tiotropium and indacaterol in patients with COPD, European Respiratory Journal ,2014,44,    ,['citation-journal'], Hoshino M. Quantitative computed tomography assessment of airway dimensions by combining tiotropium and indacaterol in patients with COPD.  European Respiratory Journal 2014;44:4668. CENTRAL    Google Scholar     ,"['', 'https://scholar.google.com/scholar_lookup?title=Quantitative+computed+tomography+assessment+of+airway+dimensions+by+combining+tiotropium+and+indacaterol+in+patients+with+COPD+&author=M+Hoshino&publication_year=2014&hl=en']",,, Hoshino 2014 {published data only}  ,excluded,CD012930-bbs2-0042, Wrong intervention (combination inhaler not used) 
CD012930-bib-0162,"Hoshino M, Ohtawa J. ",Computed tomography assessment of airway dimensions with combined tiotropium and indacaterol therapy in COPD patients, Respirology ,2014,19,    ,['citation-journal']," Hoshino M, Ohtawa J. Computed tomography assessment of airway dimensions with combined tiotropium and indacaterol therapy in COPD patients.  Respirology 2014;19(3):403‐10. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1111/resp.12256', 'https://www.ncbi.nlm.nih.gov/pubmed/24708031', 'https://scholar.google.com/scholar_lookup?title=Computed+tomography+assessment+of+airway+dimensions+with+combined+tiotropium+and+indacaterol+therapy+in+COPD+patients+&author=M+Hoshino&author=J+Ohtawa&publication_year=2014&hl=en']",24708031,https://doi.org/10.1111/resp.12256, Hoshino 2014 {published data only}  ,excluded,CD012930-bbs2-0042, Wrong intervention (combination inhaler not used) 
CD012930-bib-0164,"Ichinose M, Minakata Y, Motegi T, Ueki J, Seki T, Anzai T, et al. ","Study design of VESUTO®: efficacy of tiotropium/olodaterol on lung hyperinflation, exercise capacity, and physical activity in Japanese patients with chronic obstructive pulmonary disease", Advances in Therapy ,2017,34,    ,['citation-journal']," Ichinose M, Minakata Y, Motegi T, Ueki J, Seki T, Anzai T, et al. Study design of VESUTO®: efficacy of tiotropium/olodaterol on lung hyperinflation, exercise capacity, and physical activity in Japanese patients with chronic obstructive pulmonary disease.  Advances in Therapy 2017;34(7):1622‐35. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1007/s12325-017-0554-3', 'https://www.ncbi.nlm.nih.gov/pubmed/28537001', 'https://scholar.google.com/scholar_lookup?title=Study+design+of+VESUTO®:+efficacy+of+tiotropium/olodaterol+on+lung+hyperinflation,+exercise+capacity,+and+physical+activity+in+Japanese+patients+with+chronic+obstructive+pulmonary+disease+&author=M+Ichinose&author=Y+Minakata&author=T+Motegi&author=J+Ueki&author=T+Seki&author=T+Anzai&publication_year=2017&hl=en']",28537001,https://doi.org/10.1007/s12325-017-0554-3, Ichinose 2016 {published data only}  ,excluded,CD012930-bbs2-0043, No placebo group 
CD012930-bib-0165,"Ichinose M, Minakata Y, Motegi T, Ueki J, Seki T, Anzai T, et al. ","Study design of vesuto; study to evaluate the efficacy of tiotropium + olodaterol vs tiotropium on lung hyperinflation, exercise capacity, and physical activity in Japanese COPD patients", Respirology ,2016,21,    ,['citation-journal']," Ichinose M, Minakata Y, Motegi T, Ueki J, Seki T, Anzai T, et al. Study design of vesuto; study to evaluate the efficacy of tiotropium + olodaterol vs tiotropium on lung hyperinflation, exercise capacity, and physical activity in Japanese COPD patients.  Respirology 2016;21:179. CENTRAL    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/27005392', 'https://scholar.google.com/scholar_lookup?title=Study+design+of+vesuto;+study+to+evaluate+the+efficacy+of+tiotropium+++olodaterol+vs+tiotropium+on+lung+hyperinflation,+exercise+capacity,+and+physical+activity+in+Japanese+COPD+patients+&author=M+Ichinose&author=Y+Minakata&author=T+Motegi&author=J+Ueki&author=T+Seki&author=T+Anzai&publication_year=2016&hl=en']",27005392,, Ichinose 2016 {published data only}  ,excluded,CD012930-bbs2-0043, No placebo group 
CD012930-bib-0166,NCT02629965. ,"Comparing the efficacy of tiotropium + olodaterol fixed dose combination (FDC) over tiotropium in improvement of lung hyperinflation, exercise capacity and physical activity in Japanese COPD patients",,,,   ,['citation-other']," NCT02629965. Comparing the efficacy of tiotropium + olodaterol fixed dose combination (FDC) over tiotropium in improvement of lung hyperinflation, exercise capacity and physical activity in Japanese COPD patients. clinicaltrials.gov/ct2/show/NCT02629965 (first received 15 December 2015). CENTRAL    ",[''],,, Ichinose 2016 {published data only}  ,excluded,CD012930-bbs2-0043, No placebo group 
CD012930-bib-0167,"Ichinose M, Minakata Y, Motegi T, Ueki J, Seki T, Anzai T, et al. ","Study design of VESUTO: efficacy of tiotropium/olodaterol on lung hyperinflation, exercise capacity, and physical activity in Japanese patients with chronic obstructive pulmonary disease", Advance Therapeutics ,2017,4,    ,['citation-journal']," Ichinose M, Minakata Y, Motegi T, Ueki J, Seki T, Anzai T, et al. Study design of VESUTO: efficacy of tiotropium/olodaterol on lung hyperinflation, exercise capacity, and physical activity in Japanese patients with chronic obstructive pulmonary disease.  Advance Therapeutics 2017;4(7):1622‐35. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1007/s12325-017-0554-3', 'https://scholar.google.com/scholar_lookup?title=Study+design+of+VESUTO:+efficacy+of+tiotropium/olodaterol+on+lung+hyperinflation,+exercise+capacity,+and+physical+activity+in+Japanese+patients+with+chronic+obstructive+pulmonary+disease+&author=M+Ichinose&author=Y+Minakata&author=T+Motegi&author=J+Ueki&author=T+Seki&author=T+Anzai&publication_year=2017&hl=en']",,https://doi.org/10.1007/s12325-017-0554-3, Ichinose 2017 {published data only}  ,excluded,CD012930-bbs2-0044, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0168,"Imran M, Chhabra S, Kotwani A. ","Combinations of long acting beta<inf>2</inf> agonists to tiotropium: a randomized, double‐blind, placebo‐controlled, active‐drug controlled, parallel design academic clinical trial in moderate COPD male patients", Archives of Pharmacy Practice ,2015,6,    ,['citation-journal']," Imran M, Chhabra S, Kotwani A. Combinations of long acting beta<inf>2</inf> agonists to tiotropium: a randomized, double‐blind, placebo‐controlled, active‐drug controlled, parallel design academic clinical trial in moderate COPD male patients.  Archives of Pharmacy Practice 2015;6(2):19‐23. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.4103/2045-080X.155509', 'https://scholar.google.com/scholar_lookup?title=Combinations+of+long+acting+beta2+agonists+to+tiotropium:+a+randomized,+double‐blind,+placebo‐controlled,+active‐drug+controlled,+parallel+design+academic+clinical+trial+in+moderate+COPD+male+patients+&author=M+Imran&author=S+Chhabra&author=A+Kotwani&publication_year=2015&hl=en']",,https://doi.org/10.4103/2045-080X.155509, Imran 2015 {published data only}  ,excluded,CD012930-bbs2-0045, Duration of treatment < 3 weeks 
CD012930-bib-0169,Jones CDS. ,,The Combined Effect of Tiotropium and Formoterol on the Functional Status of Patients with Moderate‐to‐Severe COPD [Dissertation],2010,,   ,['citation-book']," Jones CDS. The Combined Effect of Tiotropium and Formoterol on the Functional Status of Patients with Moderate‐to‐Severe COPD [Dissertation]. Charleston: Proquest, Umi Dissertation Publishing, 2010. [978‐112‐405‐5602602]CENTRAL    ",[''],,, Jones 2010 {published data only}  ,excluded,CD012930-bbs2-0046, Combined inhaler not used (LAMA plus LABA in individual inhalers) 
CD012930-bib-0170,"Ayers T, Fogel R, Banerji D, Maitra S, Schubert‐Tennigkeit AA. ","QVA149, twice daily, is well tolerated in patients with moderate‐to‐severe COPD and has a safety profile similar to placebo: FLIGHT1 and FLIGHT2 pooled analysis in the subgroup of patients from the USA", Chest ,2015,148,    ,['citation-journal']," Ayers T, Fogel R, Banerji D, Maitra S, Schubert‐Tennigkeit AA. QVA149, twice daily, is well tolerated in patients with moderate‐to‐severe COPD and has a safety profile similar to placebo: FLIGHT1 and FLIGHT2 pooled analysis in the subgroup of patients from the USA.  Chest 2015;148(4):725A. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1378/chest.2279524', 'https://scholar.google.com/scholar_lookup?title=QVA149,+twice+daily,+is+well+tolerated+in+patients+with+moderate‐to‐severe+COPD+and+has+a+safety+profile+similar+to+placebo:+FLIGHT1+and+FLIGHT2+pooled+analysis+in+the+subgroup+of+patients+from+the+USA+&author=T+Ayers&author=R+Fogel&author=D+Banerji&author=S+Maitra&author=AA+Schubert‐Tennigkeit&publication_year=2015&hl=en']",,https://doi.org/10.1378/chest.2279524, Mahler 2015 {published data only}  ,excluded,CD012930-bbs2-0047, 2nd ROUND: Wrong intervention ‐ LAMA/LABA administered twice daily 
CD012930-bib-0171,"Fogel R, Ayers T, Banerji D, Maitra S, Schubert‐Tennigkeit AA. ",Cardiovascular safety of QVA149 in patients with moderate‐to‐severe COPD: pooled analysis of FLIGHT1 and FLIGHT2 clinical studies, Chest ,2015,148,    ,['citation-journal']," Fogel R, Ayers T, Banerji D, Maitra S, Schubert‐Tennigkeit AA. Cardiovascular safety of QVA149 in patients with moderate‐to‐severe COPD: pooled analysis of FLIGHT1 and FLIGHT2 clinical studies.  Chest 2015;148(4):718A. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1378/chest.2277009', 'https://scholar.google.com/scholar_lookup?title=Cardiovascular+safety+of+QVA149+in+patients+with+moderate‐to‐severe+COPD:+pooled+analysis+of+FLIGHT1+and+FLIGHT2+clinical+studies+&author=R+Fogel&author=T+Ayers&author=D+Banerji&author=S+Maitra&author=AA+Schubert‐Tennigkeit&publication_year=2015&hl=en']",,https://doi.org/10.1378/chest.2277009, Mahler 2015 {published data only}  ,excluded,CD012930-bbs2-0047, 2nd ROUND: Wrong intervention ‐ LAMA/LABA administered twice daily 
CD012930-bib-0172,"Fowler TA, Fogel R, Banerji D, Maitra S. ","Improvement in lung function, dyspnea, and health status with QVA149 compared with placebo in the subgroup of patients with COPD from the USA: FLIGHT1 and FLIGHT2 pooled analysis",,2015,,    ,['citation-other']," Fowler TA, Fogel R, Banerji D, Maitra S. Improvement in lung function, dyspnea, and health status with QVA149 compared with placebo in the subgroup of patients with COPD from the USA: FLIGHT1 and FLIGHT2 pooled analysis. Chest. F.‐Y. Chao, Emory University, Atlanta, GA, United States, 2015; Vol. 148, issue 4:718A. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Improvement+in+lung+function,+dyspnea,+and+health+status+with+QVA149+compared+with+placebo+in+the+subgroup+of+patients+with+COPD+from+the+USA:+FLIGHT1+and+FLIGHT2+pooled+analysis+&author=TA+Fowler&author=R+Fogel&author=D+Banerji&author=S+Maitra&publication_year=2015&hl=en']",,, Mahler 2015 {published data only}  ,excluded,CD012930-bbs2-0047, 2nd ROUND: Wrong intervention ‐ LAMA/LABA administered twice daily 
CD012930-bib-0173,"Jones P, Larbig M, Maitra S, Fowler‐Taylor A, Banerji D. ",Analysis of improvement in SGRQ component scores with QVA149: pooled data from the FLIGHT1 and FLIGHT2 studies, Chest ,2015,148,    ,['citation-journal']," Jones P, Larbig M, Maitra S, Fowler‐Taylor A, Banerji D. Analysis of improvement in SGRQ component scores with QVA149: pooled data from the FLIGHT1 and FLIGHT2 studies.  Chest 2015;148(4):722A. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1378/chest.2251187', 'https://scholar.google.com/scholar_lookup?title=Analysis+of+improvement+in+SGRQ+component+scores+with+QVA149:+pooled+data+from+the+FLIGHT1+and+FLIGHT2+studies+&author=P+Jones&author=M+Larbig&author=S+Maitra&author=A+Fowler‐Taylor&author=D+Banerji&publication_year=2015&hl=en']",,https://doi.org/10.1378/chest.2251187, Mahler 2015 {published data only}  ,excluded,CD012930-bbs2-0047, 2nd ROUND: Wrong intervention ‐ LAMA/LABA administered twice daily 
CD012930-bib-0174,"Jones PW, Ayers T, Fowler‐Taylor A, Larbig M, Thach C, Maitra S, et al. ","QVA149 demonstrates superior improvements in health status, as measured by SGRQ, compared with placebo in patients with moderate‐to‐severe COPD: the FLIGHT2 study", American Journal of Respiratory and Critical Care Medicine ,2015,191,    ,['citation-journal']," Jones PW, Ayers T, Fowler‐Taylor A, Larbig M, Thach C, Maitra S, et al. QVA149 demonstrates superior improvements in health status, as measured by SGRQ, compared with placebo in patients with moderate‐to‐severe COPD: the FLIGHT2 study.  American Journal of Respiratory and Critical Care Medicine 2015;191:A5747. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=QVA149+demonstrates+superior+improvements+in+health+status,+as+measured+by+SGRQ,+compared+with+placebo+in+patients+with+moderate‐to‐severe+COPD:+the+FLIGHT2+study+&author=PW+Jones&author=T+Ayers&author=A+Fowler‐Taylor&author=M+Larbig&author=C+Thach&author=S+Maitra&publication_year=2015&hl=en']",,, Mahler 2015 {published data only}  ,excluded,CD012930-bbs2-0047, 2nd ROUND: Wrong intervention ‐ LAMA/LABA administered twice daily 
CD012930-bib-0175,"Kerwin E, Ayers T, Banerji D, Maitra S, Patalano F. ",QVA149 significantly improves lung function and reduces rescue medication use compared with its monocomponents in COPD patients with moderate‐to‐severe airflow limitation: pooled analysis from the FLIGHT1 and FLIGHT2 studies, Chest ,2015,148,    ,['citation-journal']," Kerwin E, Ayers T, Banerji D, Maitra S, Patalano F. QVA149 significantly improves lung function and reduces rescue medication use compared with its monocomponents in COPD patients with moderate‐to‐severe airflow limitation: pooled analysis from the FLIGHT1 and FLIGHT2 studies.  Chest 2015;148(4):729A. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1378/chest.2276227', 'https://scholar.google.com/scholar_lookup?title=QVA149+significantly+improves+lung+function+and+reduces+rescue+medication+use+compared+with+its+monocomponents+in+COPD+patients+with+moderate‐to‐severe+airflow+limitation:+pooled+analysis+from+the+FLIGHT1+and+FLIGHT2+studies+&author=E+Kerwin&author=T+Ayers&author=D+Banerji&author=S+Maitra&author=F+Patalano&publication_year=2015&hl=en']",,https://doi.org/10.1378/chest.2276227, Mahler 2015 {published data only}  ,excluded,CD012930-bbs2-0047, 2nd ROUND: Wrong intervention ‐ LAMA/LABA administered twice daily 
CD012930-bib-0176,"Kerwin E, Ayers T, Fowler‐Taylor A, Patalano F, Banerji D, Maitra S. ",QVA149 demonstrated significant improvement in lung function compared with placebo and its monocomponents: pooled analysis from the FLIGHT1 and FLIGHT2 studies, Chest ,2015,148,    ,['citation-journal']," Kerwin E, Ayers T, Fowler‐Taylor A, Patalano F, Banerji D, Maitra S. QVA149 demonstrated significant improvement in lung function compared with placebo and its monocomponents: pooled analysis from the FLIGHT1 and FLIGHT2 studies.  Chest 2015;148(4):741A. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1378/chest.2276869', 'https://scholar.google.com/scholar_lookup?title=QVA149+demonstrated+significant+improvement+in+lung+function+compared+with+placebo+and+its+monocomponents:+pooled+analysis+from+the+FLIGHT1+and+FLIGHT2+studies+&author=E+Kerwin&author=T+Ayers&author=A+Fowler‐Taylor&author=F+Patalano&author=D+Banerji&author=S+Maitra&publication_year=2015&hl=en']",,https://doi.org/10.1378/chest.2276869, Mahler 2015 {published data only}  ,excluded,CD012930-bbs2-0047, 2nd ROUND: Wrong intervention ‐ LAMA/LABA administered twice daily 
CD012930-bib-0177,"Kerwin EM, Ayers T, Fowler‐Taylor A, Larbig M, Thach C, Maitra S, et al. ",QVA149 provides superior improvement in lung function versus its monocomponents in patients with moderate‐to‐severe COPD: the FLIGHT2 study, American Journal of Respiratory and Critical Care Medicine ,2015,191,    ,['citation-journal']," Kerwin EM, Ayers T, Fowler‐Taylor A, Larbig M, Thach C, Maitra S, et al. QVA149 provides superior improvement in lung function versus its monocomponents in patients with moderate‐to‐severe COPD: the FLIGHT2 study.  American Journal of Respiratory and Critical Care Medicine 2015;191:A5741. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=QVA149+provides+superior+improvement+in+lung+function+versus+its+monocomponents+in+patients+with+moderate‐to‐severe+COPD:+the+FLIGHT2+study+&author=EM+Kerwin&author=T+Ayers&author=A+Fowler‐Taylor&author=M+Larbig&author=C+Thach&author=S+Maitra&publication_year=2015&hl=en']",,, Mahler 2015 {published data only}  ,excluded,CD012930-bbs2-0047, 2nd ROUND: Wrong intervention ‐ LAMA/LABA administered twice daily 
CD012930-bib-0178,"Kerwin EM, Fowler‐Taylor A, Ayers T, Thach C, Maitra S, Patalano F, et al. ",QVA149 improves lung function to a greater extent than monocomponents in patients with moderate‐to‐severe COPD: the FLIGHT1 study, American Journal of Respiratory and Critical Care Medicine ,2015,191,    ,['citation-journal']," Kerwin EM, Fowler‐Taylor A, Ayers T, Thach C, Maitra S, Patalano F, et al. QVA149 improves lung function to a greater extent than monocomponents in patients with moderate‐to‐severe COPD: the FLIGHT1 study.  American Journal of Respiratory and Critical Care Medicine 2015;191:A5743. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=QVA149+improves+lung+function+to+a+greater+extent+than+monocomponents+in+patients+with+moderate‐to‐severe+COPD:+the+FLIGHT1+study+&author=EM+Kerwin&author=A+Fowler‐Taylor&author=T+Ayers&author=C+Thach&author=S+Maitra&author=F+Patalano&publication_year=2015&hl=en']",,, Mahler 2015 {published data only}  ,excluded,CD012930-bbs2-0047, 2nd ROUND: Wrong intervention ‐ LAMA/LABA administered twice daily 
CD012930-bib-0179,"Mahler D, Larbig M, Patalano F, Maitra S, Banerji D. ",Dual bronchodilation with QVA149 improves dyspnea in patients with moderate‐to‐severe COPD: pooled analysis from the FLIGHT1 and FLIGHT2 studies, Chest ,2015,148,    ,['citation-journal']," Mahler D, Larbig M, Patalano F, Maitra S, Banerji D. Dual bronchodilation with QVA149 improves dyspnea in patients with moderate‐to‐severe COPD: pooled analysis from the FLIGHT1 and FLIGHT2 studies.  Chest 2015;148(4):730A. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1378/chest.2276183', 'https://scholar.google.com/scholar_lookup?title=Dual+bronchodilation+with+QVA149+improves+dyspnea+in+patients+with+moderate‐to‐severe+COPD:+pooled+analysis+from+the+FLIGHT1+and+FLIGHT2+studies+&author=D+Mahler&author=M+Larbig&author=F+Patalano&author=S+Maitra&author=D+Banerji&publication_year=2015&hl=en']",,https://doi.org/10.1378/chest.2276183, Mahler 2015 {published data only}  ,excluded,CD012930-bbs2-0047, 2nd ROUND: Wrong intervention ‐ LAMA/LABA administered twice daily 
CD012930-bib-0180,"Mahler DA, Ayers T, Fowler‐Taylor A, Larbig M, Thach C, Maitra S, et al. ",QVA149 reduces dyspnea in patients with moderate‐to‐severe COPD as measured by the transition dyspnea index: the FLIGHT2 study, American Journal of Respiratory and Critical Care Medicine ,2015,191,    ,['citation-journal']," Mahler DA, Ayers T, Fowler‐Taylor A, Larbig M, Thach C, Maitra S, et al. QVA149 reduces dyspnea in patients with moderate‐to‐severe COPD as measured by the transition dyspnea index: the FLIGHT2 study.  American Journal of Respiratory and Critical Care Medicine 2015;191:A5751. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=QVA149+reduces+dyspnea+in+patients+with+moderate‐to‐severe+COPD+as+measured+by+the+transition+dyspnea+index:+the+FLIGHT2+study+&author=DA+Mahler&author=T+Ayers&author=A+Fowler‐Taylor&author=M+Larbig&author=C+Thach&author=S+Maitra&publication_year=2015&hl=en']",,, Mahler 2015 {published data only}  ,excluded,CD012930-bbs2-0047, 2nd ROUND: Wrong intervention ‐ LAMA/LABA administered twice daily 
CD012930-bib-0181,"Mahler DA, D'Urzo A, Peckitt C, Lassen C, Kramer B, Filcek S, et al. ",Combining once‐daily bronchodilators In COPD: Indacaterol plus tiotropium versus tiotropium alone, American Journal of Respiratory and Critical Care Medicine ,2011,183,    ,['citation-journal']," Mahler DA, D'Urzo A, Peckitt C, Lassen C, Kramer B, Filcek S, et al. Combining once‐daily bronchodilators In COPD: Indacaterol plus tiotropium versus tiotropium alone.  American Journal of Respiratory and Critical Care Medicine 2011;183:A1591. CENTRAL    Google Scholar     ","['', ""https://scholar.google.com/scholar_lookup?title=Combining+once‐daily+bronchodilators+In+COPD:+Indacaterol+plus+tiotropium+versus+tiotropium+alone+&author=DA+Mahler&author=A+D'Urzo&author=C+Peckitt&author=C+Lassen&author=B+Kramer&author=S+Filcek&publication_year=2011&hl=en""]",,, Mahler 2015 {published data only}  ,excluded,CD012930-bbs2-0047, 2nd ROUND: Wrong intervention ‐ LAMA/LABA administered twice daily 
CD012930-bib-0182,"Mahler DA, Kerwin E, Ayers T, Taylor AF, Maitra S, Thach C, et al. ",FLIGHT1 and FLIGHT2: efficacy and safety of QVA149 (indacaterol/glycopyrrolate) versus its monocomponents and placebo in patients with chronic obstructive pulmonary disease, American Journal of Respiratory and Critical Care Medicine ,2015,192,    ,['citation-journal']," Mahler DA, Kerwin E, Ayers T, Taylor AF, Maitra S, Thach C, et al. FLIGHT1 and FLIGHT2: efficacy and safety of QVA149 (indacaterol/glycopyrrolate) versus its monocomponents and placebo in patients with chronic obstructive pulmonary disease.  American Journal of Respiratory and Critical Care Medicine 2015;192(9):1068‐79. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1164/rccm.201505-1048OC', 'https://www.ncbi.nlm.nih.gov/pubmed/26177074', 'https://scholar.google.com/scholar_lookup?title=FLIGHT1+and+FLIGHT2:+efficacy+and+safety+of+QVA149+(indacaterol/glycopyrrolate)+versus+its+monocomponents+and+placebo+in+patients+with+chronic+obstructive+pulmonary+disease+&author=DA+Mahler&author=E+Kerwin&author=T+Ayers&author=AF+Taylor&author=S+Maitra&author=C+Thach&publication_year=2015&hl=en']",26177074,https://doi.org/10.1164/rccm.201505-1048OC, Mahler 2015 {published data only}  ,excluded,CD012930-bbs2-0047, 2nd ROUND: Wrong intervention ‐ LAMA/LABA administered twice daily 
CD012930-bib-0183,NCT01712516. ,"A 12‐week treatment, multi‐center, randomized, double‐blind, parallel‐group, placebo and active controlled study to assess the efficacy, safety, and tolerability of indacaterol maleate glycopyrronium bromide in COPD patients with moderate to severe airflow limitation",,,,   ,['citation-other']," NCT01712516. A 12‐week treatment, multi‐center, randomized, double‐blind, parallel‐group, placebo and active controlled study to assess the efficacy, safety, and tolerability of indacaterol maleate glycopyrronium bromide in COPD patients with moderate to severe airflow limitation. clinicaltrials.gov/ct2/show/NCT01712516 (first received 23 October 2012). CENTRAL    ",[''],,, Mahler 2015 {published data only}  ,excluded,CD012930-bbs2-0047, 2nd ROUND: Wrong intervention ‐ LAMA/LABA administered twice daily 
CD012930-bib-0184,NCT01727141. ,"A 12‐week treatment, multi‐center, randomized, double‐blind, parallel‐group, placebo and active controlled study to assess the efficacy, safety, and tolerability of indacaterol maleate / glycopyrronium bromide in COPD patients with moderate to severe airflow limitation",,,,   ,['citation-other']," NCT01727141. A 12‐week treatment, multi‐center, randomized, double‐blind, parallel‐group, placebo and active controlled study to assess the efficacy, safety, and tolerability of indacaterol maleate / glycopyrronium bromide in COPD patients with moderate to severe airflow limitation. clinicaltrials.gov/ct2/show/NCT01727141 (first received 15 November 2012). CENTRAL    ",[''],,, Mahler 2015 {published data only}  ,excluded,CD012930-bbs2-0047, 2nd ROUND: Wrong intervention ‐ LAMA/LABA administered twice daily 
CD012930-bib-0185,"Maltais F, Beck E, Webster D, Maleki‐Yazdi MR, Seibt JV, Arnoux A, et al. ",Four weeks once daily treatment with tiotropium + olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patients, European Respiratory Journal ,2010,36,    ,['citation-journal']," Maltais F, Beck E, Webster D, Maleki‐Yazdi MR, Seibt JV, Arnoux A, et al. Four weeks once daily treatment with tiotropium + olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patients.  European Respiratory Journal 2010;36(Suppl 54):1014S. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Four+weeks+once+daily+treatment+with+tiotropium+++olodaterol+(BI+1744)+fixed+dose+combination+compared+with+tiotropium+in+COPD+patients+&author=F+Maltais&author=E+Beck&author=D+Webster&author=MR+Maleki‐Yazdi&author=JV+Seibt&author=A+Arnoux&publication_year=2010&hl=en']",,, Maltais 2010 {published data only}  ,excluded,CD012930-bbs2-0048, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0186,NCT00308191. ,A phase IIIB study to compare the efficacy and safety of concomitant treatment in patients with COPD,,,,   ,['citation-other'], NCT00308191. A phase IIIB study to compare the efficacy and safety of concomitant treatment in patients with COPD. clinicaltrials.gov/ct2/show/NCT00308191 (first received 29 March 2006). CENTRAL    ,[''],,, NCT00308191 2006 {published data only}  ,excluded,CD012930-bbs2-0049, Wrong intervention (combination inhaler not used) 
CD012930-bib-0187,NCT00424528. ,Efficacy safety study of Arformoterol/Tiotropium combination versus either therapy alone in chronic obstructive pulmonary disease (COPD),,,,   ,['citation-other'], NCT00424528. Efficacy safety study of Arformoterol/Tiotropium combination versus either therapy alone in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT00424528 (first received 19 January 2006). CENTRAL    ,[''],,, NCT00424528 2006 {published data only}  ,excluded,CD012930-bbs2-0050, Wrong intervention (combination inhaler not used) 
CD012930-bib-0188,NCT00696020. ,Combination of orally inhaled BI1744CL/tiotropium bromide in patients with chronic obstructive pulmonary disease (COPD),,,,   ,['citation-other'], NCT00696020. Combination of orally inhaled BI1744CL/tiotropium bromide in patients with chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT00696020 (first received 12 June 2008). CENTRAL    ,[''],,, NCT00696020 2008 {published data only}  ,excluded,CD012930-bbs2-0051, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0189,NCT00720499. ,Efficacy and safety of 4 weeks of treatment with orally inhaled BI1744/tiotropium bromide in patients with chronic obstructive pulmonary disease (COPD),,,,   ,['citation-other'], NCT00720499. Efficacy and safety of 4 weeks of treatment with orally inhaled BI1744/tiotropium bromide in patients with chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT00720499 (first received 22 July 2008). CENTRAL    ,[''],,, NCT00720499 2008 {published data only}  ,excluded,CD012930-bbs2-0052, Wrong comparator (no placebo) 
CD012930-bib-0190,NCT00845728. ,Exacerbation study (INVIGORATE),,,,   ,['citation-other'], NCT00845728. Exacerbation study (INVIGORATE). clinicaltrials.gov/ct2/show/NCT00845728 (first received 18 February 2009). CENTRAL    ,[''],,, NCT00845728 2009 {published data only}  ,excluded,CD012930-bbs2-0053, Wrong intervention (LABA/LAMA combination not evaluated) 
CD012930-bib-0191,NCT00846586. ,Efficacy and safety of indacaterol plus tiotropium versus tiotropium alone in patients with chronic obstructive pulmonary disease,,,,   ,['citation-other'], NCT00846586. Efficacy and safety of indacaterol plus tiotropium versus tiotropium alone in patients with chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT00846586 (first received 18 February 2009). CENTRAL    ,[''],,, NCT00846586 2009 {published data only}  ,excluded,CD012930-bbs2-0054, Wrong intervention (combination inhaler not used) 
CD012930-bib-0192,NCT00877383. ,Efficacy and safety of indacaterol plus tiotropium versus tiotropium alone in patients with chronic obstructive pulmonary disease,,,,   ,['citation-other'], NCT00877383. Efficacy and safety of indacaterol plus tiotropium versus tiotropium alone in patients with chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT00877383 (first received 7 April 2009). CENTRAL    ,[''],,, NCT00877383 2009 {published data only}  ,excluded,CD012930-bbs2-0055, Wrong intervention (combination inhaler not used) 
CD012930-bib-0193,NCT01040689. ,Characterization of 24 hour spirometry profiles of inhaled BI 1744 CL and inhaled tiotropium bromide in patients with chronic obstructive pulmonary disease,,,,   ,['citation-other'], NCT01040689. Characterization of 24 hour spirometry profiles of inhaled BI 1744 CL and inhaled tiotropium bromide in patients with chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT01040689 (first received 30 December 2009). CENTRAL    ,[''],,, NCT01040689 2010 {published data only}  ,excluded,CD012930-bbs2-0056, Wrong intervention (LABA/LAMA combination not evaluated) 
CD012930-bib-0194,NCT01040728. ,"A randomized, double‐blind, 4‐way crossover study to evaluate the efficacy of 24 hour spirometry profiles of inhaled BI 1744 CL and inhaled tiotropium bromide in patients with chronic obstructive pulmonary disease",,,,   ,['citation-other']," NCT01040728. A randomized, double‐blind, 4‐way crossover study to evaluate the efficacy of 24 hour spirometry profiles of inhaled BI 1744 CL and inhaled tiotropium bromide in patients with chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT01040728 (first received 30 December 2009). CENTRAL    ",[''],,, NCT01040728 2010 {published data only}  ,excluded,CD012930-bbs2-0057, Wrong intervention (LABA/LAMA combination not evaluated) 
CD012930-bib-0195,NCT01049360. ,"Efficacy and safety study of two fixed‐dose combinations of aclidinium bromide with formoterol fumarate compared with aclidinium bromide, formoterol fumarate and placebo",,,,   ,['citation-other']," NCT01049360. Efficacy and safety study of two fixed‐dose combinations of aclidinium bromide with formoterol fumarate compared with aclidinium bromide, formoterol fumarate and placebo. clinicaltrials.gov/ct2/show/NCT01049360 (first received 14 January 2010). CENTRAL    ",[''],,, NCT01049360 2009 {published data only}  ,excluded,CD012930-bbs2-0058, Treatment duration < 3 weeks 
CD012930-bib-0196,NCT01437540. ,Safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (LAC),,,,   ,['citation-other'], NCT01437540. Safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (LAC). clinicaltrials.gov/ct2/show/NCT01437540 (first received 21 September 2011). CENTRAL    ,[''],,, NCT01437540 2011 {published data only}  ,excluded,CD012930-bbs2-0059, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0197,NCT01476813. ,Randomized cross over study to assess efficacy and safety of BDP/FF and glycopyrrolate,,,,   ,['citation-other'], NCT01476813. Randomized cross over study to assess efficacy and safety of BDP/FF and glycopyrrolate. clinicaltrials.gov/ct2/show/NCT01476813 (first received 22 November 2011). CENTRAL    ,[''],,, NCT01476813 2012 {published data only}  ,excluded,CD012930-bbs2-0060, Wrong intervention (LABA/LAMA combination not evaluated) 
CD012930-bib-0198,NCT01491802. ,Effect of a new combination bronchodilator on exercise in GOLD stage II moderate COPD,,,,   ,['citation-other'], NCT01491802. Effect of a new combination bronchodilator on exercise in GOLD stage II moderate COPD. clinicaltrials.gov/ct2/show/NCT01491802 (first received 14 December 2011). CENTRAL    ,[''],,, NCT01491802 2012 {published data only}  ,excluded,CD012930-bbs2-0061, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0199,NCT01529632. ,"Comparison of safety and efficacy of the combination product QVA149A against the concurrent administration of the individual components, QAB149 and NVA237, in patients with chronic obstructive pulmonary disease (COPD)",,,,   ,['citation-other']," NCT01529632. Comparison of safety and efficacy of the combination product QVA149A against the concurrent administration of the individual components, QAB149 and NVA237, in patients with chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01529632 (first received 9 February 2012). CENTRAL    ",[''],,, NCT01529632 2012 {published data only}  ,excluded,CD012930-bbs2-0062, Wrong comparator (both individual LAMA and LABA received) 
CD012930-bib-0200,NCT01536262. ,Japan long‐term safety for tiotropium plus olodaterol,,,,   ,['citation-other'], NCT01536262. Japan long‐term safety for tiotropium plus olodaterol. clinicaltrials.gov/ct2/show/NCT01536262 (first received 22 February 2012). CENTRAL    ,[''],,, NCT01536262 2012 {published data only}  ,excluded,CD012930-bbs2-0063, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0201,NCT01551888. ,"Pharmacokinetic, safety and tolerability study of aclidinium/formoterol fixed dose combination and formoterol in patients with moderate to severe chronic obstructive pulmonary disease (COPD)",,,,   ,['citation-other']," NCT01551888. Pharmacokinetic, safety and tolerability study of aclidinium/formoterol fixed dose combination and formoterol in patients with moderate to severe chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01551888 (first received 13 March 2012). CENTRAL    ",[''],,, NCT01551888 2012 {published data only}  ,excluded,CD012930-bbs2-0064, Treatment duration < 3 weeks 
CD012930-bib-0202,NCT01574651. ,The effect of QVA149 on health related quality of life in patients with chronic obstructive pulmonary disease (COPD) (QUANTIFY),,,,   ,['citation-other'], NCT01574651. The effect of QVA149 on health related quality of life in patients with chronic obstructive pulmonary disease (COPD) (QUANTIFY). clinicaltrials.gov/ct2/show/NCT01574651 (first received 10 April 2012). CENTRAL    ,[''],,, NCT01574651 2012 {published data only}  ,excluded,CD012930-bbs2-0065, Wrong comparator (Indaceterol or glycopyrronium (i.e. FDC evaluated in intervention arm) not evaluated in comparator arm)  
CD012930-bib-0203,NCT01682863. ,A multi‐centre randomized double blind 52‐week study to assess the safety of QVA149 compared to QAB149 in patients with COPD who have moderate to severe airflow limitation,,,,   ,['citation-other'], NCT01682863. A multi‐centre randomized double blind 52‐week study to assess the safety of QVA149 compared to QAB149 in patients with COPD who have moderate to severe airflow limitation. clinicaltrials.gov/ct2/show/NCT01682863 (first received 11 September 2012). CENTRAL    ,[''],,, NCT01682863 2012 {published data only}  ,excluded,CD012930-bbs2-0066, Wrong comparator (indacaterol dose in control arm different than used in FDC in intervention arm)  
CD012930-bib-0204,NCT01697696. ,Long term safety study of NVA237 vs QAB149 in COPD patients,,,,   ,['citation-other'], NCT01697696. Long term safety study of NVA237 vs QAB149 in COPD patients. clinicaltrials.gov/ct2/show/NCT01697696 (first received 2 October 2012). CENTRAL    ,[''],,, NCT01697696 2012 {published data only}  ,excluded,CD012930-bbs2-0067, Wrong intervention (LABA/LAMA combination not evaluated) 
CD012930-bib-0205,NCT01703845. ,A study to characterize pharmacokinetics of tiotropium + olodaterol fixed‐dose combination in Japanese patients with COPD,,,,   ,['citation-other'], NCT01703845. A study to characterize pharmacokinetics of tiotropium + olodaterol fixed‐dose combination in Japanese patients with COPD. clinicaltrials.gov/ct2/show/NCT01703845 (first received 11 October 2012). CENTRAL    ,[''],,, NCT01703845 2012 {published data only}  ,excluded,CD012930-bbs2-0068," Wrong comparator (no LAMA or LABA alone, or placebo) "
CD012930-bib-0206,NCT01817764. ,A study to compare the efficacy and safety of umeclidinium/vilanterol and fluticasone propionate/salmeterol in subjects with chronic obstructive pulmonary disease (COPD),,,,   ,['citation-other'], NCT01817764. A study to compare the efficacy and safety of umeclidinium/vilanterol and fluticasone propionate/salmeterol in subjects with chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01817764 (first received 25 March 2013). CENTRAL    ,[''],,, NCT01817764 2013 {published data only}  ,excluded,CD012930-bbs2-0069," Wrong comparator (no single agent, or placebo) "
CD012930-bib-0207,NCT01985334. ,Study to evaluate the efficacy and safety of glycopyrronium or indacaterol maleate and glycopyrronium bromide fixed‐dose combination regarding symptoms and health status in patients with moderate COPD switching from treatment with any standard COPD regimen,,,,   ,['citation-other'], NCT01985334. Study to evaluate the efficacy and safety of glycopyrronium or indacaterol maleate and glycopyrronium bromide fixed‐dose combination regarding symptoms and health status in patients with moderate COPD switching from treatment with any standard COPD regimen. clinicaltrials.gov/ct2/show/NCT01985334 (first received 15 November 2013). CENTRAL    ,[''],,, NCT01985334 2014 {published data only}  ,excluded,CD012930-bbs2-0070, Wrong comparator (individual LAMA or LABA could be used based on prior treatment) 
CD012930-bib-0208,NCT02030535. ,Study to evaluate the effect on lung function and ECG when a combination of tiotropium plus olodaterol is administered to patients with COPD either from a single inhaler or each compound is administered after each other from two different inhalers,,,,   ,['citation-other'], NCT02030535. Study to evaluate the effect on lung function and ECG when a combination of tiotropium plus olodaterol is administered to patients with COPD either from a single inhaler or each compound is administered after each other from two different inhalers. clinicaltrials.gov/ct2/show/NCT02030535 (first received 8 January 2014). CENTRAL    ,[''],,, NCT02030535 2014 {published data only}  ,excluded,CD012930-bbs2-0071, Wrong study design (single‐dose study) 
CD012930-bib-0209,NCT02059434. ,Two‐part pharmacokinetic and pharmacodynamic study of LAS190792 in patients with asthma and COPD,,,,   ,['citation-other'], NCT02059434. Two‐part pharmacokinetic and pharmacodynamic study of LAS190792 in patients with asthma and COPD. clinicaltrials.gov/ct2/show/NCT02059434 (first received 11 February 2014). CENTRAL    ,[''],,, NCT02059434 2013 {published data only}  ,excluded,CD012930-bbs2-0072, Treatment duration < 3 weeks (single ascending‐dose study) 
CD012930-bib-0210,NCT02196714. ,PK study of PT003 and PT001 in Japanese healthy subjects,,,,   ,['citation-other'], NCT02196714. PK study of PT003 and PT001 in Japanese healthy subjects. clinicaltrials.gov/ct2/show/NCT02196714 (first received 22 July 2014). CENTRAL    ,[''],,, NCT02196714 2014 {published data only}  ,excluded,CD012930-bbs2-0073, Wrong patient population (healthy volunteers) 
CD012930-bib-0211,NCT02231177. ,Pharmacokinetics and safety of BI 1744 CL plus tiotropium bromide in chronic obstructive pulmonary disease (COPD),,,,   ,['citation-other'], NCT02231177. Pharmacokinetics and safety of BI 1744 CL plus tiotropium bromide in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT02231177 (first received 4 September 2014). CENTRAL    ,[''],,, NCT02231177 2008 {published data only}  ,excluded,CD012930-bbs2-0074, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0212,NCT02296138. ,Comparing the efficacy of tiotropium + olodaterol (5/5 Âµg) fixed dose combination (FDC) over tiotropium 5Âµg in reducing moderate to severe exacerbations in patients with severe to very severe chronic obstructive pulmonary disease,,,,   ,['citation-other'], NCT02296138. Comparing the efficacy of tiotropium + olodaterol (5/5 Âµg) fixed dose combination (FDC) over tiotropium 5Âµg in reducing moderate to severe exacerbations in patients with severe to very severe chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT02296138 (first received 20 November 2014). CENTRAL    ,[''],,, NCT02296138 2015 {published data only}  ,excluded,CD012930-bbs2-0075, No placebo group 
CD012930-bib-0213,NCT02343458. ,"Study to assess the efficacy and safety of PT003, PT005, and PT001 in subjects with moderate to very severe COPD",,,,   ,['citation-other']," NCT02343458. Study to assess the efficacy and safety of PT003, PT005, and PT001 in subjects with moderate to very severe COPD. clinicaltrials.gov/ct2/show/NCT02343458 (first received 22 January 2015). CENTRAL    ",[''],,, NCT02343458 2015 {published data only}  ,excluded,CD012930-bbs2-0076, LAMA/LABA administered twice daily 
CD012930-bib-0214,NCT02429765. ,Effect of aclidinium/formoterol on nighttime lung function and morning symptoms in chronic obstructive pulmonary disease,,,,   ,['citation-other'], NCT02429765. Effect of aclidinium/formoterol on nighttime lung function and morning symptoms in chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT02429765 (first received 29 April 2015). CENTRAL    ,[''],,, NCT02429765 2015 {published data only}  ,excluded,CD012930-bbs2-0077, LAMA/LABA administered twice daily 
CD012930-bib-0215,NCT02442206. ,Effect of QVA149 (indacaterol maleate/glycopyrronium bromide) on cardiac function in COPD patients (CLAIM),,,,   ,['citation-other'], NCT02442206. Effect of QVA149 (indacaterol maleate/glycopyrronium bromide) on cardiac function in COPD patients (CLAIM). clinicaltrials.gov/ct2/show/NCT02442206 (first received 13 May 2015). CENTRAL    ,[''],,, NCT02442206 2015 {published data only}  ,excluded,CD012930-bbs2-0078, Treatment duration < 3 weeks 
CD012930-bib-0216,NCT02465567. ,Study to assess the efficacy and safety of PT010 relative to PT003 and PT009 in subjects with moderate to very severe COPD (Ethos),,,,   ,['citation-other'], NCT02465567. Study to assess the efficacy and safety of PT010 relative to PT003 and PT009 in subjects with moderate to very severe COPD (Ethos). clinicaltrials.gov/ct2/show/NCT02465567 (first received 8 June 2015). CENTRAL    ,[''],,, NCT02465567 2015 {published data only}  ,excluded,CD012930-bbs2-0079," Wrong comparator (no single agent, or placebo) "
CD012930-bib-0217,NCT02487446. ,Efficacy and safety study of QVA149 in COPD patients,,,,   ,['citation-other'], NCT02487446. Efficacy and safety study of QVA149 in COPD patients. clinicaltrials.gov/ct2/show/NCT02487446 (first received 1 July 2015). CENTRAL    ,[''],,, NCT02487446 2015 {published data only}  ,excluded,CD012930-bbs2-0080," Wrong comparator (no single agent, or placebo) "
CD012930-bib-0218,NCT02487498. ,Efficacy and safety study of indacaterol maleate/glycopyrronium bromide in chronic obstructive pulmonary disease (COPD) patients,,,,   ,['citation-other'], NCT02487498. Efficacy and safety study of indacaterol maleate/glycopyrronium bromide in chronic obstructive pulmonary disease (COPD) patients. clinicaltrials.gov/ct2/show/NCT02487498 (first received 1 July 2015). CENTRAL    ,[''],,, NCT02487498 2015 {published data only}  ,excluded,CD012930-bbs2-0081," Wrong comparator (no single agent, or placebo) "
CD012930-bib-0219,NCT02579850. ,2‐arm parallel group study of fixed combination of CHF 5993 vs ultibro® in COPD patients (TRIBUTE),,,,   ,['citation-other'], NCT02579850. 2‐arm parallel group study of fixed combination of CHF 5993 vs ultibro® in COPD patients (TRIBUTE). clinicaltrials.gov/ct2/show/NCT02579850 (first received 20 October 2015). CENTRAL    ,[''],,, NCT02579850 2015 {published data only}  ,excluded,CD012930-bbs2-0082," Wrong comparator (no single agent, or placebo) "
CD012930-bib-0220,NCT02643082. ,A study to assess the effects of PT003 and placebo MDI on specific image based parameters in subjects with moderate to severe COPD,,,,   ,['citation-other'], NCT02643082. A study to assess the effects of PT003 and placebo MDI on specific image based parameters in subjects with moderate to severe COPD. clinicaltrials.gov/ct2/show/NCT02643082 (first received 30 December 2015). CENTRAL    ,[''],,, NCT02643082 2015 {published data only}  ,excluded,CD012930-bbs2-0083, Treatment duration < 3 weeks 
CD012930-bib-0221,NCT02796677. ,AMPLIFY ‐ D6571C00001 Duaklir USA phase III study,,,,   ,['citation-other'], NCT02796677. AMPLIFY ‐ D6571C00001 Duaklir USA phase III study. clinicaltrials.gov/ct2/show/NCT02796677 (first received 13 June 2016). CENTRAL    ,[''],,, NCT02796677 2016 {published data only}  ,excluded,CD012930-bbs2-0084, LAMA/LABA administered twice daily 
CD012930-bib-0222,NCT02845752. ,The effect of STIOLTO ™ RESPIMAT® on fatigue in chronic obstructive pulmonary disease,,,,   ,['citation-other'], NCT02845752. The effect of STIOLTO ™ RESPIMAT® on fatigue in chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT02845752 (first received 27 July 2016). CENTRAL    ,[''],,, NCT02845752 2016 {published data only}  ,excluded,CD012930-bbs2-0085, Treatment duration < 3 weeks 
CD012930-bib-0223,NCT02937584. ,A study to assess the effects of PT001 and PT005 MDI on specific image based parameters in subjects with moderate to severe COPD,,,,   ,['citation-other'], NCT02937584. A study to assess the effects of PT001 and PT005 MDI on specific image based parameters in subjects with moderate to severe COPD. clinicaltrials.gov/ct2/show/NCT02937584 (first received 18 October 2016). CENTRAL    ,[''],,, NCT02937584 2016 {published data only}  ,excluded,CD012930-bbs2-0086, Wrong intervention (LABA/LAMA combination not evaluated) 
CD012930-bib-0224,NCT02988869. ,Tiotropium/formoterol Via Discair® vs tiotropium monotherapy or tiotropium + formoterol free combination treatment,,,,   ,['citation-other'], NCT02988869. Tiotropium/formoterol Via Discair® vs tiotropium monotherapy or tiotropium + formoterol free combination treatment. clinicaltrials.gov/ct2/show/NCT02988869 (first received 9 December 2016). CENTRAL    ,[''],,, NCT02988869 2016 {published data only}  ,excluded,CD012930-bbs2-0087, No placebo group 
CD012930-bib-0225,NCT03022097. ,Study to patients with stable COPD to assess the efficacy and safety of aclidinium bromide/formoterol fumarate (DUAKLIR) (AVANT),,,,   ,['citation-other'], NCT03022097. Study to patients with stable COPD to assess the efficacy and safety of aclidinium bromide/formoterol fumarate (DUAKLIR) (AVANT). clinicaltrials.gov/ct2/show/NCT03022097 (first received 16 January 2017). CENTRAL    ,[''],,, NCT03022097 2017 {published data only}  ,excluded,CD012930-bbs2-0088, LAMA/LABA administered twice daily 
CD012930-bib-0226,NCT03024346. ,A study to assess the effects of PT003 and Placebo MDI on specific image based parameters in subjects with moderate to severe COPD,,,,   ,['citation-other'], NCT03024346. A study to assess the effects of PT003 and Placebo MDI on specific image based parameters in subjects with moderate to severe COPD. https://clinicaltrials.gov/ct2/show/NCT02643082 (note: NCT03024346 is an obsolete identifier referring to NCT02643082) (first received 30 December 2015). CENTRAL    ,[''],,, NCT03024346 2016 {published data only}  ,excluded,CD012930-bbs2-0089, Duration of treatment < 3 weeks 
CD012930-bib-0227,NCT03034915. ,"A 24‐week study to compare umeclidinium/vilanterol (UMEC/VI), UMEC and salmeterol in subjects with chronic obstructive pulmonary disease (COPD)",,,,   ,['citation-other']," NCT03034915. A 24‐week study to compare umeclidinium/vilanterol (UMEC/VI), UMEC and salmeterol in subjects with chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT03034915 (first received 27 January 2017). CENTRAL    ",[''],,, NCT03034915 2017 {published data only}  ,excluded,CD012930-bbs2-0090, No placebo group 
CD012930-bib-0228,"Orevillo C, Miller J, DePetrillo P, Maes A, Siddiqui S, Reisner C. ","Pharmacokinetic and safety profile of the novel LAMA/LABA co‐suspension technology glycopyrrolate/formoterol fumarate fixed‐dose combination MDI, in Japanese healthy subjects", American Journal of Respiratory and Critical Care Medicine ,2016,193,    ,['citation-journal']," Orevillo C, Miller J, DePetrillo P, Maes A, Siddiqui S, Reisner C. Pharmacokinetic and safety profile of the novel LAMA/LABA co‐suspension technology glycopyrrolate/formoterol fumarate fixed‐dose combination MDI, in Japanese healthy subjects.  American Journal of Respiratory and Critical Care Medicine 2016;193:A6828. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Pharmacokinetic+and+safety+profile+of+the+novel+LAMA/LABA+co‐suspension+technology+glycopyrrolate/formoterol+fumarate+fixed‐dose+combination+MDI,+in+Japanese+healthy+subjects+&author=C+Orevillo&author=J+Miller&author=P+DePetrillo&author=A+Maes&author=S+Siddiqui&author=C+Reisner&publication_year=2016&hl=en']",,, Orevillo 2016 {published data only}  ,excluded,CD012930-bbs2-0091, Duration of treatment < 3 weeks 
CD012930-bib-0229,"Martinez FJ, Rabe KF, Ferguson GT, Fabbri LM, Rennard S, Feldman GJ, et al. ",Efficacy and safety of glycopyrrolate/formoterol metered dose inhaler formulated using co‐suspension delivery technology in patients with COPD, Chest ,2017,151,    ,['citation-journal']," Martinez FJ, Rabe KF, Ferguson GT, Fabbri LM, Rennard S, Feldman GJ, et al. Efficacy and safety of glycopyrrolate/formoterol metered dose inhaler formulated using co‐suspension delivery technology in patients with COPD.  Chest 2017;151(2):340‐57. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.chest.2016.11.028', 'https://www.ncbi.nlm.nih.gov/pubmed/27916620', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+glycopyrrolate/formoterol+metered+dose+inhaler+formulated+using+co‐suspension+delivery+technology+in+patients+with+COPD+&author=FJ+Martinez&author=KF+Rabe&author=GT+Ferguson&author=LM+Fabbri&author=S+Rennard&author=GJ+Feldman&publication_year=2017&hl=en']",27916620,https://doi.org/10.1016/j.chest.2016.11.028, Rabe 2015 {published data only}  ,excluded,CD012930-bbs2-0092, 2nd ROUND: Wrong intervention ‐ LAMA/LABA administered twice daily 
CD012930-bib-0230,NCT01854658. ,"Multi‐center study to assess the efficacy and safety of PT003, PT005, and PT001 in subjects with moderate to very severe COPD (PINNACLE 2)",,,,   ,['citation-other']," NCT01854658. Multi‐center study to assess the efficacy and safety of PT003, PT005, and PT001 in subjects with moderate to very severe COPD (PINNACLE 2). clinicaltrials.gov/ct2/show/NCT01854658 (first received 15 May 2013). CENTRAL    ",[''],,, Rabe 2015 {published data only}  ,excluded,CD012930-bbs2-0092, 2nd ROUND: Wrong intervention ‐ LAMA/LABA administered twice daily 
CD012930-bib-0231,"Rabe K, Martinez F, Rodriguez‐Roisin R, Fabbri LM, Ferguson GT, Jones P, et al. ","PT003, a novel co‐suspension MDI glycopyrronium/formoterol fixed‐dose combination is superior to monocomponents in patients with COPD", European Respiratory Journal ,2015,46,    ,['citation-journal']," Rabe K, Martinez F, Rodriguez‐Roisin R, Fabbri LM, Ferguson GT, Jones P, et al. PT003, a novel co‐suspension MDI glycopyrronium/formoterol fixed‐dose combination is superior to monocomponents in patients with COPD.  European Respiratory Journal 2015;46:PA4363. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=PT003,+a+novel+co‐suspension+MDI+glycopyrronium/formoterol+fixed‐dose+combination+is+superior+to+monocomponents+in+patients+with+COPD+&author=K+Rabe&author=F+Martinez&author=R+Rodriguez‐Roisin&author=LM+Fabbri&author=GT+Ferguson&author=P+Jones&publication_year=2015&hl=en']",,, Rabe 2015 {published data only}  ,excluded,CD012930-bbs2-0092, 2nd ROUND: Wrong intervention ‐ LAMA/LABA administered twice daily 
CD012930-bib-0232,"Reisner C, Fogarty C, Spangenthal S, Dunn L, Kerwin E, Quinn D, et al. ","Novel combination of glycopyrrolate and formoterol MDI (GFF‐MDI) provides superior bronchodilation compared to its components administered alone, tiotropium DPI, and formoterol DPI in a randomized, double‐blind, placebo‐controlled phase 2b study In patients with COPD", American Journal of Respiratory and Critical Care Medicine ,2011,183,    ,['citation-journal']," Reisner C, Fogarty C, Spangenthal S, Dunn L, Kerwin E, Quinn D, et al. Novel combination of glycopyrrolate and formoterol MDI (GFF‐MDI) provides superior bronchodilation compared to its components administered alone, tiotropium DPI, and formoterol DPI in a randomized, double‐blind, placebo‐controlled phase 2b study In patients with COPD.  American Journal of Respiratory and Critical Care Medicine 2011;183(1):A6435. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Novel+combination+of+glycopyrrolate+and+formoterol+MDI+(GFF‐MDI)+provides+superior+bronchodilation+compared+to+its+components+administered+alone,+tiotropium+DPI,+and+formoterol+DPI+in+a+randomized,+double‐blind,+placebo‐controlled+phase+2b+study+In+patients+with+COPD+&author=C+Reisner&author=C+Fogarty&author=S+Spangenthal&author=L+Dunn&author=E+Kerwin&author=D+Quinn&publication_year=2011&hl=en']",,, Reisner 2011 {published data only}  ,excluded,CD012930-bbs2-0093, Duration of treatment < 3 weeks 
CD012930-bib-0233,"Reisner C, Rennard SI, Fogarty C, Fischer T, St Rose E, Fernandez C. ","Pearl therapeutics' combination LAMA/LABA MDI (GFF‐MDI, PT003) provides a significant benefit on home peak expiratory flow rate (PEFR) and reduces the need for rescue albuterol use compared to its components administered alone, Spiriva(R) Handihaler(R), and Foradil(R) Aerolizer(R) in a randomized, double‐blind, placebo‐controlled phase 2b study in patients with COPD", American Journal of Respiratory and Critical Care Medicine ,2012,185,    ,['citation-journal']," Reisner C, Rennard SI, Fogarty C, Fischer T, St Rose E, Fernandez C. Pearl therapeutics' combination LAMA/LABA MDI (GFF‐MDI, PT003) provides a significant benefit on home peak expiratory flow rate (PEFR) and reduces the need for rescue albuterol use compared to its components administered alone, Spiriva(R) Handihaler(R), and Foradil(R) Aerolizer(R) in a randomized, double‐blind, placebo‐controlled phase 2b study in patients with COPD.  American Journal of Respiratory and Critical Care Medicine 2012;185:A2259. CENTRAL    Google Scholar     ","['', ""https://scholar.google.com/scholar_lookup?title=Pearl+therapeutics'+combination+LAMA/LABA+MDI+(GFF‐MDI,+PT003)+provides+a+significant+benefit+on+home+peak+expiratory+flow+rate+(PEFR)+and+reduces+the+need+for+rescue+albuterol+use+compared+to+its+components+administered+alone,+Spiriva(R)+Handihaler(R),+and+Foradil(R)+Aerolizer(R)+in+a+randomized,+double‐blind,+placebo‐controlled+phase+2b+study+in+patients+with+COPD+&author=C+Reisner&author=SI+Rennard&author=C+Fogarty&author=T+Fischer&author=E+Rose&author=C+Fernandez&publication_year=2012&hl=en""]",,, Reisner 2011 {published data only}  ,excluded,CD012930-bbs2-0093, Duration of treatment < 3 weeks 
CD012930-bib-0234,"Reisner C, Orevillo CJ, Fernandez C, St Rose E, Kollar C, Rutty D, et al. ","Pearl Therapuetics' combination LAMA/LABA (GFF MDI, PT003) provides comparable safety as measured by 24‐hour holter monitoring to its components (GP MDI, PT001 And FF MDI, PT005) and Foradil ® Aerolizer®", American Journal of Respiratory and Critical Care Medicine ,2013,187,    ,['citation-journal']," Reisner C, Orevillo CJ, Fernandez C, St Rose E, Kollar C, Rutty D, et al. Pearl Therapuetics' combination LAMA/LABA (GFF MDI, PT003) provides comparable safety as measured by 24‐hour holter monitoring to its components (GP MDI, PT001 And FF MDI, PT005) and Foradil ® Aerolizer®.  American Journal of Respiratory and Critical Care Medicine 2013;187:A1485. CENTRAL    Google Scholar     ","['', ""https://scholar.google.com/scholar_lookup?title=Pearl+Therapuetics'+combination+LAMA/LABA+(GFF+MDI,+PT003)+provides+comparable+safety+as+measured+by+24‐hour+holter+monitoring+to+its+components+(GP+MDI,+PT001+And+FF+MDI,+PT005)+and+Foradil+®+Aerolizer®+&author=C+Reisner&author=CJ+Orevillo&author=C+Fernandez&author=E+Rose&author=C+Kollar&author=D+Rutty&publication_year=2013&hl=en""]",,, Reisner 2013 {published data only}  ,excluded,CD012930-bbs2-0094, Duration of treatment < 3 weeks 
CD012930-bib-0235,"Reisner C, Gottschlich G, Fakih F, Koser A, Krainson J, Delacruz L, et al. ","24‐Hour lung function profile of novel co‐suspension technology glycopyrrolate/formoterol metered dose inhaler versus placebo and spiriva respimat, in patients with moderate‐to‐very‐severe chronic obstructive pulmonary disease", American Journal of Respiratory and Critical Care Medicine ,2016,193,    ,['citation-journal']," Reisner C, Gottschlich G, Fakih F, Koser A, Krainson J, Delacruz L, et al. 24‐Hour lung function profile of novel co‐suspension technology glycopyrrolate/formoterol metered dose inhaler versus placebo and spiriva respimat, in patients with moderate‐to‐very‐severe chronic obstructive pulmonary disease.  American Journal of Respiratory and Critical Care Medicine 2016;193:A6823. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=24‐Hour+lung+function+profile+of+novel+co‐suspension+technology+glycopyrrolate/formoterol+metered+dose+inhaler+versus+placebo+and+spiriva+respimat,+in+patients+with+moderate‐to‐very‐severe+chronic+obstructive+pulmonary+disease+&author=C+Reisner&author=G+Gottschlich&author=F+Fakih&author=A+Koser&author=J+Krainson&author=L+Delacruz&publication_year=2016&hl=en']",,, Reisner 2016 {published data only}  ,excluded,CD012930-bbs2-0095, 2nd ROUND: Wrong intervention ‐ LAMA/LABA administered twice daily 
CD012930-bib-0236,"Reisner C, Fabbri L, Kerwin E, Fogarty C, Spangenthal S, Rabe K, et al. ","A randomized, seven‐day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed‐dose combination metered dose inhaler using novel Co‐SuspensionTM Delivery Technology in patients with moderate‐to‐very severe chronic obstructive pulmonary disease", Respiratory Research ,2017,18,    ,['citation-journal']," Reisner C, Fabbri L, Kerwin E, Fogarty C, Spangenthal S, Rabe K, et al. A randomized, seven‐day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed‐dose combination metered dose inhaler using novel Co‐SuspensionTM Delivery Technology in patients with moderate‐to‐very severe chronic obstructive pulmonary disease.  Respiratory Research 2017;18(1):8. [1465‐993X]CENTRAL    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/28061907', 'https://scholar.google.com/scholar_lookup?title=A+randomized,+seven‐day+study+to+assess+the+efficacy+and+safety+of+a+glycopyrrolate/formoterol+fumarate+fixed‐dose+combination+metered+dose+inhaler+using+novel+Co‐SuspensionTM+Delivery+Technology+in+patients+with+moderate‐to‐very+severe+chronic+obstructive+pulmonary+disease+&author=C+Reisner&author=L+Fabbri&author=E+Kerwin&author=C+Fogarty&author=S+Spangenthal&author=K+Rabe&publication_year=2017&hl=en']",28061907,, Reisner 2017 {published data only}  ,excluded,CD012930-bbs2-0096, Duration of treatment < 3 weeks 
CD012930-bib-0237,"Reisner C, Fabbri LM, Kerwin EM, Fogarty C, Spangenthal S, Rabe KF, et al. ","A randomized, seven‐day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed‐dose combination metered dose inhaler using novel Co‐Suspension™ Delivery Technology in patients with moderate‐to‐very severe chronic obstructive pulmonary disease", Respiratory Research ,2017,18,    ,['citation-journal']," Reisner C, Fabbri LM, Kerwin EM, Fogarty C, Spangenthal S, Rabe KF, et al. A randomized, seven‐day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed‐dose combination metered dose inhaler using novel Co‐Suspension™ Delivery Technology in patients with moderate‐to‐very severe chronic obstructive pulmonary disease.  Respiratory Research 2017;18(1):8. CENTRAL    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/28061907', 'https://scholar.google.com/scholar_lookup?title=A+randomized,+seven‐day+study+to+assess+the+efficacy+and+safety+of+a+glycopyrrolate/formoterol+fumarate+fixed‐dose+combination+metered+dose+inhaler+using+novel+Co‐Suspension™+Delivery+Technology+in+patients+with+moderate‐to‐very+severe+chronic+obstructive+pulmonary+disease+&author=C+Reisner&author=LM+Fabbri&author=EM+Kerwin&author=C+Fogarty&author=S+Spangenthal&author=KF+Rabe&publication_year=2017&hl=en']",28061907,, Reisner 2017 {published data only}  ,excluded,CD012930-bbs2-0096, Duration of treatment < 3 weeks 
CD012930-bib-0238,"Reisner C, Fernandez C, Orevillo C, St Rose E, Kollar C. ","Pearl Therapeutics' combination LAMA/LABA MDI (GFF MDI, PT003) provides comparable metabolic and ECG safety to Spiriva(R) handihaler(R) and placebo In patients with COPD", American Journal of Respiratory and Critical Care Medicine ,2012,185,    ,['citation-journal']," Reisner C, Fernandez C, Orevillo C, St Rose E, Kollar C. Pearl Therapeutics' combination LAMA/LABA MDI (GFF MDI, PT003) provides comparable metabolic and ECG safety to Spiriva(R) handihaler(R) and placebo In patients with COPD.  American Journal of Respiratory and Critical Care Medicine 2012;185:A2925. CENTRAL    Google Scholar     ","['', ""https://scholar.google.com/scholar_lookup?title=Pearl+Therapeutics'+combination+LAMA/LABA+MDI+(GFF+MDI,+PT003)+provides+comparable+metabolic+and+ECG+safety+to+Spiriva(R)+handihaler(R)+and+placebo+In+patients+with+COPD+&author=C+Reisner&author=C+Fernandez&author=C+Orevillo&author=E+Rose&author=C+Kollar&publication_year=2012&hl=en""]",,, Reisner 2017 {published data only}  ,excluded,CD012930-bbs2-0096, Duration of treatment < 3 weeks 
CD012930-bib-0239,NCT02347072. ,"24‐hour lung function in subjects with moderate to very severe COPD after treatment with PT003, open‐label Spiriva® Respimat® as an active control, and placebo",,,,   ,['citation-other']," NCT02347072. 24‐hour lung function in subjects with moderate to very severe COPD after treatment with PT003, open‐label Spiriva® Respimat® as an active control, and placebo. clinicaltrials.gov/ct2/show/NCT02347072 (first received 27 January 2015). CENTRAL    ",[''],,, Reisner 2017b {published data only}  ,excluded,CD012930-bbs2-0097, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0240,NCT02347085. ,24‐hour lung function in subjects with moderate to very severe COPD after treatment with PT003 and placebo MDI,,,,   ,['citation-other'], NCT02347085. 24‐hour lung function in subjects with moderate to very severe COPD after treatment with PT003 and placebo MDI. clinicaltrials.gov/ct2/show/NCT02347085 (first received 27 January 2015). CENTRAL    ,[''],,, Reisner 2017b {published data only}  ,excluded,CD012930-bbs2-0097, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0241,"Reisner C, Gottschlich G, Fakih F, Koser A, Krainson J, Delacruz L, et al. ",24‐h bronchodilation and inspiratory capacity improvements with glycopyrrolate/formoterol fumarate via co‐suspension delivery technology in COPD, Respiratory Research ,2017,18,    ,['citation-journal']," Reisner C, Gottschlich G, Fakih F, Koser A, Krainson J, Delacruz L, et al. 24‐h bronchodilation and inspiratory capacity improvements with glycopyrrolate/formoterol fumarate via co‐suspension delivery technology in COPD.  Respiratory Research 2017;18(1):157. [DOI: 10.1186/s12931‐017‐0636‐4]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1186/s12931-017-0636-4', 'https://www.ncbi.nlm.nih.gov/pubmed/28821260', 'https://scholar.google.com/scholar_lookup?title=24‐h+bronchodilation+and+inspiratory+capacity+improvements+with+glycopyrrolate/formoterol+fumarate+via+co‐suspension+delivery+technology+in+COPD+&author=C+Reisner&author=G+Gottschlich&author=F+Fakih&author=A+Koser&author=J+Krainson&author=L+Delacruz&publication_year=2017&hl=en']",28821260,https://doi.org/10.1186/s12931-017-0636-4, Reisner 2017b {published data only}  ,excluded,CD012930-bbs2-0097, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0242,"Sadigov A, Akhundov S, Bagirov R. ",Analysis of chronic obstructive pulmonary disease exacerbations with the triple therapy compared with dual and single bronchodilator therapy: which treatment is better for patients with severe disease?, Chest ,2014,145,    ,['citation-journal']," Sadigov A, Akhundov S, Bagirov R. Analysis of chronic obstructive pulmonary disease exacerbations with the triple therapy compared with dual and single bronchodilator therapy: which treatment is better for patients with severe disease?.  Chest 2014;145(3):425A. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1378/chest.1834832', 'https://scholar.google.com/scholar_lookup?title=Analysis+of+chronic+obstructive+pulmonary+disease+exacerbations+with+the+triple+therapy+compared+with+dual+and+single+bronchodilator+therapy:+which+treatment+is+better+for+patients+with+severe+disease?+&author=A+Sadigov&author=S+Akhundov&author=R+Bagirov&publication_year=2014&hl=en']",,https://doi.org/10.1378/chest.1834832, Sadigov 2014 {published data only}  ,excluded,CD012930-bbs2-0098, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0243,NCT01699685. ,Swiss studY for the treatment of COPD patients with the free combiNation of indacatERol and GlYcopyrroniumbromide (SYNERGY),,,,   ,['citation-other'], NCT01699685. Swiss studY for the treatment of COPD patients with the free combiNation of indacatERol and GlYcopyrroniumbromide (SYNERGY). clinicaltrials.gov/ct2/show/NCT01699685 (first received 4 October 2012). CENTRAL    ,[''],,, Salomon 2017 {published data only}  ,excluded,CD012930-bbs2-0099, Wrong intervention (LABA/LAMA not administered in combined inhaler) 
CD012930-bib-0244,"Salomon J, Stolz D, Domenighetti G, Frey JG, Turk AJ, Azzola A, et al. ",Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD ‐ a randomised controlled study, Respiratory Research ,2017,18,    ,['citation-journal']," Salomon J, Stolz D, Domenighetti G, Frey JG, Turk AJ, Azzola A, et al. Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD ‐ a randomised controlled study.  Respiratory Research 2017;18(1):13. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1186/s12931-016-0498-1', 'https://www.ncbi.nlm.nih.gov/pubmed/28077140', 'https://scholar.google.com/scholar_lookup?title=Indacaterol+and+glycopyrronium+versus+indacaterol+on+body+plethysmography+measurements+in+COPD+‐+a+randomised+controlled+study+&author=J+Salomon&author=D+Stolz&author=G+Domenighetti&author=JG+Frey&author=AJ+Turk&author=A+Azzola&publication_year=2017&hl=en']",28077140,https://doi.org/10.1186/s12931-016-0498-1, Salomon 2017 {published data only}  ,excluded,CD012930-bbs2-0099, Wrong intervention (LABA/LAMA not administered in combined inhaler) 
CD012930-bib-0245,Setoguchi Y. ,Indactaterol mono‐and combination therapy with inhaled tiotropium bromide in COPD: a 52‐week study, American Journal of Respiratory and Critical Care Medicine ,2015,191,    ,['citation-journal'], Setoguchi Y. Indactaterol mono‐and combination therapy with inhaled tiotropium bromide in COPD: a 52‐week study.  American Journal of Respiratory and Critical Care Medicine 2015;191:A5748. CENTRAL    Google Scholar     ,"['', 'https://scholar.google.com/scholar_lookup?title=Indactaterol+mono‐and+combination+therapy+with+inhaled+tiotropium+bromide+in+COPD:+a+52‐week+study+&author=Y+Setoguchi&publication_year=2015&hl=en']",,, Setoguchi 2015 {published data only}  ,excluded,CD012930-bbs2-0100, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0246,Setoguchi Y. ,The combination therapy with inhaled tiotropium bromide and indacaterol in COPD improves the peripheral airway function in static and dynamic status, European Respiratory Journal ,2014,44,    ,['citation-journal'], Setoguchi Y. The combination therapy with inhaled tiotropium bromide and indacaterol in COPD improves the peripheral airway function in static and dynamic status.  European Respiratory Journal 2014;44:P896. CENTRAL    Google Scholar     ,"['', 'https://scholar.google.com/scholar_lookup?title=The+combination+therapy+with+inhaled+tiotropium+bromide+and+indacaterol+in+COPD+improves+the+peripheral+airway+function+in+static+and+dynamic+status+&author=Y+Setoguchi&publication_year=2014&hl=en']",,, Setoguchi 2015 {published data only}  ,excluded,CD012930-bbs2-0100, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0247,"Bateman ED, Chapman KR, Singh D, D'Urzo AD, Molins E, Leselbaum A, et al. ","Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT)", Respiratory Research ,2015,16,    ,['citation-journal']," Bateman ED, Chapman KR, Singh D, D'Urzo AD, Molins E, Leselbaum A, et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT).  Respiratory Research 2015;16:92. [1465‐993X]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1186/s12931-015-0250-2', 'https://www.ncbi.nlm.nih.gov/pubmed/26233481', ""https://scholar.google.com/scholar_lookup?title=Aclidinium+bromide+and+formoterol+fumarate+as+a+fixed‐dose+combination+in+COPD:+pooled+analysis+of+symptoms+and+exacerbations+from+two+six‐month,+multicentre,+randomised+studies+(ACLIFORM+and+AUGMENT)+&author=ED+Bateman&author=KR+Chapman&author=D+Singh&author=AD+D'Urzo&author=E+Molins&author=A+Leselbaum&publication_year=2015&hl=en""]",26233481,https://doi.org/10.1186/s12931-015-0250-2, Singh 2014 {published data only}  ,excluded,CD012930-bbs2-0101, 2nd ROUND: Wrong intervention ‐ LAMA/LABA administered twice daily 
CD012930-bib-0248,"Jones PW, Singh D, Bateman ED, Korn S, Serra C, Molins E, et al. ",The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study, American Journal of Respiratory and Critical Care Medicine ,2014,189,    ,['citation-journal']," Jones PW, Singh D, Bateman ED, Korn S, Serra C, Molins E, et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study.  American Journal of Respiratory and Critical Care Medicine 2014;189:A3764. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=The+effect+of+aclidinium/formoterol+fixed‐dose+combination+on+COPD+symptoms+and+health+status+in+patients+with+COPD:+results+from+the+ACLIFORM/COPD+study+&author=PW+Jones&author=D+Singh&author=ED+Bateman&author=S+Korn&author=C+Serra&author=E+Molins&publication_year=2014&hl=en']",,, Singh 2014 {published data only}  ,excluded,CD012930-bbs2-0101, 2nd ROUND: Wrong intervention ‐ LAMA/LABA administered twice daily 
CD012930-bib-0249,"Miravitlles M, Chapman KR, Chuecos F, Ribera A, Garcia Gil E. ",The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis, International Journal of Chronic Obstructive Pulmonary Disease ,2016,11,    ,['citation-journal']," Miravitlles M, Chapman KR, Chuecos F, Ribera A, Garcia Gil E. The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis.  International Journal of Chronic Obstructive Pulmonary Disease 2016;11(1):2041‐52. [1178‐2005]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.2147/COPD.S114566', 'https://www.ncbi.nlm.nih.gov/pubmed/27621610', 'https://scholar.google.com/scholar_lookup?title=The+efficacy+of+aclidinium/formoterol+on+lung+function+and+symptoms+in+patients+with+COPD+categorized+by+symptom+status:+a+pooled+analysis+&author=M+Miravitlles&author=KR+Chapman&author=F+Chuecos&author=A+Ribera&author=E+GarciaGil&publication_year=2016&hl=en']",27621610,https://doi.org/10.2147/COPD.S114566, Singh 2014 {published data only}  ,excluded,CD012930-bbs2-0101, 2nd ROUND: Wrong intervention ‐ LAMA/LABA administered twice daily 
CD012930-bib-0250,"Miravitlles M, Garcia Gil E, Chuecos F, Lamarca R. ",Morning and nighttime symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients, European Respiratory Journal ,2015,46,    ,['citation-journal']," Miravitlles M, Garcia Gil E, Chuecos F, Lamarca R. Morning and nighttime symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients.  European Respiratory Journal 2015;46:OA1968. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Morning+and+nighttime+symptoms+in+COPD+and+efficacy+of+aclidinium/formoterol+in+symptomatic+vs+asymptomatic+patients+&author=M+Miravitlles&author=E+GarciaGil&author=F+Chuecos&author=R+Lamarca&publication_year=2015&hl=en']",,, Singh 2014 {published data only}  ,excluded,CD012930-bbs2-0101, 2nd ROUND: Wrong intervention ‐ LAMA/LABA administered twice daily 
CD012930-bib-0251,NCT01462942. ,Long‐term efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combination,,,,   ,['citation-other'], NCT01462942. Long‐term efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combination. clinicaltrials.gov/ct2/show/NCT01462942 (first received 1 November 2011). CENTRAL    ,[''],,, Singh 2014 {published data only}  ,excluded,CD012930-bbs2-0101, 2nd ROUND: Wrong intervention ‐ LAMA/LABA administered twice daily 
CD012930-bib-0252,"Singh D, Jones P, Bateman E, Korn S, Serra C, Molins E, et al. ",Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the acliform study, Chest ,2014,145,    ,['citation-journal']," Singh D, Jones P, Bateman E, Korn S, Serra C, Molins E, et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the acliform study.  Chest 2014;145(3):375A. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1378/chest.1796046', 'https://scholar.google.com/scholar_lookup?title=Evaluation+of+the+efficacy+and+safety+of+two+doses+of+aclidinium+and+formoterol+in+fixed‐dose+combination+in+patients+with+COPD:+the+acliform+study+&author=D+Singh&author=P+Jones&author=E+Bateman&author=S+Korn&author=C+Serra&author=E+Molins&publication_year=2014&hl=en']",,https://doi.org/10.1378/chest.1796046, Singh 2014 {published data only}  ,excluded,CD012930-bbs2-0101, 2nd ROUND: Wrong intervention ‐ LAMA/LABA administered twice daily 
CD012930-bib-0253,"Singh D, Jones PW, Bateman ED, Korn S, Serra C, Molins E, et al. ",Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study, American Journal of Respiratory and Critical Care Medicine ,2014,189,    ,['citation-journal']," Singh D, Jones PW, Bateman ED, Korn S, Serra C, Molins E, et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study.  American Journal of Respiratory and Critical Care Medicine 2014;189:A5987. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Aclidinium/formoterol+fixed‐dose+combination+improves+bronchodilation+and+is+well+tolerated+in+patients+with+COPD:+results+from+the+ACLIFORM/COPD+study+&author=D+Singh&author=PW+Jones&author=ED+Bateman&author=S+Korn&author=C+Serra&author=E+Molins&publication_year=2014&hl=en']",,, Singh 2014 {published data only}  ,excluded,CD012930-bbs2-0101, 2nd ROUND: Wrong intervention ‐ LAMA/LABA administered twice daily 
CD012930-bib-0254,"Singh D, Jones PW, Bateman ED, Korn S, Serra C, Molins E, et al. ","Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study", BMC Pulmonary Medicine ,2014,14,    ,['citation-journal']," Singh D, Jones PW, Bateman ED, Korn S, Serra C, Molins E, et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study.  BMC Pulmonary Medicine 2014;14(1):178. [1471‐2466]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1186/1471-2466-14-178', 'https://www.ncbi.nlm.nih.gov/pubmed/25404569', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+aclidinium+bromide/formoterol+fumarate+fixed‐dose+combinations+compared+with+individual+components+and+placebo+in+patients+with+COPD+(ACLIFORM‐COPD):+a+multicentre,+randomised+study+&author=D+Singh&author=PW+Jones&author=ED+Bateman&author=S+Korn&author=C+Serra&author=E+Molins&publication_year=2014&hl=en']",25404569,https://doi.org/10.1186/1471-2466-14-178, Singh 2014 {published data only}  ,excluded,CD012930-bbs2-0101, 2nd ROUND: Wrong intervention ‐ LAMA/LABA administered twice daily 
CD012930-bib-0255,"Sliwinski P, Perng DW, Chuchalin A, Jones PW. ",Efficacy and safety of once‐daily aclidinium bromide 200 muG in combination with formoterol in patients with COPD, Thorax ,2010,65,    ,['citation-journal']," Sliwinski P, Perng DW, Chuchalin A, Jones PW. Efficacy and safety of once‐daily aclidinium bromide 200 muG in combination with formoterol in patients with COPD.  Thorax 2010;65:A136 [P137]. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1136/thx.2010.150987.38', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+once‐daily+aclidinium+bromide+200+muG+in+combination+with+formoterol+in+patients+with+COPD+&author=P+Sliwinski&author=DW+Perng&author=A+Chuchalin&author=PW+Jones&publication_year=2010&hl=en']",,https://doi.org/10.1136/thx.2010.150987.38, Sliwinski 2010 {published data only}  ,excluded,CD012930-bbs2-0102, Wrong intervention (LABA/LAMA not administered in combined inhaler) 
CD012930-bib-0256,"Tanaka Y, Hino M, Gemma A, Kobayashi Y, Katoh Y. ","2nd interim report: Effect of tiotropium monotherapy versus tiotropium plus indacaterol in patients with chronic obstructive pulmonary disease ‐ single‐centre, randomized, prospective, real‐world study", Respirology ,2015,20,    ,['citation-journal']," Tanaka Y, Hino M, Gemma A, Kobayashi Y, Katoh Y. 2nd interim report: Effect of tiotropium monotherapy versus tiotropium plus indacaterol in patients with chronic obstructive pulmonary disease ‐ single‐centre, randomized, prospective, real‐world study.  Respirology 2015;20:37. [1323‐7799]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=2nd+interim+report:+Effect+of+tiotropium+monotherapy+versus+tiotropium+plus+indacaterol+in+patients+with+chronic+obstructive+pulmonary+disease+‐+single‐centre,+randomized,+prospective,+real‐world+study+&author=Y+Tanaka&author=M+Hino&author=A+Gemma&author=Y+Kobayashi&author=Y+Katoh&publication_year=2015&hl=en']",,, Tanaka 2015 {published data only}  ,excluded,CD012930-bbs2-0103, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0257,"Tanaka Y, Hino M, Naitoh T, Aoyama J, Kato Y, Kosaihira S, et al. ","3rd interim report: Effect of tiotropium monotherapy versus tiotropium plus indacaterol in patients with chronic obstructive pulmonary disease ‐ single‐centre, randomised, prospective, real‐world study", Respirology ,2016,21,    ,['citation-journal']," Tanaka Y, Hino M, Naitoh T, Aoyama J, Kato Y, Kosaihira S, et al. 3rd interim report: Effect of tiotropium monotherapy versus tiotropium plus indacaterol in patients with chronic obstructive pulmonary disease ‐ single‐centre, randomised, prospective, real‐world study.  Respirology 2016;21:176. [1323‐7799]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=3rd+interim+report:+Effect+of+tiotropium+monotherapy+versus+tiotropium+plus+indacaterol+in+patients+with+chronic+obstructive+pulmonary+disease+‐+single‐centre,+randomised,+prospective,+real‐world+study+&author=Y+Tanaka&author=M+Hino&author=T+Naitoh&author=J+Aoyama&author=Y+Kato&author=S+Kosaihira&publication_year=2016&hl=en']",,, Tanaka 2015 {published data only}  ,excluded,CD012930-bbs2-0103, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0258,NCT00139932. ,Tiotropium bromide alone vs tiotropium bromide and formoterol fumarate in subjects with COPD (study P04272),,,,   ,['citation-other'], NCT00139932. Tiotropium bromide alone vs tiotropium bromide and formoterol fumarate in subjects with COPD (study P04272). clinicaltrials.gov/ct2/show/NCT00139932 (first received 31 August 2005). CENTRAL    ,[''],,, Tashkin 2007 {published data only}  ,excluded,CD012930-bbs2-0104, Wrong intervention (LABA/LAMA not administered in combined inhaler) 
CD012930-bib-0264,Tashkin D. ,Formoterol and tiotropium reduces rescue medication use more than tiotropium alone in patients with moderate COPD: findings from a 12 week randomized placebo controlled trial,,2008,,    ,['citation-other'], Tashkin D. Formoterol and tiotropium reduces rescue medication use more than tiotropium alone in patients with moderate COPD: findings from a 12 week randomized placebo controlled trial. American Thoracic Society International Conference; 2008 May 16‐21; Toronto. 2008:A647[#F5]. CENTRAL    Google Scholar     ,"['', 'https://scholar.google.com/scholar_lookup?title=Formoterol+and+tiotropium+reduces+rescue+medication+use+more+than+tiotropium+alone+in+patients+with+moderate+COPD:+findings+from+a+12+week+randomized+placebo+controlled+trial+&author=D+Tashkin&publication_year=2008&hl=en']",,, Tashkin 2007 {published data only}  ,excluded,CD012930-bbs2-0104, Wrong intervention (LABA/LAMA not administered in combined inhaler) 
CD012930-bib-0259,"Tashkin D, Pearle J, Iezzoni D, Varghese S. ",Formoterol and tiotropium compared with tiotropium alone for treatment of COPD, COPD ,2009,6,    ,['citation-journal']," Tashkin D, Pearle J, Iezzoni D, Varghese S. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD.  COPD 2009;6(1):17‐25. [1541‐2563]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1080/15412550902724073', 'https://www.ncbi.nlm.nih.gov/pubmed/19229704', 'https://scholar.google.com/scholar_lookup?title=Formoterol+and+tiotropium+compared+with+tiotropium+alone+for+treatment+of+COPD&author=D+Tashkin&author=J+Pearle&author=D+Iezzoni&author=S+Varghese&publication_year=2009&hl=en']",19229704,https://doi.org/10.1080/15412550902724073, Tashkin 2007 {published data only}  ,excluded,CD012930-bbs2-0104, Wrong intervention (LABA/LAMA not administered in combined inhaler) 
CD012930-bib-0260,"Tashkin D, Pearle J, Varghese S. ","Improvement of lung function with coadministered formoterol and tiotropium, regardless of smoking status in patients with chronic obstructive pulmonary disease", Chest ,2008,134,    ,['citation-journal']," Tashkin D, Pearle J, Varghese S. Improvement of lung function with coadministered formoterol and tiotropium, regardless of smoking status in patients with chronic obstructive pulmonary disease.  Chest 2008;134(4):103002s. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1378/chest.134.4_MeetingAbstracts.p103002', 'https://scholar.google.com/scholar_lookup?title=Improvement+of+lung+function+with+coadministered+formoterol+and+tiotropium,+regardless+of+smoking+status+in+patients+with+chronic+obstructive+pulmonary+disease+&author=D+Tashkin&author=J+Pearle&author=S+Varghese&publication_year=2008&hl=en']",,https://doi.org/10.1378/chest.134.4_MeetingAbstracts.p103002, Tashkin 2007 {published data only}  ,excluded,CD012930-bbs2-0104, Wrong intervention (LABA/LAMA not administered in combined inhaler) 
CD012930-bib-0261,"Tashkin D, Varghese S. ","Combined treatment with formoterol and tiotropium is more efficacious than treatment with tiotropium alone in patients with chronic obstructive pulmonary disease, regardless of smoking status, inhaled corticosteroid use, baseline severity, or gender", Pulmonary Pharmacology and Therapeutics ,2011,24,    ,['citation-journal']," Tashkin D, Varghese S. Combined treatment with formoterol and tiotropium is more efficacious than treatment with tiotropium alone in patients with chronic obstructive pulmonary disease, regardless of smoking status, inhaled corticosteroid use, baseline severity, or gender.  Pulmonary Pharmacology and Therapeutics 2011;24(1):147‐52. [1094‐5539]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.pupt.2010.07.003', 'https://www.ncbi.nlm.nih.gov/pubmed/20659577', 'https://scholar.google.com/scholar_lookup?title=Combined+treatment+with+formoterol+and+tiotropium+is+more+efficacious+than+treatment+with+tiotropium+alone+in+patients+with+chronic+obstructive+pulmonary+disease,+regardless+of+smoking+status,+inhaled+corticosteroid+use,+baseline+severity,+or+gender+&author=D+Tashkin&author=S+Varghese&publication_year=2011&hl=en']",20659577,https://doi.org/10.1016/j.pupt.2010.07.003, Tashkin 2007 {published data only}  ,excluded,CD012930-bbs2-0104, Wrong intervention (LABA/LAMA not administered in combined inhaler) 
CD012930-bib-0262,"Tashkin D, Varghese S. ",Formoterol treatment plus tiotropium results in greater improvements in lung function compared with tiotropium administered alone in patients with COPD, Journal of Allergy and Clinical Immunology ,2007,119,    ,['citation-journal']," Tashkin D, Varghese S. Formoterol treatment plus tiotropium results in greater improvements in lung function compared with tiotropium administered alone in patients with COPD.  Journal of Allergy and Clinical Immunology 2007;119(1):S4 [13]. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1016/j.jaci.2006.11.031', 'https://scholar.google.com/scholar_lookup?title=Formoterol+treatment+plus+tiotropium+results+in+greater+improvements+in+lung+function+compared+with+tiotropium+administered+alone+in+patients+with+COPD+&author=D+Tashkin&author=S+Varghese&publication_year=2007&hl=en']",,https://doi.org/10.1016/j.jaci.2006.11.031, Tashkin 2007 {published data only}  ,excluded,CD012930-bbs2-0104, Wrong intervention (LABA/LAMA not administered in combined inhaler) 
CD012930-bib-0263,"Tashkin D, Varghese S. ","The therapeutic effect of treatment with formoterol plus tiotropium was greater than the effect of treatment with tiotropium alone in COPD: findings from a 12‐week, multicenter, double‐blind, placebo‐controlled, trial", Chest ,2007,132,    ,['citation-journal']," Tashkin D, Varghese S. The therapeutic effect of treatment with formoterol plus tiotropium was greater than the effect of treatment with tiotropium alone in COPD: findings from a 12‐week, multicenter, double‐blind, placebo‐controlled, trial.  Chest 2007;132(4):529a. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1378/chest.132.4_MeetingAbstracts.529a', 'https://scholar.google.com/scholar_lookup?title=The+therapeutic+effect+of+treatment+with+formoterol+plus+tiotropium+was+greater+than+the+effect+of+treatment+with+tiotropium+alone+in+COPD:+findings+from+a+12‐week,+multicenter,+double‐blind,+placebo‐controlled,+trial+&author=D+Tashkin&author=S+Varghese&publication_year=2007&hl=en']",,https://doi.org/10.1378/chest.132.4_MeetingAbstracts.529a, Tashkin 2007 {published data only}  ,excluded,CD012930-bbs2-0104, Wrong intervention (LABA/LAMA not administered in combined inhaler) 
CD012930-bib-0265,"Reisner C, Gotfried M, Denenberg MB, Fernandez C, St Rose E, Fortner P, et al. ","Low doses of Pearl Therapeutics' LAMA/LABA Combination MDI (GFF MDI, PT003) provide superior bronchodilation compared to components and to open‐label spiriva handihaler in a randomized, double‐blind, placebo‐controlled phase IIb study in patients with COPD", American Journal of Respiratory and Critical Care Medicine ,2013,187,    ,['citation-journal']," Reisner C, Gotfried M, Denenberg MB, Fernandez C, St Rose E, Fortner P, et al. Low doses of Pearl Therapeutics' LAMA/LABA Combination MDI (GFF MDI, PT003) provide superior bronchodilation compared to components and to open‐label spiriva handihaler in a randomized, double‐blind, placebo‐controlled phase IIb study in patients with COPD.  American Journal of Respiratory and Critical Care Medicine 2013;187:A2434. CENTRAL    Google Scholar     ","['', ""https://scholar.google.com/scholar_lookup?title=Low+doses+of+Pearl+Therapeutics'+LAMA/LABA+Combination+MDI+(GFF+MDI,+PT003)+provide+superior+bronchodilation+compared+to+components+and+to+open‐label+spiriva+handihaler+in+a+randomized,+double‐blind,+placebo‐controlled+phase+IIb+study+in+patients+with+COPD+&author=C+Reisner&author=M+Gotfried&author=MB+Denenberg&author=C+Fernandez&author=E+Rose&author=P+Fortner&publication_year=2013&hl=en""]",,, Tashkin 2016 {published data only}  ,excluded,CD012930-bbs2-0105, Duration of treatment < 3 weeks 
CD012930-bib-0266,"Tashkin DP, Martinez FJ, Rodriguez‐Roisin R, Fogarty C, Gotfried M, Denenberg M, et al. ","A multicenter, randomized, double‐blind dose‐ranging study of glycopyrrolate/formoterol fumarate fixed‐dose combination metered dose inhaler compared to the monocomponents and open‐label tiotropium dry powder inhaler in patients with moderate‐to‐severe COPD", Respiratory Medicine ,2016,120,    ,['citation-journal']," Tashkin DP, Martinez FJ, Rodriguez‐Roisin R, Fogarty C, Gotfried M, Denenberg M, et al. A multicenter, randomized, double‐blind dose‐ranging study of glycopyrrolate/formoterol fumarate fixed‐dose combination metered dose inhaler compared to the monocomponents and open‐label tiotropium dry powder inhaler in patients with moderate‐to‐severe COPD.  Respiratory Medicine 2016;120:16‐24. CENTRAL    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/27817811', 'https://scholar.google.com/scholar_lookup?title=A+multicenter,+randomized,+double‐blind+dose‐ranging+study+of+glycopyrrolate/formoterol+fumarate+fixed‐dose+combination+metered+dose+inhaler+compared+to+the+monocomponents+and+open‐label+tiotropium+dry+powder+inhaler+in+patients+with+moderate‐to‐severe+COPD+&author=DP+Tashkin&author=FJ+Martinez&author=R+Rodriguez‐Roisin&author=C+Fogarty&author=M+Gotfried&author=M+Denenberg&publication_year=2016&hl=en']",27817811,, Tashkin 2016 {published data only}  ,excluded,CD012930-bbs2-0105, Duration of treatment < 3 weeks 
CD012930-bib-0267,"Ulubay G, Eyuboglu Oner F, Savas Bozbas S, Simsek A. ",Three regimens of inhaled bronchodilators for chronic obstructive pulmonary disease: comparison of pulmonary function and cardiopulmonary exercise test parameters, Turkish Respiratory Journal ,2005,6,    ,['citation-journal']," Ulubay G, Eyuboglu Oner F, Savas Bozbas S, Simsek A. Three regimens of inhaled bronchodilators for chronic obstructive pulmonary disease: comparison of pulmonary function and cardiopulmonary exercise test parameters.  Turkish Respiratory Journal 2005;6(2):89‐94. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Three+regimens+of+inhaled+bronchodilators+for+chronic+obstructive+pulmonary+disease:+comparison+of+pulmonary+function+and+cardiopulmonary+exercise+test+parameters+&author=G+Ulubay&author=F+EyubogluOner&author=S+SavasBozbas&author=A+Simsek&publication_year=2005&hl=en']",,, Ulubay 2005 {published data only}  ,excluded,CD012930-bbs2-0106, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0268,"Fabbri LM, Van de Maele B, Lemmens B, Martin C, Horton R, Dolker M, et al. ","Cardiovascular safety of qva149, a novel combination of indacaterol and glycopyrronium, compared with indacaterol and placebo in patients with COPD",,2009,,    ,['citation-other']," Fabbri LM, Van de Maele B, Lemmens B, Martin C, Horton R, Dolker M, et al. Cardiovascular safety of qva149, a novel combination of indacaterol and glycopyrronium, compared with indacaterol and placebo in patients with COPD. European Respiratory Society 19th Annual Congress; 2009 Sep 12‐15; Vienna. 2009:[P2027]. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Cardiovascular+safety+of+qva149,+a+novel+combination+of+indacaterol+and+glycopyrronium,+compared+with+indacaterol+and+placebo+in+patients+with+COPD+&author=LM+Fabbri&author=B+Maele&author=B+Lemmens&author=C+Martin&author=R+Horton&author=M+Dolker&publication_year=2009&hl=en']",,, Van de Maele 2010 {published data only}  ,excluded,CD012930-bbs2-0107, Duration of treatment < 3 weeks 
CD012930-bib-0269,"Van de Maele B, Fabbri LM, Martin C, Horton R, Dolker M, Overend T. ","Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients", COPD ,2010,7,    ,['citation-journal']," Van de Maele B, Fabbri LM, Martin C, Horton R, Dolker M, Overend T. Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients.  COPD 2010;7:418‐27. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.3109/15412555.2010.528812', 'https://www.ncbi.nlm.nih.gov/pubmed/21166630', 'https://scholar.google.com/scholar_lookup?title=Cardiovascular+safety+of+QVA149,+a+combination+of+Indacaterol+and+NVA237,+in+COPD+patients+&author=B+Maele&author=LM+Fabbri&author=C+Martin&author=R+Horton&author=M+Dolker&author=T+Overend&publication_year=2010&hl=en']",21166630,https://doi.org/10.3109/15412555.2010.528812, Van de Maele 2010 {published data only}  ,excluded,CD012930-bbs2-0107, Duration of treatment < 3 weeks 
CD012930-bib-0270,"Van Noord J, Aumann J, Janssens E, Mueller A, Cornelissen P. ","Relation between the acute response to salbutamol and long term FEV1 responses to tiotropium (TIO), formoterol (FORM) and its combination (T=F) in COPD patients", European Respiratory Journal ,2003,22,    ,['citation-journal']," Van Noord J, Aumann J, Janssens E, Mueller A, Cornelissen P. Relation between the acute response to salbutamol and long term FEV1 responses to tiotropium (TIO), formoterol (FORM) and its combination (T=F) in COPD patients.  European Respiratory Journal 2003;22:153. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Relation+between+the+acute+response+to+salbutamol+and+long+term+FEV1+responses+to+tiotropium+(TIO),+formoterol+(FORM)+and+its+combination+(T=F)+in+COPD+patients+&author=J+Noord&author=J+Aumann&author=E+Janssens&author=A+Mueller&author=P+Cornelissen&publication_year=2003&hl=en']",,, Van Noord 2005 {published data only}  ,excluded,CD012930-bbs2-0108, Wrong intervention (LABA/LAMA not administered in combined inhaler) 
CD012930-bib-0271,"Van Noord J, Qumann J, Janssens E, Mueller A, Cornelissen P, Aumann J, et al. ","Comparison of once daily tiotropium, twice daily formoterol and the free combination, once daily, in patients with COPD",,2003,,    ,['citation-other']," Van Noord J, Qumann J, Janssens E, Mueller A, Cornelissen P, Aumann J, et al. Comparison of once daily tiotropium, twice daily formoterol and the free combination, once daily, in patients with COPD. American Thoracic Society 99th International Conference; 2003 May 16‐21; Seattle. 2003:B024 Poster 421. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Comparison+of+once+daily+tiotropium,+twice+daily+formoterol+and+the+free+combination,+once+daily,+in+patients+with+COPD+&author=J+Noord&author=J+Qumann&author=E+Janssens&author=A+Mueller&author=P+Cornelissen&author=J+Aumann&publication_year=2003&hl=en']",,, Van Noord 2005 {published data only}  ,excluded,CD012930-bbs2-0108, Wrong intervention (LABA/LAMA not administered in combined inhaler) 
CD012930-bib-0272,"Van Noord JA, Aumann JL, Janssens E, Smeets JJ, Verhaert J, Disse B, et al. ","Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD", European Respiratory Journal ,2005,26,    ,['citation-journal']," Van Noord JA, Aumann JL, Janssens E, Smeets JJ, Verhaert J, Disse B, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD.  European Respiratory Journal 2005;26(2):214‐22. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1183/09031936.05.00140404', 'https://www.ncbi.nlm.nih.gov/pubmed/16055868', 'https://scholar.google.com/scholar_lookup?title=Comparison+of+tiotropium+once+daily,+formoterol+twice+daily+and+both+combined+once+daily+in+patients+with+COPD+&author=JA+Noord&author=JL+Aumann&author=E+Janssens&author=JJ+Smeets&author=J+Verhaert&author=B+Disse&publication_year=2005&hl=en']",16055868,https://doi.org/10.1183/09031936.05.00140404, Van Noord 2005 {published data only}  ,excluded,CD012930-bbs2-0108, Wrong intervention (LABA/LAMA not administered in combined inhaler) 
CD012930-bib-0273,"Van Noord J, Buhl R, Laforce C, Martin C, Jones F, Dolker M, et al. ",QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease, Thorax ,2010,65,    ,['citation-journal']," Van Noord J, Buhl R, Laforce C, Martin C, Jones F, Dolker M, et al. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease.  Thorax 2010;65(12):1086‐91. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1136/thx.2010.139113', 'https://www.ncbi.nlm.nih.gov/pubmed/20978028', 'https://scholar.google.com/scholar_lookup?title=QVA149+demonstrates+superior+bronchodilation+compared+with+indacaterol+or+placebo+in+patients+with+chronic+obstructive+pulmonary+disease+&author=J+Noord&author=R+Buhl&author=C+Laforce&author=C+Martin&author=F+Jones&author=M+Dolker&publication_year=2010&hl=en']",20978028,https://doi.org/10.1136/thx.2010.139113, Van Noord 2010 {published data only}  ,excluded,CD012930-bbs2-0109, Duration of treatment < 3 weeks 
CD012930-bib-0274,"Van Noord JA, Buhl R, LaForce C, Martin C, Jones F, Dolker M, et al. ","Qva149, a novel combination of indacaterol and glycopyrronium, demonstrates superior bronchodilation compared with indacaterol or placebo in patients with COPD",,2009,,    ,['citation-other']," Van Noord JA, Buhl R, LaForce C, Martin C, Jones F, Dolker M, et al. Qva149, a novel combination of indacaterol and glycopyrronium, demonstrates superior bronchodilation compared with indacaterol or placebo in patients with COPD. European Respiratory Society 19th Annual Congress; 2009 Sep 12‐15; Vienna. 2009:[E4347]. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Qva149,+a+novel+combination+of+indacaterol+and+glycopyrronium,+demonstrates+superior+bronchodilation+compared+with+indacaterol+or+placebo+in+patients+with+COPD+&author=JA+Noord&author=R+Buhl&author=C+LaForce&author=C+Martin&author=F+Jones&author=M+Dolker&publication_year=2009&hl=en']",,, Van Noord 2010 {published data only}  ,excluded,CD012930-bbs2-0109, Duration of treatment < 3 weeks 
CD012930-bib-0275,"Velazquez‐Uncal M, Ramirez‐Venegas A, Sansores R, Perez‐Bautista O, Hernandez‐Zenteno R, Velazquez A, et al. ",Clinically significant impact of tiotropium and indacaterol on six‐minute walking test and inspiratory capacity in women with chronic obstructive pulmonary disease associated to biomass exposure, American Journal of Respiratory and Critical Care Medicine ,2016,193,    ,['citation-journal']," Velazquez‐Uncal M, Ramirez‐Venegas A, Sansores R, Perez‐Bautista O, Hernandez‐Zenteno R, Velazquez A, et al. Clinically significant impact of tiotropium and indacaterol on six‐minute walking test and inspiratory capacity in women with chronic obstructive pulmonary disease associated to biomass exposure.  American Journal of Respiratory and Critical Care Medicine 2016;193:A3534. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Clinically+significant+impact+of+tiotropium+and+indacaterol+on+six‐minute+walking+test+and+inspiratory+capacity+in+women+with+chronic+obstructive+pulmonary+disease+associated+to+biomass+exposure+&author=M+Velazquez‐Uncal&author=A+Ramirez‐Venegas&author=R+Sansores&author=O+Perez‐Bautista&author=R+Hernandez‐Zenteno&author=A+Velazquez&publication_year=2016&hl=en']",,, Velazquez‐Uncal 2016 {published data only}  ,excluded,CD012930-bbs2-0110, Wrong intervention (LABA/LAMA not evaluated) 
CD012930-bib-0276,NCT01604278. ,"Efficacy, safety and tolerability of the co‐administration of NVA237 plus indacaterol once daily versus indacaterol once daily in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (GLOW6)",,,,   ,['citation-other']," NCT01604278. Efficacy, safety and tolerability of the co‐administration of NVA237 plus indacaterol once daily versus indacaterol once daily in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (GLOW6). clinicaltrials.gov/ct2/show/NCT01604278 (first received 23 May 2012). CENTRAL    ",[''],,, Vincken 2013 {published data only}  ,excluded,CD012930-bbs2-0111, Wrong intervention (LABA/LAMA not administered in combined inhaler) 
CD012930-bib-0277,"Vincken W, Aumann J, Chen H, Henley M, McBryan D, Goyal P. ",Efficacy and safety of coadministration of once‐daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study, International Journal of Chronic Obstructive Pulmonary Disease ,2014,9,    ,['citation-journal']," Vincken W, Aumann J, Chen H, Henley M, McBryan D, Goyal P. Efficacy and safety of coadministration of once‐daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study.  International Journal of Chronic Obstructive Pulmonary Disease 2014;9:215‐28. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.2147/COPD.S51592', 'https://www.ncbi.nlm.nih.gov/pubmed/24596459', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+coadministration+of+once‐daily+indacaterol+and+glycopyrronium+versus+indacaterol+alone+in+COPD+patients:+the+GLOW6+study+&author=W+Vincken&author=J+Aumann&author=H+Chen&author=M+Henley&author=D+McBryan&author=P+Goyal&publication_year=2014&hl=en']",24596459,https://doi.org/10.2147/COPD.S51592, Vincken 2013 {published data only}  ,excluded,CD012930-bbs2-0111, Wrong intervention (LABA/LAMA not administered in combined inhaler) 
CD012930-bib-0278,"Vincken W, Aumann J, Jack D, Chen H, Henley M, Goyal P. ",Once‐daily co‐administration of glycopyrronium and indacaterol via BreezhalerÂ® device improves lung function and symptoms in patients with COPD versus indacaterol alone: the GLOW6 study,,2013,,    ,['citation-other']," Vincken W, Aumann J, Jack D, Chen H, Henley M, Goyal P. Once‐daily co‐administration of glycopyrronium and indacaterol via BreezhalerÂ® device improves lung function and symptoms in patients with COPD versus indacaterol alone: the GLOW6 study. Thorax. 2013:A181 [P232]. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Once‐daily+co‐administration+of+glycopyrronium+and+indacaterol+via+BreezhalerÂ®+device+improves+lung+function+and+symptoms+in+patients+with+COPD+versus+indacaterol+alone:+the+GLOW6+study+&author=W+Vincken&author=J+Aumann&author=D+Jack&author=H+Chen&author=M+Henley&author=P+Goyal&publication_year=2013&hl=en']",,, Vincken 2013 {published data only}  ,excluded,CD012930-bbs2-0111, Wrong intervention (LABA/LAMA not administered in combined inhaler) 
CD012930-bib-0279,"Arievich H, Potena A, Fonay K, Vogelmeier CF, Overend T, Smith J, et al. ",Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients, European Respiratory Journal ,2006,28,    ,['citation-journal']," Arievich H, Potena A, Fonay K, Vogelmeier CF, Overend T, Smith J, et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients.  European Respiratory Journal 2006;28:440s [P2514]. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Formoterol+given+either+alone+or+together+with+tiotropium+reduces+the+rate+of+exacerbations+in+stable+COPD+patients+&author=H+Arievich&author=A+Potena&author=K+Fonay&author=CF+Vogelmeier&author=T+Overend&author=J+Smith&publication_year=2006&hl=en']",,, Vogelmeier 2008 {published data only}  ,excluded,CD012930-bbs2-0112, Wrong intervention (LABA/LAMA not administered in combined inhaler) 
CD012930-bib-0280,"Vogelmeier C, Kardos P, Harari S, Gans S, Stenglein S, Thirlwell J. ",Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study, Respiratory Medicine ,2008,102,    ,['citation-journal']," Vogelmeier C, Kardos P, Harari S, Gans S, Stenglein S, Thirlwell J. Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study.  Respiratory Medicine 2008;102(11):1511‐20. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.rmed.2008.07.020', 'https://www.ncbi.nlm.nih.gov/pubmed/18804362', 'https://scholar.google.com/scholar_lookup?title=Formoterol+mono‐+and+combination+therapy+with+tiotropium+in+patients+with+COPD:+a+6‐month+study+&author=C+Vogelmeier&author=P+Kardos&author=S+Harari&author=S+Gans&author=S+Stenglein&author=J+Thirlwell&publication_year=2008&hl=en']",18804362,https://doi.org/10.1016/j.rmed.2008.07.020, Vogelmeier 2008 {published data only}  ,excluded,CD012930-bbs2-0112, Wrong intervention (LABA/LAMA not administered in combined inhaler) 
CD012930-bib-0281,"Vogelmeier CF, Harari SA, Fonay K, Beier J, Overend T, Till D, et al. ",Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together, European Respiratory Journal ,2006,28,    ,['citation-journal']," Vogelmeier CF, Harari SA, Fonay K, Beier J, Overend T, Till D, et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together.  European Respiratory Journal 2006;28:429s [P2506]. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Formoterol+and+tiotropium+both+improve+lung+function+in+stable+COPD+patients+with+some+additional+benefit+when+given+together+&author=CF+Vogelmeier&author=SA+Harari&author=K+Fonay&author=J+Beier&author=T+Overend&author=D+Till&publication_year=2006&hl=en']",,, Vogelmeier 2008 {published data only}  ,excluded,CD012930-bbs2-0112, Wrong intervention (LABA/LAMA not administered in combined inhaler) 
CD012930-bib-0282,"Vogelmeier C, Bateman E, Pallante J, Bryant H, Alagappan V, D'Andrea P, et al. ",QVA149 once daily is safe and well tolerated in patients with COPD: the ILLUMINATE study, American Journal of Respiratory and Critical Care Medicine ,2013,187,    ,['citation-journal']," Vogelmeier C, Bateman E, Pallante J, Bryant H, Alagappan V, D'Andrea P, et al. QVA149 once daily is safe and well tolerated in patients with COPD: the ILLUMINATE study.  American Journal of Respiratory and Critical Care Medicine 2013;187:A1477. CENTRAL    Google Scholar     ","['', ""https://scholar.google.com/scholar_lookup?title=QVA149+once+daily+is+safe+and+well+tolerated+in+patients+with+COPD:+the+ILLUMINATE+study+&author=C+Vogelmeier&author=E+Bateman&author=J+Pallante&author=H+Bryant&author=V+Alagappan&author=P+D'Andrea&publication_year=2013&hl=en""]",,, Vogelmeier 2013 {published data only}  ,excluded,CD012930-bbs2-0113, Wrong comparator (LABA/LAMA vs LABA steroids) 
CD012930-bib-0283,"Vogelmeier CF, Bateman ED, Pallante J, Alagappan VK, D'Andrea P, Chen H, et al. ","Efficacy and safety of once‐daily QVA149 compared with twice‐daily salmeterol‐fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double‐blind, parallel group study", Lancet Respiratory Medicine ,2013,1,    ,['citation-journal']," Vogelmeier CF, Bateman ED, Pallante J, Alagappan VK, D'Andrea P, Chen H, et al. Efficacy and safety of once‐daily QVA149 compared with twice‐daily salmeterol‐fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double‐blind, parallel group study.  Lancet Respiratory Medicine 2013;1(1):51‐60. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/S2213-2600(12)70052-8', 'https://www.ncbi.nlm.nih.gov/pubmed/24321804', ""https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+once‐daily+QVA149+compared+with+twice‐daily+salmeterol‐fluticasone+in+patients+with+chronic+obstructive+pulmonary+disease+(ILLUMINATE):+a+randomised,+double‐blind,+parallel+group+study+&author=CF+Vogelmeier&author=ED+Bateman&author=J+Pallante&author=VK+Alagappan&author=P+D'Andrea&author=H+Chen&publication_year=2013&hl=en""]",24321804,https://doi.org/10.1016/S2213-2600(12)70052-8, Vogelmeier 2013 {published data only}  ,excluded,CD012930-bbs2-0113, Wrong comparator (LABA/LAMA vs LABA steroids) 
CD012930-bib-0284,"Aymerich JG, Watz H, Beeh KM, Paggiaro P, Moya M, Notari M, et al. ",Use of the Daily PROactive instrument to evaluate physical activity in patients with COPD: results from ACTIVATE, European Respiratory Journal ,2017,50,    ,['citation-journal']," Aymerich JG, Watz H, Beeh KM, Paggiaro P, Moya M, Notari M, et al. Use of the Daily PROactive instrument to evaluate physical activity in patients with COPD: results from ACTIVATE.  European Respiratory Journal 2017;50:PA4964. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Use+of+the+Daily+PROactive+instrument+to+evaluate+physical+activity+in+patients+with+COPD:+results+from+ACTIVATE+&author=JG+Aymerich&author=H+Watz&author=KM+Beeh&author=P+Paggiaro&author=M+Moya&author=M+Notari&publication_year=2017&hl=en']",,, Watz 2017 {published data only}  ,excluded,CD012930-bbs2-0114, 2nd ROUND: Wrong intervention ‐ LAMA/LABA administered twice daily 
CD012930-bib-0285,NCT02424344. ,"Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in moderate to severe COPD patients",,,,   ,['citation-other']," NCT02424344. Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in moderate to severe COPD patients. clinicaltrials.gov/ct2/show/NCT02424344 (first received 23 April 2015). CENTRAL    ",[''],,, Watz 2017 {published data only}  ,excluded,CD012930-bbs2-0114, 2nd ROUND: Wrong intervention ‐ LAMA/LABA administered twice daily 
CD012930-bib-0286,"Watz H, Troosters T, Beeh KM, Garcia Aymerich J, Paggiaro P, Molins E, et al. ",ACTIVATE: effect of aclidinium/formoterol on physical activity in patients with COPD, European Respiratory Journal ,2017,50,    ,['citation-journal']," Watz H, Troosters T, Beeh KM, Garcia Aymerich J, Paggiaro P, Molins E, et al. ACTIVATE: effect of aclidinium/formoterol on physical activity in patients with COPD.  European Respiratory Journal 2017;50:PA687. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=ACTIVATE:+effect+of+aclidinium/formoterol+on+physical+activity+in+patients+with+COPD&author=H+Watz&author=T+Troosters&author=KM+Beeh&author=J+GarciaAymerich&author=P+Paggiaro&author=E+Molins&publication_year=2017&hl=en']",,, Watz 2017 {published data only}  ,excluded,CD012930-bbs2-0114, 2nd ROUND: Wrong intervention ‐ LAMA/LABA administered twice daily 
CD012930-bib-0287,"Watz H, Troosters T, Beeh KM, Garcia‐Aymerich J, Paggiaro P, Molins E, et al. ","ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD", International Journal of Chronic Obstructive Pulmonary Disease ,2017,12,    ,['citation-journal']," Watz H, Troosters T, Beeh KM, Garcia‐Aymerich J, Paggiaro P, Molins E, et al. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD.  International Journal of Chronic Obstructive Pulmonary Disease 2017;12:2545‐58. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.2147/COPD.S143488', 'https://www.ncbi.nlm.nih.gov/pubmed/28883722', 'https://scholar.google.com/scholar_lookup?title=ACTIVATE:+the+effect+of+aclidinium/formoterol+on+hyperinflation,+exercise+capacity,+and+physical+activity+in+patients+with+COPD+&author=H+Watz&author=T+Troosters&author=KM+Beeh&author=J+Garcia‐Aymerich&author=P+Paggiaro&author=E+Molins&publication_year=2017&hl=en']",28883722,https://doi.org/10.2147/COPD.S143488, Watz 2017 {published data only}  ,excluded,CD012930-bbs2-0114, 2nd ROUND: Wrong intervention ‐ LAMA/LABA administered twice daily 
CD012930-bib-0288,"Webb KA, Ciavaglia CE, Preston M, O'Donnell DE. ","Effects of dual umeclidinium/vilanterol compared to umeclidinum on exertional dyspnea, respiratory mechanics and neural drive in patients with moderate COPD", American Journal of Respiratory and Critical Care Medicine ,2015,191,    ,['citation-journal']," Webb KA, Ciavaglia CE, Preston M, O'Donnell DE. Effects of dual umeclidinium/vilanterol compared to umeclidinum on exertional dyspnea, respiratory mechanics and neural drive in patients with moderate COPD.  American Journal of Respiratory and Critical Care Medicine 2015;191:A5735. CENTRAL    Google Scholar     ","['', ""https://scholar.google.com/scholar_lookup?title=Effects+of+dual+umeclidinium/vilanterol+compared+to+umeclidinum+on+exertional+dyspnea,+respiratory+mechanics+and+neural+drive+in+patients+with+moderate+COPD+&author=KA+Webb&author=CE+Ciavaglia&author=M+Preston&author=DE+O'Donnell&publication_year=2015&hl=en""]",,, Webb 2015 {published data only}  ,excluded,CD012930-bbs2-0115, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0289,CQVA149A2303. ,"A 26‐week treatment, multi‐center, randomized, double‐blind, parallel‐group, placebo and active controlled (open label) study to assess the efficacy, safety and tolerability of QVA149 (110/50 μg q.d.) in patients with moderate to severe chronic obstructive pulmonary disease (COPD)",,,,   ,['citation-other']," CQVA149A2303. A 26‐week treatment, multi‐center, randomized, double‐blind, parallel‐group, placebo and active controlled (open label) study to assess the efficacy, safety and tolerability of QVA149 (110/50 μg q.d.) in patients with moderate to severe chronic obstructive pulmonary disease (COPD). www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=7983 (first received 21 September 2010). CENTRAL    ",[''],,, Wedzicha 2013 {published data only}  ,excluded,CD012930-bbs2-0116, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0290,"Decramer M, Wedzicha JA, Ficker J, Fowler‐Taylor A, D'Andrea P, Arrasate C, et al. ",Once‐daily QVA149 improves health‐related quality of life in patients with severe to very severe COPD: the Spark study, American Journal of Respiratory and Critical Care Medicine ,2013,187,    ,['citation-journal']," Decramer M, Wedzicha JA, Ficker J, Fowler‐Taylor A, D'Andrea P, Arrasate C, et al. Once‐daily QVA149 improves health‐related quality of life in patients with severe to very severe COPD: the Spark study.  American Journal of Respiratory and Critical Care Medicine 2013;187:A4257. CENTRAL    Google Scholar     ","['', ""https://scholar.google.com/scholar_lookup?title=Once‐daily+QVA149+improves+health‐related+quality+of+life+in+patients+with+severe+to+very+severe+COPD:+the+Spark+study+&author=M+Decramer&author=JA+Wedzicha&author=J+Ficker&author=A+Fowler‐Taylor&author=P+D'Andrea&author=C+Arrasate&publication_year=2013&hl=en""]",,, Wedzicha 2013 {published data only}  ,excluded,CD012930-bbs2-0116, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0291,"Ficker JH, Wedzicha JA, Decramer M, Fowler‐Taylor A, D'Andrea P, Arrasate C, et al. ",QVA149 reduces COPD exacerbation rate in various subgroups of patients: the SPARK study,,2013,,    ,['citation-other']," Ficker JH, Wedzicha JA, Decramer M, Fowler‐Taylor A, D'Andrea P, Arrasate C, et al. QVA149 reduces COPD exacerbation rate in various subgroups of patients: the SPARK study. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42:3s [182]. CENTRAL    Google Scholar     ","['', ""https://scholar.google.com/scholar_lookup?title=QVA149+reduces+COPD+exacerbation+rate+in+various+subgroups+of+patients:+the+SPARK+study+&author=JH+Ficker&author=JA+Wedzicha&author=M+Decramer&author=A+Fowler‐Taylor&author=P+D'Andrea&author=C+Arrasate&publication_year=2013&hl=en""]",,, Wedzicha 2013 {published data only}  ,excluded,CD012930-bbs2-0116, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0292,"Mezzi K, Wedzicha J, Decramer M, Fowler‐Taylor A, Fogel R, Chen H, et al. ",QVA149 provides greater improvement in patient reported symptom scores compared to glycopyrronium and tiotropium in patients with severe to very severe COPD: the SPARK study [Abstract],,2014,,    ,['citation-other']," Mezzi K, Wedzicha J, Decramer M, Fowler‐Taylor A, Fogel R, Chen H, et al. QVA149 provides greater improvement in patient reported symptom scores compared to glycopyrronium and tiotropium in patients with severe to very severe COPD: the SPARK study [Abstract]. 7th International Primary Care Respiratory Group (IPCRG) World Conference; 2014 May 21‐24; Athens. 2014:PO005‐FRI. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=QVA149+provides+greater+improvement+in+patient+reported+symptom+scores+compared+to+glycopyrronium+and+tiotropium+in+patients+with+severe+to+very+severe+COPD:+the+SPARK+study+[Abstract]+&author=K+Mezzi&author=J+Wedzicha&author=M+Decramer&author=A+Fowler‐Taylor&author=R+Fogel&author=H+Chen&publication_year=2014&hl=en']",,, Wedzicha 2013 {published data only}  ,excluded,CD012930-bbs2-0116, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0293,"Van Meerhaeghe A, Vanhaeverbeek M. ",QVA149 versus glycopyrronium for COPD, Lancet Respiratory Medicine ,2013,1,    ,['citation-journal']," Van Meerhaeghe A, Vanhaeverbeek M. QVA149 versus glycopyrronium for COPD.  Lancet Respiratory Medicine 2013;1(5):e22‐3. [2213‐2600]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/S2213-2600(13)70115-2', 'https://www.ncbi.nlm.nih.gov/pubmed/24429209', 'https://scholar.google.com/scholar_lookup?title=QVA149+versus+glycopyrronium+for+COPD&author=A+Meerhaeghe&author=M+Vanhaeverbeek&publication_year=2013&hl=en']",24429209,https://doi.org/10.1016/S2213-2600(13)70115-2, Wedzicha 2013 {published data only}  ,excluded,CD012930-bbs2-0116, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0294,"Wedzicha J, Decramer M, Ficker J, Fowler Taylor A, D'Andrea P, Arrasate C, et al. ",Once‐daily glycopyrronium improves lung function and reduces exacerbations in severe‐to‐very severe COPD patients: The SPARK study [Abstract],,2013,,    ,['citation-other']," Wedzicha J, Decramer M, Ficker J, Fowler Taylor A, D'Andrea P, Arrasate C, et al. Once‐daily glycopyrronium improves lung function and reduces exacerbations in severe‐to‐very severe COPD patients: The SPARK study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42:3s [180]. CENTRAL    Google Scholar     ","['', ""https://scholar.google.com/scholar_lookup?title=Once‐daily+glycopyrronium+improves+lung+function+and+reduces+exacerbations+in+severe‐to‐very+severe+COPD+patients:+The+SPARK+study+[Abstract]+&author=J+Wedzicha&author=M+Decramer&author=J+Ficker&author=A+FowlerTaylor&author=P+D'Andrea&author=C+Arrasate&publication_year=2013&hl=en""]",,, Wedzicha 2013 {published data only}  ,excluded,CD012930-bbs2-0116, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0295,"Wedzicha J, Decramer M, Ficker J, Fowler‐Taylor A, D'Andrea P, Arrasate C, et al. ",Dual bronchodilation with QVA149 reduces COPD exacerbations: the Spark study, American Journal of Respiratory and Critical Care Medicine ,2013,187,    ,['citation-journal']," Wedzicha J, Decramer M, Ficker J, Fowler‐Taylor A, D'Andrea P, Arrasate C, et al. Dual bronchodilation with QVA149 reduces COPD exacerbations: the Spark study.  American Journal of Respiratory and Critical Care Medicine 2013;187:A2428. CENTRAL    Google Scholar     ","['', ""https://scholar.google.com/scholar_lookup?title=Dual+bronchodilation+with+QVA149+reduces+COPD+exacerbations:+the+Spark+study&author=J+Wedzicha&author=M+Decramer&author=J+Ficker&author=A+Fowler‐Taylor&author=P+D'Andrea&author=C+Arrasate&publication_year=2013&hl=en""]",,, Wedzicha 2013 {published data only}  ,excluded,CD012930-bbs2-0116, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0296,"Wedzicha J, Decramer M, Ficker J, Niewoehner D, Sandstrom T, Fowler‐Taylor A. ",Efficacy and safety of QVA149 versus glycopyrronium and tiotropium in severe to very severe COPD: the Spark study, American Journal of Respiratory and Critical Care Medicine ,2013,187,    ,['citation-journal']," Wedzicha J, Decramer M, Ficker J, Niewoehner D, Sandstrom T, Fowler‐Taylor A. Efficacy and safety of QVA149 versus glycopyrronium and tiotropium in severe to very severe COPD: the Spark study.  American Journal of Respiratory and Critical Care Medicine 2013;187:A2429. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+QVA149+versus+glycopyrronium+and+tiotropium+in+severe+to+very+severe+COPD:+the+Spark+study+&author=J+Wedzicha&author=M+Decramer&author=J+Ficker&author=D+Niewoehner&author=T+Sandstrom&author=A+Fowler‐Taylor&publication_year=2013&hl=en']",,, Wedzicha 2013 {published data only}  ,excluded,CD012930-bbs2-0116, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0297,"Wedzicha J, Decramer M, Ficker J, Niewohner D, Sandstrom T, Fowler‐Taylor A, et al. ","Dual bronchodilation with once‐daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe‐to‐very severe COPD patients: the SPARK study", European Respiratory Journal ,2013,42,    ,['citation-journal']," Wedzicha J, Decramer M, Ficker J, Niewohner D, Sandstrom T, Fowler‐Taylor A, et al. Dual bronchodilation with once‐daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe‐to‐very severe COPD patients: the SPARK study.  European Respiratory Journal 2013;42:3s [181]. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Dual+bronchodilation+with+once‐daily+QVA149+reduces+exacerbations,+improves+lung+function+and+health+status+versus+glycopyrronium+and+tiotropium+in+severe‐to‐very+severe+COPD+patients:+the+SPARK+study+&author=J+Wedzicha&author=M+Decramer&author=J+Ficker&author=D+Niewohner&author=T+Sandstrom&author=A+Fowler‐Taylor&publication_year=2013&hl=en']",,, Wedzicha 2013 {published data only}  ,excluded,CD012930-bbs2-0116, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0298,"Wedzicha J, Decramer M, Ficker J, Sandstrom T, Taylor A, D'Andrea P, et al. ",Qva149 provides greater improvement in patient reported symptom scores compared to glycopyrronium and tiotropium in patients with severe to very severe COPD: the SPARK study, American Journal of Respiratory and Critical Care Medicine ,2014,189,    ,['citation-journal']," Wedzicha J, Decramer M, Ficker J, Sandstrom T, Taylor A, D'Andrea P, et al. Qva149 provides greater improvement in patient reported symptom scores compared to glycopyrronium and tiotropium in patients with severe to very severe COPD: the SPARK study.  American Journal of Respiratory and Critical Care Medicine 2014;189:A3761. CENTRAL    Google Scholar     ","['', ""https://scholar.google.com/scholar_lookup?title=Qva149+provides+greater+improvement+in+patient+reported+symptom+scores+compared+to+glycopyrronium+and+tiotropium+in+patients+with+severe+to+very+severe+COPD:+the+SPARK+study+&author=J+Wedzicha&author=M+Decramer&author=J+Ficker&author=T+Sandstrom&author=A+Taylor&author=P+D'Andrea&publication_year=2014&hl=en""]",,, Wedzicha 2013 {published data only}  ,excluded,CD012930-bbs2-0116, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0299,"Wedzicha J, Ficker J, Fowler‐Taylor A, D'Andrea P, Arrasate C, Chen H, et al. ",Once‐daily QVA149 reduces exacerbations and improves health status in comparison with glycopyrronium and tiotropium in patients with severe‐to‐very severe COPD: the spark study, American College of Chest Physicians ,2014,145,    ,['citation-journal']," Wedzicha J, Ficker J, Fowler‐Taylor A, D'Andrea P, Arrasate C, Chen H, et al. Once‐daily QVA149 reduces exacerbations and improves health status in comparison with glycopyrronium and tiotropium in patients with severe‐to‐very severe COPD: the spark study.  American College of Chest Physicians 2014;145(3):427A. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1378/chest.1824414', ""https://scholar.google.com/scholar_lookup?title=Once‐daily+QVA149+reduces+exacerbations+and+improves+health+status+in+comparison+with+glycopyrronium+and+tiotropium+in+patients+with+severe‐to‐very+severe+COPD:+the+spark+study+&author=J+Wedzicha&author=J+Ficker&author=A+Fowler‐Taylor&author=P+D'Andrea&author=C+Arrasate&author=H+Chen&publication_year=2014&hl=en""]",,https://doi.org/10.1378/chest.1824414, Wedzicha 2013 {published data only}  ,excluded,CD012930-bbs2-0116, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0300,"Wedzicha J, Ficker J, Niewohner D, Sandstrom T, Fowler‐Taylor A, Banerji D. ","Dual bronchodilation with once‐daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe‐to‐very severe COPD patients: the spark study", American College of Chest Physicians ,2014,145,    ,['citation-journal']," Wedzicha J, Ficker J, Niewohner D, Sandstrom T, Fowler‐Taylor A, Banerji D. Dual bronchodilation with once‐daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe‐to‐very severe COPD patients: the spark study.  American College of Chest Physicians 2014;145(3):406A. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1378/chest.1824370', 'https://scholar.google.com/scholar_lookup?title=Dual+bronchodilation+with+once‐daily+QVA149+reduces+exacerbations,+improves+lung+function+and+health+status+versus+glycopyrronium+and+tiotropium+in+severe‐to‐very+severe+COPD+patients:+the+spark+study+&author=J+Wedzicha&author=J+Ficker&author=D+Niewohner&author=T+Sandstrom&author=A+Fowler‐Taylor&author=D+Banerji&publication_year=2014&hl=en']",,https://doi.org/10.1378/chest.1824370, Wedzicha 2013 {published data only}  ,excluded,CD012930-bbs2-0116, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0301,"Wedzicha JA, D'Urzo A, Mezzi K, Chen H, Banerji D, Fogel R. ",QVA149 showed significant improvements in lung function and health status and was well tolerated versus glycopyrronium and tiotropium in patients with severe COPD: the SPARK study, European Respiratory Journal ,2014,44,    ,['citation-journal']," Wedzicha JA, D'Urzo A, Mezzi K, Chen H, Banerji D, Fogel R. QVA149 showed significant improvements in lung function and health status and was well tolerated versus glycopyrronium and tiotropium in patients with severe COPD: the SPARK study.  European Respiratory Journal 2014;44:1893. CENTRAL    Google Scholar     ","['', ""https://scholar.google.com/scholar_lookup?title=QVA149+showed+significant+improvements+in+lung+function+and+health+status+and+was+well+tolerated+versus+glycopyrronium+and+tiotropium+in+patients+with+severe+COPD:+the+SPARK+study+&author=JA+Wedzicha&author=A+D'Urzo&author=K+Mezzi&author=H+Chen&author=D+Banerji&author=R+Fogel&publication_year=2014&hl=en""]",,, Wedzicha 2013 {published data only}  ,excluded,CD012930-bbs2-0116, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0302,"Wedzicha JA, Decramer M, Ficker JH, Niewoehner DE, SandstrÃƒÂ¶m T, Taylor AF, et al. ","Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double‐blind, parallel‐group study", Lancet Respiratory Medicine ,2013,1,    ,['citation-journal']," Wedzicha JA, Decramer M, Ficker JH, Niewoehner DE, SandstrÃƒÂ¶m T, Taylor AF, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double‐blind, parallel‐group study.  Lancet Respiratory Medicine 2013;1(3):199‐209. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/S2213-2600(13)70052-3', 'https://www.ncbi.nlm.nih.gov/pubmed/24429126', 'https://scholar.google.com/scholar_lookup?title=Analysis+of+chronic+obstructive+pulmonary+disease+exacerbations+with+the+dual+bronchodilator+QVA149+compared+with+glycopyrronium+and+tiotropium+(SPARK):+a+randomised,+double‐blind,+parallel‐group+study+&author=JA+Wedzicha&author=M+Decramer&author=JH+Ficker&author=DE+Niewoehner&author=T+SandstrÃƒÂ¶m&author=AF+Taylor&publication_year=2013&hl=en']",24429126,https://doi.org/10.1016/S2213-2600(13)70052-3, Wedzicha 2013 {published data only}  ,excluded,CD012930-bbs2-0116, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0303,"Wedzicha JA, Mezzi K, Fogel R, Banerji D. ",Baseline symptom scores and future risk of severe exacerbation: the SPARK study, European Respiratory Journal ,2015,46,    ,['citation-journal']," Wedzicha JA, Mezzi K, Fogel R, Banerji D. Baseline symptom scores and future risk of severe exacerbation: the SPARK study.  European Respiratory Journal 2015;46(Suppl 59):PA1006. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Baseline+symptom+scores+and+future+risk+of+severe+exacerbation:+the+SPARK+study&author=JA+Wedzicha&author=K+Mezzi&author=R+Fogel&author=D+Banerji&publication_year=2015&hl=en']",,, Wedzicha 2013 {published data only}  ,excluded,CD012930-bbs2-0116, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0304,"Yosuke T, Mitsunori H, Naomi O, Hiroyuki T, Seiji K, Norihisa M, et al. ",Comparison of monotherapy with a long‐acting muscarinic antagonist versus combination therapy with a long‐acting muscarinic antagonist plus a long‐acting beta2‐agonist in patients with chronic obstructive pulmonary disease, Respirology ,2014,19,    ,['citation-journal']," Yosuke T, Mitsunori H, Naomi O, Hiroyuki T, Seiji K, Norihisa M, et al. Comparison of monotherapy with a long‐acting muscarinic antagonist versus combination therapy with a long‐acting muscarinic antagonist plus a long‐acting beta2‐agonist in patients with chronic obstructive pulmonary disease.  Respirology 2014;19:122. CENTRAL    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/24372635', 'https://scholar.google.com/scholar_lookup?title=Comparison+of+monotherapy+with+a+long‐acting+muscarinic+antagonist+versus+combination+therapy+with+a+long‐acting+muscarinic+antagonist+plus+a+long‐acting+beta2‐agonist+in+patients+with+chronic+obstructive+pulmonary+disease+&author=T+Yosuke&author=H+Mitsunori&author=O+Naomi&author=T+Hiroyuki&author=K+Seiji&author=M+Norihisa&publication_year=2014&hl=en']",24372635,, Yosuke 2014 {published data only}  ,excluded,CD012930-bbs2-0117, 2nd Round: Wrong comparator (no placebo) 
CD012930-bib-0305,NCT01694771. ,Co‐administration of olodaterol Respimat® and tiotropium Handihaler®,,,,   ,['citation-other'], NCT01694771. Co‐administration of olodaterol Respimat® and tiotropium Handihaler®. clinicaltrials.gov/ct2/show/NCT01694771 (first received 4 September 2014). CENTRAL    ,[''],,, ZuWallack 2014 {published data only}  ,excluded,CD012930-bbs2-0118, Wrong intervention (LABA/LAMA not administered in combined inhaler) 
CD012930-bib-0306,NCT01696058. ,Co‐administration of olodaterol Respimat® and tiotropium Handihaler®,,,,   ,['citation-other'], NCT01696058. Co‐administration of olodaterol Respimat® and tiotropium Handihaler®. clinicaltrials.gov/ct2/show/NCT01696058 (first received 28 September 2012). CENTRAL    ,[''],,, ZuWallack 2014 {published data only}  ,excluded,CD012930-bbs2-0118, Wrong intervention (LABA/LAMA not administered in combined inhaler) 
CD012930-bib-0307,"Wallack RZ, Allen L, Hernandez G, Ting N, Abrahams R. ","Health status of patients with COPD receiving the combination of olodaterol respimat and tiotropium handihaler compared with tiotropium: results from two replicate, randomized, double‐blind studies", Chest ,2014,146,    ,['citation-journal']," Wallack RZ, Allen L, Hernandez G, Ting N, Abrahams R. Health status of patients with COPD receiving the combination of olodaterol respimat and tiotropium handihaler compared with tiotropium: results from two replicate, randomized, double‐blind studies.  Chest 2014;146(4):46A. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1378/chest.1994369', 'https://scholar.google.com/scholar_lookup?title=Health+status+of+patients+with+COPD+receiving+the+combination+of+olodaterol+respimat+and+tiotropium+handihaler+compared+with+tiotropium:+results+from+two+replicate,+randomized,+double‐blind+studies+&author=RZ+Wallack&author=L+Allen&author=G+Hernandez&author=N+Ting&author=R+Abrahams&publication_year=2014&hl=en']",,https://doi.org/10.1378/chest.1994369, ZuWallack 2014 {published data only}  ,excluded,CD012930-bbs2-0118, Wrong intervention (LABA/LAMA not administered in combined inhaler) 
CD012930-bib-0308,"ZuWallack R, Allen L, Hernandez G, Ting N, Abrahams R. ","Efficacy and safety of combining olodaterol Respimat((R)) and tiotropium HandiHaler((R)) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies", International Journal of Chronic Obstructive Pulmonary Disease ,2014,9,    ,['citation-journal']," ZuWallack R, Allen L, Hernandez G, Ting N, Abrahams R. Efficacy and safety of combining olodaterol Respimat((R)) and tiotropium HandiHaler((R)) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies.  International Journal of Chronic Obstructive Pulmonary Disease 2014;9:1133‐44. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.2147/COPD.S72482', 'https://www.ncbi.nlm.nih.gov/pubmed/25342898', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+combining+olodaterol+Respimat((R))+and+tiotropium+HandiHaler((R))+in+patients+with+COPD:+results+of+two+randomized,+double‐blind,+active‐controlled+studies+&author=R+ZuWallack&author=L+Allen&author=G+Hernandez&author=N+Ting&author=R+Abrahams&publication_year=2014&hl=en']",25342898,https://doi.org/10.2147/COPD.S72482, ZuWallack 2014 {published data only}  ,excluded,CD012930-bbs2-0118, Wrong intervention (LABA/LAMA not administered in combined inhaler) 
CD012930-bib-0310,"Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, et al. ","Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial", Annals of Internal Medicine ,2007,146,    ,['citation-journal']," Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.  Annals of Internal Medicine 2007;146(8):545‐55.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.7326/0003-4819-146-8-200704170-00152', 'https://www.ncbi.nlm.nih.gov/pubmed/17310045', 'https://scholar.google.com/scholar_lookup?title=Tiotropium+in+combination+with+placebo,+salmeterol,+or+fluticasone‐salmeterol+for+treatment+of+chronic+obstructive+pulmonary+disease:+a+randomized+trial+&author=SD+Aaron&author=KL+Vandemheen&author=D+Fergusson&author=F+Maltais&author=J+Bourbeau&author=R+Goldstein&publication_year=2007&hl=en']",17310045,https://doi.org/10.7326/0003-4819-146-8-200704170-00152, Aaron 2007 ,additional,CD012930-bbs2-0120,
CD012930-bib-0311,"Aaron SD, Fergusson D, Marks GB, Suissa S, Vandemheen KL, Doucette S, et al. ","Counting, analysing and reporting exacerbations of COPD in randomised controlled trials", Thorax ,2008,63,    ,['citation-journal']," Aaron SD, Fergusson D, Marks GB, Suissa S, Vandemheen KL, Doucette S, et al. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials.  Thorax 2008;63(2):122‐8.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1136/thx.2007.082636', 'https://www.ncbi.nlm.nih.gov/pubmed/17702790', 'https://scholar.google.com/scholar_lookup?title=Counting,+analysing+and+reporting+exacerbations+of+COPD+in+randomised+controlled+trials&author=SD+Aaron&author=D+Fergusson&author=GB+Marks&author=S+Suissa&author=KL+Vandemheen&author=S+Doucette&publication_year=2008&hl=en']",17702790,https://doi.org/10.1136/thx.2007.082636, Aaron 2008 ,additional,CD012930-bbs2-0121,
CD012930-bib-0312,"Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. ",Fixed‐dose combinations improve medication compliance: a meta‐analysis, American Journal of Medicine ,2007,120,    ,['citation-journal']," Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed‐dose combinations improve medication compliance: a meta‐analysis.  American Journal of Medicine 2007;120(8):713‐9.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.amjmed.2006.08.033', 'https://www.ncbi.nlm.nih.gov/pubmed/17679131', 'https://scholar.google.com/scholar_lookup?title=Fixed‐dose+combinations+improve+medication+compliance:+a+meta‐analysis&author=S+Bangalore&author=G+Kamalakkannan&author=S+Parkar&author=FH+Messerli&publication_year=2007&hl=en']",17679131,https://doi.org/10.1016/j.amjmed.2006.08.033, Bangalore 2007 ,additional,CD012930-bbs2-0122,
CD012930-bib-0313,"Barnes PJ, Burney PGJ, Silverman EK, Celli BR, Vestbo J, Wedzicha JA, et al. ",Chronic obstructive pulmonary disease, Nature Reviews Disease Primers ,2015,122,    ,['citation-journal']," Barnes PJ, Burney PGJ, Silverman EK, Celli BR, Vestbo J, Wedzicha JA, et al. Chronic obstructive pulmonary disease.  Nature Reviews Disease Primers 2015;122:15076.    Link to article     Google Scholar     ","['https://doi.org/10.1038/nrdp.2015.76', 'https://scholar.google.com/scholar_lookup?title=Chronic+obstructive+pulmonary+disease&author=PJ+Barnes&author=PGJ+Burney&author=EK+Silverman&author=BR+Celli&author=J+Vestbo&author=JA+Wedzicha&publication_year=2015&hl=en']",,https://doi.org/10.1038/nrdp.2015.76, Barnes 2015 ,additional,CD012930-bbs2-0123,
CD012930-bib-0314,"Bateman ED, Chapman KR, Singh D, D’Urzo AD, Molins E, Leselbaum A, et al. ","Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT)", Respiratory Research ,2015,16,    ,['citation-journal']," Bateman ED, Chapman KR, Singh D, D’Urzo AD, Molins E, Leselbaum A, et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT).  Respiratory Research 2015;16(1):92.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1186/s12931-015-0250-2', 'https://www.ncbi.nlm.nih.gov/pubmed/26233481', 'https://scholar.google.com/scholar_lookup?title=Aclidinium+bromide+and+formoterol+fumarate+as+a+fixed‐dose+combination+in+COPD:+pooled+analysis+of+symptoms+and+exacerbations+from+two+six‐month,+multicentre,+randomised+studies+(ACLIFORM+and+AUGMENT)+&author=ED+Bateman&author=KR+Chapman&author=D+Singh&author=AD+D’Urzo&author=E+Molins&author=A+Leselbaum&publication_year=2015&hl=en']",26233481,https://doi.org/10.1186/s12931-015-0250-2, Bateman 2015 ,additional,CD012930-bbs2-0124,
CD012930-bib-0315,"Beeh KM, Burgel P‐R, Franssen FME, Lopez‐Campos JL, Loukides S, Hurst JR, et al. ",How do dual long‐acting bronchodilators prevent exacerbations of chronic obstructive pulmonary disease?, American Journal of Respiratory and Critical Care Medicine ,2016,196,    ,['citation-journal']," Beeh KM, Burgel P‐R, Franssen FME, Lopez‐Campos JL, Loukides S, Hurst JR, et al. How do dual long‐acting bronchodilators prevent exacerbations of chronic obstructive pulmonary disease?.  American Journal of Respiratory and Critical Care Medicine 2016;196(2):139‐49.    Link to article     Google Scholar     ","['https://doi.org/10.1164/rccm.201609-1794CI', 'https://scholar.google.com/scholar_lookup?title=How+do+dual+long‐acting+bronchodilators+prevent+exacerbations+of+chronic+obstructive+pulmonary+disease?+&author=KM+Beeh&author=P‐R+Burgel&author=FME+Franssen&author=JL+Lopez‐Campos&author=S+Loukides&author=JR+Hurst&publication_year=2016&hl=en']",,https://doi.org/10.1164/rccm.201609-1794CI, Beeh 2016 ,additional,CD012930-bbs2-0125,
CD012930-bib-0316,Calverley PMA. ,Minimal clinically important difference ‐ exacerbations of COPD, COPD ,2005,2,    ,['citation-journal'], Calverley PMA. Minimal clinically important difference ‐ exacerbations of COPD.  COPD 2005;2(1):143‐8.    Link to article     PubMed     Google Scholar     ,"['https://doi.org/10.1081/COPD-200050647', 'https://www.ncbi.nlm.nih.gov/pubmed/17136975', 'https://scholar.google.com/scholar_lookup?title=Minimal+clinically+important+difference+‐+exacerbations+of+COPD&author=PMA+Calverley&publication_year=2005&hl=en']",17136975,https://doi.org/10.1081/COPD-200050647, Calverley 2005 ,additional,CD012930-bbs2-0126,
CD012930-bib-0317,"Calzetta L, Matera MG, Cazzola M. ",Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy, European Journal of Pharmacology ,2015,761,    ,['citation-journal']," Calzetta L, Matera MG, Cazzola M. Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy.  European Journal of Pharmacology 2015;761(C):168–73.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.ejphar.2015.05.020', 'https://www.ncbi.nlm.nih.gov/pubmed/25981302', 'https://scholar.google.com/scholar_lookup?title=Pharmacological+interaction+between+LABAs+and+LAMAs+in+the+airways:+optimizing+synergy&author=L+Calzetta&author=MG+Matera&author=M+Cazzola&publication_year=2015&hl=en']",25981302,https://doi.org/10.1016/j.ejphar.2015.05.020, Calzetta 2015 ,additional,CD012930-bbs2-0127,
CD012930-bib-0318,"Calzetta L, Rogliani P, Matera MG, Cazzola M. ",A systematic review with meta‐analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD, Chest ,2016,149,    ,['citation-journal']," Calzetta L, Rogliani P, Matera MG, Cazzola M. A systematic review with meta‐analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD.  Chest 2016;149(5):1181‐96.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.chest.2016.02.646', 'https://www.ncbi.nlm.nih.gov/pubmed/26923629', 'https://scholar.google.com/scholar_lookup?title=A+systematic+review+with+meta‐analysis+of+dual+bronchodilation+with+LAMA/LABA+for+the+treatment+of+stable+COPD+&author=L+Calzetta&author=P+Rogliani&author=MG+Matera&author=M+Cazzola&publication_year=2016&hl=en']",26923629,https://doi.org/10.1016/j.chest.2016.02.646, Calzetta 2016 ,additional,CD012930-bbs2-0128,
CD012930-bib-0319,"Calzetta L, Rogliani P, Ora J, Puxeddu E, Cazzola M, Matera MG. ",LABA/LAMA combination in COPD: a meta‐analysis on the duration of treatment, European Respiratory Review ,2017,26,    ,['citation-journal']," Calzetta L, Rogliani P, Ora J, Puxeddu E, Cazzola M, Matera MG. LABA/LAMA combination in COPD: a meta‐analysis on the duration of treatment.  European Respiratory Review 2017;26(143):160043.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1183/16000617.0043-2016', 'https://www.ncbi.nlm.nih.gov/pubmed/28096283', 'https://scholar.google.com/scholar_lookup?title=LABA/LAMA+combination+in+COPD:+a+meta‐analysis+on+the+duration+of+treatment&author=L+Calzetta&author=P+Rogliani&author=J+Ora&author=E+Puxeddu&author=M+Cazzola&author=MG+Matera&publication_year=2017&hl=en']",28096283,https://doi.org/10.1183/16000617.0043-2016, Calzetta 2017 ,additional,CD012930-bbs2-0129,
CD012930-bib-0320,"Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, et al. ",Outcomes for COPD pharmacological trials: from lung function to biomarkers, European Respiratory Journal ,2008,31,    ,['citation-journal']," Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers.  European Respiratory Journal 2008;31(2):416‐69.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1183/09031936.00099306', 'https://www.ncbi.nlm.nih.gov/pubmed/18238951', 'https://scholar.google.com/scholar_lookup?title=Outcomes+for+COPD+pharmacological+trials:+from+lung+function+to+biomarkers&author=M+Cazzola&author=W+MacNee&author=FJ+Martinez&author=KF+Rabe&author=LG+Franciosi&author=PJ+Barnes&publication_year=2008&hl=en']",18238951,https://doi.org/10.1183/09031936.00099306, Cazzola 2008 ,additional,CD012930-bbs2-0130,
CD012930-bib-0321,"Cazzola M, Molimard M. ",The scientific rationale for combining long‐acting & beta2‐agonists and muscarinic antagonists in COPD, Pulmonary Pharmacology ,2010,23,    ,['citation-journal']," Cazzola M, Molimard M. The scientific rationale for combining long‐acting & beta2‐agonists and muscarinic antagonists in COPD.  Pulmonary Pharmacology 2010;23(4):257–67.    Google Scholar     ",['https://scholar.google.com/scholar_lookup?title=The+scientific+rationale+for+combining+long‐acting+&+beta2‐agonists+and+muscarinic+antagonists+in+COPD+&author=M+Cazzola&author=M+Molimard&publication_year=2010&hl=en'],,, Cazzola 2010 ,additional,CD012930-bbs2-0131,
CD012930-bib-0322,"Cazzola M, Calzetta L, Ora J, Puxeddu E, Rogliani P, Matera MG. ",Searching for the synergistic effect between aclidinium and formoterol: from bench to bedside., Respiratory Medicine ,2015,109,    ,['citation-journal']," Cazzola M, Calzetta L, Ora J, Puxeddu E, Rogliani P, Matera MG. Searching for the synergistic effect between aclidinium and formoterol: from bench to bedside..  Respiratory Medicine 2015;109(10):1305‐11.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.rmed.2015.08.005', 'https://www.ncbi.nlm.nih.gov/pubmed/26303336', 'https://scholar.google.com/scholar_lookup?title=Searching+for+the+synergistic+effect+between+aclidinium+and+formoterol:+from+bench+to+bedside.+&author=M+Cazzola&author=L+Calzetta&author=J+Ora&author=E+Puxeddu&author=P+Rogliani&author=MG+Matera&publication_year=2015&hl=en']",26303336,https://doi.org/10.1016/j.rmed.2015.08.005, Cazzola 2015 ,additional,CD012930-bbs2-0132,
CD012930-bib-0323,Center for Disease Control. ,"Chronic obstructive pulmonary disease among adults ‐ United States, 2016",,,,. www.cdc.gov/copd/index.html (accessed 1 Apr 2017).   ,['citation-other']," Center for Disease Control. Chronic obstructive pulmonary disease among adults ‐ United States, 2016. www.cdc.gov/copd/index.html (accessed 1 Apr 2017).    ",[],,, CDC 2016 ,additional,CD012930-bbs2-0133,
CD012930-bib-0324,"Chapman KR, Bergeron C, Bhutani M, Bourbeau J, Grossman RF, Hernandez P, et al. ",Do we know the minimal clinically important difference (MCID) for COPD exacerbations?, COPD ,2013,10,    ,['citation-journal']," Chapman KR, Bergeron C, Bhutani M, Bourbeau J, Grossman RF, Hernandez P, et al. Do we know the minimal clinically important difference (MCID) for COPD exacerbations?.  COPD 2013;10(2):243‐9.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.3109/15412555.2012.733463', 'https://www.ncbi.nlm.nih.gov/pubmed/23514218', 'https://scholar.google.com/scholar_lookup?title=Do+we+know+the+minimal+clinically+important+difference+(MCID)+for+COPD+exacerbations?&author=KR+Chapman&author=C+Bergeron&author=M+Bhutani&author=J+Bourbeau&author=RF+Grossman&author=P+Hernandez&publication_year=2013&hl=en']",23514218,https://doi.org/10.3109/15412555.2012.733463, Chapman 2013 ,additional,CD012930-bbs2-0134,
CD012930-bib-0325,Donohue JF. ,Minimal clinically important differences in COPD lung function, COPD ,2005,2,    ,['citation-journal'], Donohue JF. Minimal clinically important differences in COPD lung function.  COPD 2005;2(1):111‐24.    Link to article     PubMed     Google Scholar     ,"['https://doi.org/10.1081/COPD-200053377', 'https://www.ncbi.nlm.nih.gov/pubmed/17136971', 'https://scholar.google.com/scholar_lookup?title=Minimal+clinically+important+differences+in+COPD+lung+function&author=JF+Donohue&publication_year=2005&hl=en']",17136971,https://doi.org/10.1081/COPD-200053377, Donohue 2005 ,additional,CD012930-bbs2-0135,
CD012930-bib-0326,"Farne HA, Cates CJ. ",Long‐acting beta2‐agonist in addition to tiotropium versus either tiotropium or long‐acting beta2‐agonist alone for chronic obstructive pulmonary disease, Cochrane Database of Systematic Reviews ,2015,,    ,['citation-journal']," Farne HA, Cates CJ. Long‐acting beta2‐agonist in addition to tiotropium versus either tiotropium or long‐acting beta2‐agonist alone for chronic obstructive pulmonary disease.  Cochrane Database of Systematic Reviews 2015, Issue 10. [DOI: 10.1002/14651858.CD008989.pub3]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1002/14651858.CD008989.pub3', 'https://www.ncbi.nlm.nih.gov/pubmed/26490945', 'https://scholar.google.com/scholar_lookup?title=Long‐acting+beta2‐agonist+in+addition+to+tiotropium+versus+either+tiotropium+or+long‐acting+beta2‐agonist+alone+for+chronic+obstructive+pulmonary+disease+&author=HA+Farne&author=CJ+Cates&publication_year=2015&hl=en']",26490945,https://doi.org/10.1002/14651858.CD008989.pub3, Farne 2015 ,additional,CD012930-bbs2-0136,
CD012930-bib-0327,Global Initiative for Chronic Obstructive Lung Disease. ,"From the global strategy for the diagnosis, management and prevention of COPD, global initiative for chronic obstructive lung disease (GOLD) 2018",,,,. goldcopd.org/gold‐reports/ (accessed prior to 28 September 2018).   ,['citation-other']," Global Initiative for Chronic Obstructive Lung Disease. From the global strategy for the diagnosis, management and prevention of COPD, global initiative for chronic obstructive lung disease (GOLD) 2018. goldcopd.org/gold‐reports/ (accessed prior to 28 September 2018).    ",[],,, GOLD 2017 ,additional,CD012930-bbs2-0137,
CD012930-bib-0328,"Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. ",A measure of quality of life for clinical trials in chronic lung disease, Thorax ,1987,42,    ,['citation-journal']," Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease.  Thorax 1987;42(10):773‐8.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1136/thx.42.10.773', 'https://www.ncbi.nlm.nih.gov/pubmed/3321537', 'https://scholar.google.com/scholar_lookup?title=A+measure+of+quality+of+life+for+clinical+trials+in+chronic+lung+disease&author=GH+Guyatt&author=LB+Berman&author=M+Townsend&author=SO+Pugsley&author=LW+Chambers&publication_year=1987&hl=en']",3321537,https://doi.org/10.1136/thx.42.10.773, Guyatt 1987 ,additional,CD012930-bbs2-0138,
CD012930-bib-0329,"Higgins JPT, Green S, editor(s). ","Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 (updated March 2011). The Cochrane Collaboration, 2011",,,,. Available from www.handbook.cochrane.org.   ,['citation-other']," Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.    ",[],,, Higgins 2011 ,additional,CD012930-bbs2-0139,
CD012930-bib-0330,"Jones PW, Quirk FH, Baveystock CM, Littlejohns P. ",A self‐complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire, American Review of Respiratory Disease ,1992,145,    ,['citation-journal']," Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self‐complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire.  American Review of Respiratory Disease 1992;145(6):1321‐7.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1164/ajrccm/145.6.1321', 'https://www.ncbi.nlm.nih.gov/pubmed/1595997', ""https://scholar.google.com/scholar_lookup?title=A+self‐complete+measure+of+health+status+for+chronic+airflow+limitation.+The+St.+George's+Respiratory+Questionnaire+&author=PW+Jones&author=FH+Quirk&author=CM+Baveystock&author=P+Littlejohns&publication_year=1992&hl=en""]",1595997,https://doi.org/10.1164/ajrccm/145.6.1321, Jones 1992 ,additional,CD012930-bbs2-0140,
CD012930-bib-0331,"Higgins J, Lasserson T, Chandler J, Tovey D, Churchill R. ","Standards for the conduct and reporting of new Cochrane Intervention Reviews, reporting of protocols and the planning, conduct and reporting of updates (Version 1.05)",,,,. community.cochrane.org/mecir‐manual (accessed prior to 28 September 2018).   ,['citation-other']," Higgins J, Lasserson T, Chandler J, Tovey D, Churchill R. Standards for the conduct and reporting of new Cochrane Intervention Reviews, reporting of protocols and the planning, conduct and reporting of updates (Version 1.05). community.cochrane.org/mecir‐manual (accessed prior to 28 September 2018).    ",[],,, MECIR 2018 ,additional,CD012930-bbs2-0141,
CD012930-bib-0332,"Oba Y, Sarva ST, Dias S. ",Efficacy and safety of long‐acting β‐agonist/long‐acting muscarinic antagonist combinations in COPD: a network meta‐analysis, Thorax ,2016,71,    ,['citation-journal']," Oba Y, Sarva ST, Dias S. Efficacy and safety of long‐acting β‐agonist/long‐acting muscarinic antagonist combinations in COPD: a network meta‐analysis.  Thorax 2016;71(1):15‐25.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1136/thoraxjnl-2014-206732', 'https://www.ncbi.nlm.nih.gov/pubmed/26490732', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+long‐acting+β‐agonist/long‐acting+muscarinic+antagonist+combinations+in+COPD:+a+network+meta‐analysis+&author=Y+Oba&author=ST+Sarva&author=S+Dias&publication_year=2016&hl=en']",26490732,https://doi.org/10.1136/thoraxjnl-2014-206732, Oba 2016 ,additional,CD012930-bbs2-0142,
CD012930-bib-0333,"Polkey MI, Spruit M, Edwards LD, Watkins ML, Pinto‐Plata V, Vestbo JÃ, et al. ",Six‐minute‐walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization, American Journal of Respiratory and Critical Care Medicine ,2013,187,    ,['citation-journal']," Polkey MI, Spruit M, Edwards LD, Watkins ML, Pinto‐Plata V, Vestbo JÃ, et al. Six‐minute‐walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization.  American Journal of Respiratory and Critical Care Medicine 2013;187(4):382‐6.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1164/rccm.201209-1596OC', 'https://www.ncbi.nlm.nih.gov/pubmed/23262518', 'https://scholar.google.com/scholar_lookup?title=Six‐minute‐walk+test+in+chronic+obstructive+pulmonary+disease:+minimal+clinically+important+difference+for+death+or+hospitalization+&author=MI+Polkey&author=M+Spruit&author=LD+Edwards&author=ML+Watkins&author=V+Pinto‐Plata&author=JÃ+Vestbo&publication_year=2013&hl=en']",23262518,https://doi.org/10.1164/rccm.201209-1596OC, Polkey 2013 ,additional,CD012930-bbs2-0143,
CD012930-bib-0334,"Puhan MA, Soesilo I, Guyatt GH, Schunemann HJ. ",Combining scores from different patient reported outcome measures in meta‐analyses: when is it justified?, Health and Quality of Life Outcomes ,2006,4,    ,['citation-journal']," Puhan MA, Soesilo I, Guyatt GH, Schunemann HJ. Combining scores from different patient reported outcome measures in meta‐analyses: when is it justified?.  Health and Quality of Life Outcomes 2006;4:94.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1186/1477-7525-4-94', 'https://www.ncbi.nlm.nih.gov/pubmed/17156420', 'https://scholar.google.com/scholar_lookup?title=Combining+scores+from+different+patient+reported+outcome+measures+in+meta‐analyses:+when+is+it+justified?+&author=MA+Puhan&author=I+Soesilo&author=GH+Guyatt&author=HJ+Schunemann&publication_year=2006&hl=en']",17156420,https://doi.org/10.1186/1477-7525-4-94, Puhan 2006 ,additional,CD012930-bbs2-0144,
CD012930-bib-0335,"Qaseem A, Wilt TJ, Weinberger SE, Hanania NA, Criner G, van der Molen T, et al. ","Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society", Annals of Internal Medicine ,2011,155,    ,['citation-journal']," Qaseem A, Wilt TJ, Weinberger SE, Hanania NA, Criner G, van der Molen T, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society.  Annals of Internal Medicine 2011;155:179‐91.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.7326/0003-4819-155-3-201108020-00008', 'https://www.ncbi.nlm.nih.gov/pubmed/21810710', 'https://scholar.google.com/scholar_lookup?title=Diagnosis+and+management+of+stable+chronic+obstructive+pulmonary+disease:+a+clinical+practice+guideline+update+from+the+American+College+of+Physicians,+American+College+of+Chest+Physicians,+American+Thoracic+Society,+and+European+Respiratory+Society+&author=A+Qaseem&author=TJ+Wilt&author=SE+Weinberger&author=NA+Hanania&author=G+Criner&author=T+Molen&publication_year=2011&hl=en']",21810710,https://doi.org/10.7326/0003-4819-155-3-201108020-00008, Quaseem 2011 ,additional,CD012930-bbs2-0145,
CD012930-bib-0336,"Sarai M, Sin D, FitzGerald JM, Aaron S. ",Long‐acting beta2‐agonists and long‐acting muscarinic antagonists in a combined inhaler versus either agent alone or placebo for chronic obstructive pulmonary disease, Cochrane Database of Systematic Reviews ,2014,,    ,['citation-journal']," Sarai M, Sin D, FitzGerald JM, Aaron S. Long‐acting beta2‐agonists and long‐acting muscarinic antagonists in a combined inhaler versus either agent alone or placebo for chronic obstructive pulmonary disease.  Cochrane Database of Systematic Reviews 2014, Issue 9. [DOI: 10.1002/14651858.CD011282]    Link to article     Google Scholar     ","['https://doi.org/10.1002/14651858.CD011282', 'https://scholar.google.com/scholar_lookup?title=Long‐acting+beta2‐agonists+and+long‐acting+muscarinic+antagonists+in+a+combined+inhaler+versus+either+agent+alone+or+placebo+for+chronic+obstructive+pulmonary+disease+&author=M+Sarai&author=D+Sin&author=JM+FitzGerald&author=S+Aaron&publication_year=2014&hl=en']",,https://doi.org/10.1002/14651858.CD011282, Sarai 2014 ,additional,CD012930-bbs2-0146,
CD012930-bib-0337,"Schunemann HJ, Griffith L, Jaeschke R, Goldstein R, Stubbing D, Guyatt GH. ",Evaluation of the minimal important difference for the feeling thermometer and the St. George's Respiratory Questionnaire in patients with chronic airflow obstruction, Journal of Clinical Epidemiology ,2003,56,    ,['citation-journal']," Schunemann HJ, Griffith L, Jaeschke R, Goldstein R, Stubbing D, Guyatt GH. Evaluation of the minimal important difference for the feeling thermometer and the St. George's Respiratory Questionnaire in patients with chronic airflow obstruction.  Journal of Clinical Epidemiology 2003;56(12):1170‐6.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S0895-4356(03)00115-X', 'https://www.ncbi.nlm.nih.gov/pubmed/14680667', ""https://scholar.google.com/scholar_lookup?title=Evaluation+of+the+minimal+important+difference+for+the+feeling+thermometer+and+the+St.+George's+Respiratory+Questionnaire+in+patients+with+chronic+airflow+obstruction+&author=HJ+Schunemann&author=L+Griffith&author=R+Jaeschke&author=R+Goldstein&author=D+Stubbing&author=GH+Guyatt&publication_year=2003&hl=en""]",14680667,https://doi.org/10.1016/S0895-4356(03)00115-X, Schunemann 2003 ,additional,CD012930-bbs2-0147,
CD012930-bib-0338,"Schunemann HJ, Puhan M, Goldstein R, Jaeschke R, Guyatt GH. ",Measurement properties and interpretability of the chronic respiratory disease questionnaire (CRQ), COPD ,2005,2,    ,['citation-journal']," Schunemann HJ, Puhan M, Goldstein R, Jaeschke R, Guyatt GH. Measurement properties and interpretability of the chronic respiratory disease questionnaire (CRQ).  COPD 2005;2(1):81‐9.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1081/COPD-200050651', 'https://www.ncbi.nlm.nih.gov/pubmed/17136967', 'https://scholar.google.com/scholar_lookup?title=Measurement+properties+and+interpretability+of+the+chronic+respiratory+disease+questionnaire+(CRQ)+&author=HJ+Schunemann&author=M+Puhan&author=R+Goldstein&author=R+Jaeschke&author=GH+Guyatt&publication_year=2005&hl=en']",17136967,https://doi.org/10.1081/COPD-200050651, Schunemann 2005 ,additional,CD012930-bbs2-0148,
CD012930-bib-0339,Jones P. ,St George’s Respiratory Questionnaire for COPD patients (SGRQ‐C),,,,. www.healthstatus.sgul.ac.uk/SGRQ_download/SGRQ‐C%20Manual%20March%202016.pdf (accessed 10 May 2018).   ,['citation-other'], Jones P. St George’s Respiratory Questionnaire for COPD patients (SGRQ‐C). www.healthstatus.sgul.ac.uk/SGRQ_download/SGRQ‐C%20Manual%20March%202016.pdf (accessed 10 May 2018).    ,[],,, SGRQ‐C Manual ,additional,CD012930-bbs2-0149,
CD012930-bib-0340,"Singh D, Jones PW, Bateman ED, Korn S, Serra C, Molins E, et al. ","Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study", BMC Pulmonary Medicine ,2014,14,    ,['citation-journal']," Singh D, Jones PW, Bateman ED, Korn S, Serra C, Molins E, et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study.  BMC Pulmonary Medicine 2014;14:178.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1186/1471-2466-14-178', 'https://www.ncbi.nlm.nih.gov/pubmed/25404569', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+aclidinium+bromide/formoterol+fumarate+fixed‐dose+combinations+compared+with+individual+components+and+placebo+in+patients+with+COPD+(ACLIFORM‐COPD):+a+multicentre,+randomised+study+&author=D+Singh&author=PW+Jones&author=ED+Bateman&author=S+Korn&author=C+Serra&author=E+Molins&publication_year=2014&hl=en']",25404569,https://doi.org/10.1186/1471-2466-14-178, Singh 2014a ,additional,CD012930-bbs2-0150,
CD012930-bib-0341,"Singh SJ, Puhan MA, Andrianopoulos V, Hernandes NA, Mitchell KE, Hill CJ, et al. ",An official systematic review of the European Respiratory Society/American Thoracic Society: measurement properties of field walking tests in chronic respiratory disease, European Respiratory Journal ,2014,44,    ,['citation-journal']," Singh SJ, Puhan MA, Andrianopoulos V, Hernandes NA, Mitchell KE, Hill CJ, et al. An official systematic review of the European Respiratory Society/American Thoracic Society: measurement properties of field walking tests in chronic respiratory disease.  European Respiratory Journal 2014;44:1447‐78.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1183/09031936.00150414', 'https://www.ncbi.nlm.nih.gov/pubmed/25359356', 'https://scholar.google.com/scholar_lookup?title=An+official+systematic+review+of+the+European+Respiratory+Society/American+Thoracic+Society:+measurement+properties+of+field+walking+tests+in+chronic+respiratory+disease+&author=SJ+Singh&author=MA+Puhan&author=V+Andrianopoulos&author=NA+Hernandes&author=KE+Mitchell&author=CJ+Hill&publication_year=2014&hl=en']",25359356,https://doi.org/10.1183/09031936.00150414, Singh 2014b ,additional,CD012930-bbs2-0151,
CD012930-bib-0342,"Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, et al. ","Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease", American Journal of Respiratory and Critical Care Medicine ,2013,187,    ,['citation-journal']," Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease.  American Journal of Respiratory and Critical Care Medicine 2013;187(4):347–65.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1164/rccm.201204-0596PP', 'https://www.ncbi.nlm.nih.gov/pubmed/22878278', 'https://scholar.google.com/scholar_lookup?title=Global+strategy+for+the+diagnosis,+management,+and+prevention+of+chronic+obstructive+pulmonary+disease+&author=J+Vestbo&author=SS+Hurd&author=AG+Agustí&author=PW+Jones&author=C+Vogelmeier&author=A+Anzueto&publication_year=2013&hl=en']",22878278,https://doi.org/10.1164/rccm.201204-0596PP, Vestbo 2013 ,additional,CD012930-bbs2-0152,
CD012930-bib-0343,"Wedzicha JA, Decramer M, Ficker JH, Niewoehner DE, Sandström T, Taylor AF, et al. ","Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double‐blind, parallel‐group study", Lancet Respiratory Medicine ,2013,1,    ,['citation-journal']," Wedzicha JA, Decramer M, Ficker JH, Niewoehner DE, Sandström T, Taylor AF, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double‐blind, parallel‐group study.  Lancet Respiratory Medicine 2013;1(3):199–209.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S2213-2600(13)70052-3', 'https://www.ncbi.nlm.nih.gov/pubmed/24429126', 'https://scholar.google.com/scholar_lookup?title=Analysis+of+chronic+obstructive+pulmonary+disease+exacerbations+with+the+dual+bronchodilator+QVA149+compared+with+glycopyrronium+and+tiotropium+(SPARK):+a+randomised,+double‐blind,+parallel‐group+study+&author=JA+Wedzicha&author=M+Decramer&author=JH+Ficker&author=DE+Niewoehner&author=T+Sandström&author=AF+Taylor&publication_year=2013&hl=en']",24429126,https://doi.org/10.1016/S2213-2600(13)70052-3, Wedzicha 2014 ,additional,CD012930-bbs2-0153,
CD012930-bib-0344,"Wedzicha JA, Calverley PMA, Albert RK, Anzueto A, Criner GJ, Hurst JR, et al. ",Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline, European Respiratory Journal ,2017,50,    ,['citation-journal']," Wedzicha JA, Calverley PMA, Albert RK, Anzueto A, Criner GJ, Hurst JR, et al. Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline.  European Respiratory Journal 2017;50(3):1602265.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1183/13993003.02265-2016', 'https://www.ncbi.nlm.nih.gov/pubmed/28889106', 'https://scholar.google.com/scholar_lookup?title=Prevention+of+COPD+exacerbations:+a+European+Respiratory+Society/American+Thoracic+Society+guideline+&author=JA+Wedzicha&author=PMA+Calverley&author=RK+Albert&author=A+Anzueto&author=GJ+Criner&author=JR+Hurst&publication_year=2017&hl=en']",28889106,https://doi.org/10.1183/13993003.02265-2016, Wedzicha 2017 ,additional,CD012930-bbs2-0154,
CD012930-bib-0345,"Westwood M, Bourbeau J, Jones PW, Cerulli A, Capkun‐Niggli G, Worthy G. ",Relationship between FEV1 change and patient‐reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review, Respiratory Research ,2011,12,    ,['citation-journal']," Westwood M, Bourbeau J, Jones PW, Cerulli A, Capkun‐Niggli G, Worthy G. Relationship between FEV1 change and patient‐reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review.  Respiratory Research 2011;12:40.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1186/1465-9921-12-40', 'https://www.ncbi.nlm.nih.gov/pubmed/21477298', 'https://scholar.google.com/scholar_lookup?title=Relationship+between+FEV1+change+and+patient‐reported+outcomes+in+randomised+trials+of+inhaled+bronchodilators+for+stable+COPD:+a+systematic+review+&author=M+Westwood&author=J+Bourbeau&author=PW+Jones&author=A+Cerulli&author=G+Capkun‐Niggli&author=G+Worthy&publication_year=2011&hl=en']",21477298,https://doi.org/10.1186/1465-9921-12-40, Westwood 2011 ,additional,CD012930-bbs2-0155,
CD012930-bib-0346,World Health Organization. ,Global health estimates ‐ year 2015,,,,. www.who.int/mediacentre/factsheets/fs310/en/ (accessed 1 April 2017).   ,['citation-other'], World Health Organization. Global health estimates ‐ year 2015. www.who.int/mediacentre/factsheets/fs310/en/ (accessed 1 April 2017).    ,[],,, WHO 2015 ,additional,CD012930-bbs2-0156,
CD012930-bib-0309,NCT02233543. ,"A multicenter, 4‐week crossover (total duration 12 weeks), placebo‐controlled, double‐blind study to determine the impact of QVA149 (indacaterol/glycopyrronium) 85/43 Âµg on nocturnal oxygen levels in chronic obstructive pulmonary disease (COPD)",,,,   ,['citation-other']," NCT02233543. A multicenter, 4‐week crossover (total duration 12 weeks), placebo‐controlled, double‐blind study to determine the impact of QVA149 (indacaterol/glycopyrronium) 85/43 Âµg on nocturnal oxygen levels in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT02233543 (first received 8 September 2014). CENTRAL    ",[''],,, NCT02233543 2014 {published data only}  ,awaiting_assessment,CD012930-bbs2-0119,
